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Figure 1 – General Structure of an ABP, comprising a reactive group, a linker and a tag, 
and general overview of an ABPP experiment, where an ABP is incubated with a complex 
proteome, labeling its targets that are in a catalytically active state. This is followed by 
analysis via gel-based methods or streptavidin enrichment of labeled proteins and analysis 
by mass spectrometry. 
Figure 2 – Application of ABPs in the discovery of enzymatic activities potentially 
responsible for specific phenotypes. Different phenotypes can be incubated with the same 
ABP and analyzed by ABPP techniques to identify enzymatic activities that are 
upregulated or downregulated and can potentially be responsible for the phenotype. 
Figure 3 – Example of an FP ABP commonly used for ABPP of serine hydrolases. The 
probe uses an FP reactive group, an alkyl linker containing an amide and a rhodamine 
tag. 
Figure 4 – Common reactive groups in ABPP. 
Figure 5 – Commonly tags in ABPP. 
Figure 6 – Common linkers in ABPP: A. Alkyl linker; B. PEG linker; C. Peptidic linker 
(functions as a spacer but can also help define specificity of the probe).  
Figure 7 – TEV-biotin linker/tag. The TEV cleavage site is labeled in red.  
Figure 8 – A. ABPP-ReDiMe. B. ABPP-SILAC. C. TMT tags used in 10plex TMT. 
Figure 9 – Competitive ABPP Workflow. Separate samples are prepared for DMSO 
(control) and compound treatment. The compound will label its targets in the proteome. 
Both samples are then labeled with an appropriate broad reactivity ABP. The results can 
be read by SDS-PAGE (fluorescent ABP) or mass spectrometry (biotinylated ABP). If an 
enzyme is a target of the compound being tested the signal corresponding to this enzyme 
will be absent or attenuated when compared with the DMSO control. 
Figure 10 – Serine-reactive electrophiles. Adapted from Shannon and Weerapana.  
Figure 11 – FP-Biotin ABP. 
Figure 12 – ABPs based on β-Lactam, β-Lactone and β-Sultam reactive groups. 
Figure 13 – COPD Etiology. 
Figure 14 – Examples of HNE Inhibitors based on the β-Lactam scaffold. 
Figure 15 – HNE Inhibitors; A. ONO-6818, a transition state analog; B. 1,2,5-
thiadiazolidin-3-one 1,1-dioxide compounds, mechanism-based inhibitors; C. 
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Lyngbyastatin 7, a natural product-derived HNE inhibitor; D. “C-shaped” aurones, non-
covalent inhibitor. 
Figure 16 – ABPs for HNE (reactive groups are highlighted in red): A. Diphenyl 
phosphonate ABP developed by Gilmore et al.; B. ABPs based on the optimized 
tetrapeptides generated by the HyCoSul strategy by Kasperkiewicz et al.; C. Peptidic 
ABP developed by Grzywa et al.; D. 4-Oxo-β-Lactam ABPs developed by Ruivo et a; E. 
Diphenylphosphonate ABPs developed by Edington-Mitchel et al.; F. Peptidic ABP 
developed by Schulz-Fincke et al. G. ABP developed by Schulz-Fincke and coworkers 
based on a suicide inhibition mechanism dependent on a Lossen rearrangement. H. NIR 
fluorescence ABP developed by Liu et al. 
Figure 17 – Overview of selected DPP serine hydrolases and their main localization and 
functions. Adapted from Waumans et al.  
Figure 18 – A. Val-BoroPro; B.1G244. 
Figure 19 – Carbamate (A) and urea (B) selective inhibitors of ABHD6 developed by the 
Cravatt lab. C. β-lactone-based inhibitor of ABHD16a. 
Figure 20 – 4-Oxo-β-Lactam HNE inhibitors developed by Mulchande et al. 
Figure 21 – Overview of the project. 
Figure 22 – Azides used in the CuAAC derivatization of 3-Oxo-β-Sultams. 
Figure 23 – 3-Oxo-β-Sultam library of compounds. 
Figure 24 – Dose-response curves for HNE inhibition by compound 101. 
Figure 25 – Concentration range tests for 3-Oxo-β-Sultam ABP 92 in two different whole 
cell lysates of HEK293T and U937. Labeling of proteins is clearly visible around 5-10 
µM and background labeling seems to increase significantly at high concentrations 75-
100 µM. FP-Rhodamine (1 µM) labeling is shown for comparison. 
Figure 26 – Labeling of THP-1 and HEK293T whole cell lysates (1 mg/mL) with 
increasing concentrations of 3-Oxo-β-Sultam 108 in whole cell lysates of THP-1 and 
HEK293T cell lines. Labeling seems to be reasonably selective up to high concentrations 
of 50 µM. 
Figure 27 – Labeling of decreasing concentrations of pure HNE by 3-Oxo-β-Sultams 92 
and 108 at 50 µM. Compound 92 was clicked with Rhodamine azide after incubation with 
the proteome. While labeling is clearly observed with the Rhodamine probe, the alkyne 
probe provides a weak signal, only visible at 500 nM of HNE. 
Figure 28 – HNE spiking experiments in HEK293T cells. 3-Oxo-β-Sultam-Rhodamine 
108 labeling of pure HNE (first lane) and spiking of pure HNE in decreasing 
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concentrations into HEK293T whole cell lysates (1mg/mL). Labeling of HNE is observed 
even in the presence of a complete proteome but not completely selective. As spiked HNE 
concentration decreases, labeling of some proteins clearly increases, indicating these 
might be HNE substrates. 
Figure 29 – Testing of HNE labeling in a pure form, spiked into a complete proteome and 
in a cell line that expresses active HNE with compound 108. Labeling is clearly visible 
in all three types of experiments, being suppressed by pre-incubation with ONO-6818. 
When in the presence of a complete proteome, labeling of additional proteins is visible. 
Figure 30 – Competitive ABPP of 3-Oxo-β-Sultam compounds 109, 92 and 102 against 
FP-Rhodamine (left) and Iodoacetamide-Rhodamine (right). 
Figure 31 – ReDiMe results for 3-Oxo-β-Sultams. A ratio higher than 3 is considered a 
hit. The results were filtered to show only the serine hydrolase family of proteins. Each 
line represents one experiment. 
Figure 32 – ABPP-SILAC results for 3-Oxo-β-Sultams. The results were filtered for the 
serine hydrolase family. Hits were considered when the protein is enriched with a ratio of 
at least 3 when compared with a DMSO control in at least two experiments. A.109 [10 
µM (Probe VS. DMSO)]; B.109 [50 µM (Probe VS. DMSO)]; C. [108 (100µM) VS. 
DMSO], then 109 (10 µM); D. [(108 (100µM) VS. DMSO)], then 109 (50 µM). 
Figure 33 - Example of the peptide count plotted against observed ratios for: A. 109, 10 
µM vs. DMSO experiment; B. 109, 10 µM vs. DMSO experiment; C. Probe vs. probe 
experiment. Pre-incubation with 108, 10 µM or DMSO, and then 109, 10 µM; D. Probe 
vs. probe experiment. Pre-incubation with 108, 50 µM or DMSO, and then 109, 50 µM. 
Figure 34 – Native PPE crystals obtained when screening different conditions for PPE 
crystallization. 
Figure 35 – Reaction of compound 94 with PPE via attack of the catalytic serine to the 
sulfonyl group of 94. Active site zoomed view of the complexes between PPE and 
compounds 94, 95 and 96 with PPE.  
Figure 36 – Electron density map around the covalently bound 95 (A) and 96 (B) ligands 
of PPE, |2Fo-Fc| map is depicted in blue mesh and contoured at 1σ level. Color code: 
carbon in yellow, oxygen in red, nitrogen in blue, sulfur in green, and Br atoms in dark 
red. 
Figure 37 - Surface representation of HNE:102 (A) and PPE:94 (B) with ligands depicted 
in sticks (carbon in yellow, oxygen in red, nitrogen in blue, sulfur in green, and halide 
atoms in dark red (C) or light blue (D)); catalytic serine is colored in orange. Zoomed 
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view of active site of HNE:102 (C) and PPE:94 (D) with |2Fo-Fc| electron density map 
drawn in blue mesh (at 1σ contour) around the covalently bound 3-Oxo-β-Sultam ligands. 
Figure 38 – Atomic interactions around the ligands in HNE:102 (A) and PPE:94 (B). 
Hydrophobic interactions are displayed in green. 
Figure 39 – Competitive ABPP platform for the evaluation of 4-Oxo-β-Lactam 
compounds. 
Figure 40 – Concentration range tests for 4-Oxo-β-Lactam-alkyne 111 in HEK293T and 
U937 whole cell lysates. The ABPs were clicked with Rhodamine-azide after incubation 
with the proteomes for 30 minutes. Labeling of proteins is clearly visible starting at low 
concentrations 0.1-1 µM and appears to be concentration-dependent, with little to no 
background at higher concentrations. FP-Rhodamine (1 µM) labeling is shown for 
comparison. 
Figure 41 – Concentration range tests for 4-Oxo-β-Lactam-rhodamine 113 in HEK293T 
and U937 whole cell lysates. The ABPs were incubated with the proteomes for 30 
minutes. Labeling of proteins is clearly visible starting at low concentrations 0.1-1 µM 
and appears to be concentration-dependent, with little to no background at higher 
concentrations. 
Figure 42 – Competitive ABPP for the biotinylated 4-Oxo-β-Lactam 112 compound in 
U937 whole cell lysates, U937 soluble protein fraction and U937 membrane protein 
fraction against FP-Rhodamine. 
Figure 43 – ReDiMe results for 4-Oxo-β-Lactams. Probe vs. DMSO and competitive 
experiments. The results were filtered for serine hydrolases. Preliminary results, only one 
replicate was performed. 
Figure 44 – SILAC-MudPIT results for 4-Oxo-β-Lactams. Results were filtered for serine 
hydrolases. The results present an average ratio of at least 2 replicates and only when the 
target was identified in at least two experiments is the target shown. 
Figure 45 – Library of 4-Oxo-β-Lactams. 
Figure 46 – Example of a competitive ABPP experiment for selected para-substituted 4-
Oxo-β-Lactam compounds (117, 121, 122, 123, 124, 125) compounds in U937 whole cell 
lysates against FP-Rhodamine (1 µM). The region between 75 and 150 kDa is reproduced 
on the right with higher contrast. 
Figure 47 – Example of a competitive ABPP experiments for selected para-substituted 
4-Oxo-β-Lactam compounds (132, 133, 134, 135, 136, 137) compounds in U937 whole 
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cell lysates against FP-Rhodamine (1 µM). The region between 75 and 150 kDa is 
reproduced on the right with higher contrast. 
Figure 48 – Competitive ABPP gels with soluble and membrane fractions of U937 cells 
for selected compounds. Disappearance of a band when compared with DMSO control 
indicates that band is a target of the compound. Clear inhibition of some targets is 
observed. Analysis of the molecular weights seems to suggest that the compounds are 
inhibitors of DPP8 and/or DPP9 (soluble fraction, ~100 kDa), PREP (soluble fraction, 
~75 kDa) and HNE (membrane fraction, ~25 kDa). 
Figure 49 – Competitive ABPP in U937 whole cells using selected compounds from the 
4-Oxo-β-Lactam library. The full gels are shown in A. A cropped version with higher 
contrast to emphasize lower abundance proteins is shown in B. 
Figure 50 – Overview of a competitive SILAC-ABPP-MudPIT Protocol for 4-Oxo-β-
Lactam compounds. The proteomes of SILAC “light” cells and SILAC “heavy” cells are 
incubated with either 4-Oxo-β-Lactam compound or DMSO. Both samples are then 
treated with FP-Biotin to label the serine hydrolases that are not inhibited by the 4-Oxo-
β-Lactam compound. The reaction is quenched, the samples are combined and processed 
for LC-MS/MS analysis. Determination of heavy/light ratios gives the IDs of serine 
hydrolases inhibited by the 4-Oxo-β-Lactam compound.  
Figure 51 – Competitive ABPP-MudPIT experiments for selected compounds of the 4-
Oxo-β-Lactam library. Heavy/light ratios are presented. Values higher than 3 are 
considered a hit. The results were filtered for serine hydrolases (n = 2). 
Figure 52 – Overexpression of Serine Hydrolases via PEI-mediated transient transfection 
of plasmid DNA containing a selected serine hydrolase gene. The PEI/DNA complex is 
internalized, and the DNA is released in the cell. Transcription of the DNA into mRNA 
and then mRNA translation leads to the overexpression of the desired serine hydrolase. 
Figure 53 – Overexpression of selected serine hydrolases and labeling by FP-Rhodamine. 
Figure 54 – Western blot of overexpressed HNE using an anti-FLAG antibody. The Mock 
used was overexpressed METTL7A. 
Figure 55 – Western blot of HNE in U937 membrane and soluble fractions using an anti-
HNE antibody. The fractioned samples are presented in triplicate. 
Figure 56 – Preliminary testing of the inhibition of selected serine hydrolases by 
compounds 117 and 135. 
Figure 57 – Examples of determination of the IC50 for selected compound-protein pairs: 
132-HNE; 135-DPP8; 139-DPP9. FP-labeling blocking is analyzed by SDS-PAGE and 
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gel band intensity is quantified and plotted, allowing the IC50 to be calculated from the 
graphical projection of the remaining enzymatic activity against the logarithm of the 
inhibitor concentration. 
Figure 58 – Preliminary testing for selected serine hydrolase-compound pairs at 1 µM 
concentration. 
Figure 59 – Competitive ABPP experiment (A) and full proteome reactivity experiment 
(B) with the 4-Oxo-β-Lactam alkynylated probe 151. 
Figure 60 – Projection (t-distributed stochastic neighborhood embedding) of topological 
pharmacophore descriptor (CATS2) space. Orange: DPP8 ligands; Blue: DPP9 ligands. 
Gradient depicts activity values for individual compounds. Data shows that compound 
139 (black dot) presents an unusual pattern among DDP8 and DPP9 ligands. 
Figure 61 – Graphical representation of the cell viability assay performed for selected 4-
Oxo-β-Lactam compounds. 
Figure 62 – Co-crystallization of compound 132 with DPP8, revealing a covalent reaction 
with the catalytic Ser-755 and the extension of the inhibitor across a hydrophobic canyon, 
a novel binding site for extended ligands, different from previously described ligand-
DPP8 interactions. Ligand binding induces disordering of structures (colored in green) 
which were essential for previously studied compounds. 
Figure 63 – IC50 of N-O derivatives of 4-Oxo-β-Lactams for HNE inhibition. 
Figure 64 – Structures of the NBD-derivatized bile acids synthesized by Mello-Vieira et 
al. 










Table 1 – IC50, LE and LLE values for HNE inhibition by 3-Oxo-β-Sultams. 
Table 2 – Biochemical selectivity against selected serine hydrolases (n = 3). 
Table 3 – Summary of the IC50 values determined by competitive ABPP for the tested 
compound-target pairs. 
Table 4 – Pyroptosys IC50s for selected 4-Oxo-β-Lactam compounds in the AML cell 
line, MV4;11. 
Table 5 – Ki values for DPP8 and DPP9 inhibition by compounds 132, 135, 138 and 139 












Scheme 1 – Representative mechanism of serine hydrolase catalytic activity. 
Scheme 2 – ONO-5046 (Sivelestat) and its mechanism of HNE inhibition. Adapted from 
Lucas et al.  
Scheme 3 – Irreversible inhibition of HNE by a saccharin-based suicide inhibitor. 
Scheme 4 – A. 3-Oxo-β-Sultam general structure. B. Possible mechanisms of attack of a 
nucleophile to a 3-Oxo-β-Sultam. 
Scheme 5 – Difference in the hydrolysis of an N-benzoyl β-Sultam and a 3-Oxo-β-Sultam. 
Scheme 6 – A. 4-Oxo-β-Lactam general structure. B. Mechanism of the reaction of 4-
Oxo-β-Lactams with nucleophiles. 
Scheme 7 – A. Synthesis of 4-Oxo-β-Lactams described by Chavan et al.; B. Proposed 
mechanism for the alternative synthesis of 4-Oxo-β-Lactams described by Chavan et al. 
Scheme 8 – Synthesis of a benzylated 4,4-dimethyl 3-Oxo-β-Sultam. 
Scheme 9 – Synthesis of 2-ethylbutanoic anhydride from 2-ethylbutanoic acid. 
Scheme 10 – Synthesis of a 4,4-diethyl 3-Oxo-β-Sultam alkyne and derivatization by 
CuAAC. 
Scheme 11 – Cyclization of a 3-Oxo-β-Sultam with ammonia. Alkylation reactions N-H 
3-Oxo-β-Sultams. 
Scheme 12 – Synthesis of an NBD azide. 
Scheme 13 – Derivatization of Rhodamine B with 2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethan-1-amine. 
Scheme 14 – Mechanism of inhibition of a putative Serine hydrolase by a 3-Oxo-β-
Compound. Inhibition can occur by either acylation or sulfonylation. 
Scheme 15. A. Synthesis of an alkynylated 4-Oxo-β-Lactam; B. Synthesis of a 
biotinylated 4-Oxo-β-Lactam ABP; C. Synthesis of a rhodamine-derivatized 4-Oxo-β-
Lactam ABP. 
Scheme 16 – Optimization of the synthesis of the 4-Oxo-β-Lactam scaffold using the 
example of compound 114: A. the classic synthesis of 4OBLs, which resulted in the 
unwanted diamide as the major product; B. Optimized synthesis of 4-Oxo-β-Lactams, 
which results in near-quantitative yields in selected cases. 
Scheme 17. Synthesis of compound 117. 
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Scheme. 18 – Synthesis of 4-Oxo-β-Lactam compounds 119  and 120. A. Synthesis of a 
4-Oxo-β-Lactam with N-benzyl substituent, 119, from benzyl 4-(aminomethyl)benzoate; 
B. Synthesis of a 4-Oxo-β-Lactam with a free carboxylic acid, 120, by hydrogenation of 
120. 
Scheme 19 – Synthesis of a clickable 4-Oxo-β-Lactam 151 using 1-prop-2-
ynylpiperazine. 
Scheme 20 – A. 4-Oxo-β-Lactam containing an N-O bond; these compounds will take 
advantage of the Lossen Rearrangement, which will lead to a suicide mechanism. B. 
Mechanism of HNE inhibition by 4-Oxo-β-Lactam suicide inhibitors. After attack of 
HNE to the 4-Oxo-β-Lactam ring, a Lossen rearrangement generates an isocyanate, which 
is then attacked a second time by HNE, leading to an irreversibly inactivated enzyme.  
Scheme 21 – Synthesis of compound 153. 
Scheme 22 – Synthesis of compound 154. 
Scheme 23 – Activation mechanism of compound 154 upon attack by HNE. 
Scheme 24 – Synthesis of a fluorescein tagged 4-Oxo-β-Lactam 155 by CuAAC. 
Scheme 25 – Synthesis of an NBD-tagged vinyl sulfone ABP to target cysteine proteases. 








Equation 1 – LE calculation. 










2-AG – 2-arachidonoylglycerol 
ABHD10 – α/β hydrolase domain fold family protein 10 
ABHD12 – α/β hydrolase domain fold family protein 12 
ABHD16A – α/β hydrolase domain fold family protein 16A 
ABHD2 – α/β hydrolase domain fold family protein 2 
ABHD3 – α/β hydrolase domain fold family protein 3 
ABHD6 – α/β hydrolase domain fold family protein 6 
ABP – Activity-based Probe 
ABPP – Activity-based Protein Profiling 
ACOT7 – Cytosolic acyl coenzyme A thioester hydrolase 
APEH – Acylamino-acid-releasing enzyme 
CDCA – Chenodeoxycholic acid 
CES1 – Carboxylesterase 1 
CES2 – Carboxylesterase 2 
CES3 – Carboxylesterase 3 
COPD – Chronic Obstructive Pulmonary Disease 
CPVL – Carboxypeptidase 
CUAAC – Copper-catalyzed azide-alkyne cyclocondensation 
DCA – Deoxycholic acid 
DPP4 – Dipeptidyl dipeptidase 4 
DPP7 – Dipeptidyl dipeptidase 7 
DPP8 – Dipeptidyl dipeptidase 8 
DPP9 – Dipeptidyl dipeptidase 9 
FAAH – Fatty acid amide hydrolase 
FAP – Fibroblast activation protein/FAP Seprase 
FASN – Fatty acid synthase 
FluoPol – Fluorescence Polarization 
GLP-1 - Glucagon-like peptide-1 
HMGB1 – Alarmin high mobility group box 1 
HNE – Human Neutrophil Elastase 
HyCoSul – Hybrid combinatorial substrate library 
ICAT – Isotope-coded affinity tag 
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LE – Ligand Efficiency 
LLE – Ligand Lipophilic Efficiency 
LYPLA1 – Acyl-protein thioesterase 1 
LYPLA2 – Acyl-protein thioesterase 2 
MAGL – Monoacylglycerol lipase 
MHC – Major histocompatibility complex 
MMP-2 – Matrix metalloproteinase-2  
MMP-9 – Matrix metalloproteinase-9 
MRSA – methicillin-Resistant S. Aureus 
MudPIT – Multidimensional Protein Identification Technology 
NBD – Nitrobenz-2-oxa-1,3-diazole 
NET – Neutrophil extracellular trap 
NSCLC – Non-small cell lung cancer 
PAFAH2 - Platelet-activating factor acetylhydrolase 2 
PBP – Penicillin binding proteins 
PEI – Polyethyleneimine 
PPE – Porcine Pancreatic Elastase 
PR3 – Proteinase 3 
PRCP – Lysosomal Pro-X carboxypeptidase 
PREP – Prolyl endopeptidase 
ReDiMe – Reductive dimethylation 
ROS – Reactive oxygen species 
SAR – structure-activity relationship 
SCPEP1 – Retinoid-inducible serine carboxypeptidase 
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SILAC – Stable isotope labeling by amino acids in cell culture 
SLPI – Secretory leukocyte protease inhibitor 
SUMO1 – Small ubiquitin-related modifier 1 
TEV – Tobacco etch virus 
TMT – Tandem mass tag 
TOP – Tandem orthogonal proteolysis 
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Activity-based protein profiling (ABPP) is a technique that analyzes the dynamics in 
enzymatic activity in complex proteomes by using small molecular probes, deemed 
activity-based probes (ABPs), containing a reactive group to covalently bind enzyme 
catalytic residues, a tag for detection of labeled targets and a linker as a spacer and also 
specificity-enhancing. Different reactive groups have been developed to engage a wide 
range of enzymatic families but there is a constant need to create new chemical tools to 
expand the pool of engageable targets. In this work we evaluated two 4-membered ring 
chemotypes as new reactive groups for ABPP of serine hydrolases. The 3-Oxo-β-Sultam 
was revealed to be a highly reactive chemotype which labels a wide range of proteins 
with limited target occupancy. A crystallographic analysis of the reaction of 3-Oxo-β-
Sultams with elastase enzymes revealed a previously unknown mechanism of inhibition 
of these enzymes by sulfonylation, suggesting 3-Oxo-β-Sultam compounds could be used 
to expand the pool of available sulfonylating tools in chemical biology. 4-Oxo-β-Lactams 
were shown to potently hit a selected group of serine hydrolase with high target 
occupancy, including human neutrophil elastase (HNE) and members of the ABHD and 
DPP families of enzymes. A competitive-ABPP approach revealed high potency of a 
library of 4-Oxo-β-Lactams to target these enzymes. 4-Oxo-β-Lactams were identified as 
a new chemotype for DPP8 and DPP9 inhibition. Crystallography experiments revealed 
a new binding mode of these enzymes with 4-Oxo-β-Lactams, highlighting that these 
compounds could be used to pursue selective DPP8 or DPP9 inhibitors, a highly pursued 
field in current medicinal chemistry.  
 
Keywords: activity-based protein profiling • activity-based probe • serine hydrolase • 4-













A análise de proteínas baseada na actividade (ABPP) é uma técnica que possibilita o 
estudo da actividade de proteínas em proteomas complexos. A principal vantagem desta 
técnica em relação a outras técnicas de quantificação é que o resultado reportado 
corresponde somente à fracção activa da enzima em estudo, permitindo associar padrões 
complexos de actividade enzimática a fenótipos da amostra em estudo. 
O conceito de ABPP depende das sondas baseadas na actividade (ABPs), que contém um 
grupo reactivo, responsável pela reacção com formação de ligação covalente com uma 
proteína alvo ou um grupo de proteínas, e um elemento marcador, que produz um sinal 
mensurável que permite reportar a actividade da proteína alvo ou facilitar a sua 
purificação. Estes dois elementos são normalmente separados por um elemento de 
espaçamento, diminuindo possíveis impedimentos estéreos e podendo contribuir para o 
aumento da especificidade da sonda. Uma experiência de ABPP envolve a incubação das 
ABPs com proteomas complexos, onde as sondas se vão ligar apenas à forma activa das 
suas enzimas alvo. As enzimas que reagiram com a ABP podem ser identificadas por 
ensaios de gel de electroforese de proteínas, caso o elemento marcador da ABP seja um 
fluoróforo, através da leitura directa de fluorescência no gel. Alternativamente, se o 
elemento sinalizador da ABP é a biotina, as proteínas alvo são enriquecidas através de 
incubação com streptavidina e analisadas por espectrometria de massa para identificação 
exacta da identidade das proteínas atingidas. A análise simultânea de várias amostras 
permite comparar padrões de actividade enzimática e potencialmente definir novos 
biomarcadores associados a um fenótipo específico. 
Existe uma procura contínua de novos grupos reactivos de modo a aumentar a 
variabilidade de ferramentas disponíveis e conseguir cobrir o maior número possível de 
famílias enzimáticas. Hidrolases de serina são uma das maiores famílias de enzimas, 
tendo papéis relevantes em inúmeros processos biológicos e patológicos e existindo um 
interesse contínuo no seu estudo para desenvolvimento de inibidores e sondas. Análises 
ABPP de hidrolases de serina são normalmente realizadas com o grupo reactivo 
fluorofosfonato. Neste trabalho estudámos dois potenciais grupos reactivos baseados em 
anéis de 4 membros, as 3-Oxo-β-Sultamas e as 4-Oxo-β-Lactamas para análise de 
hidrolases de serina. 
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As 3-Oxo-β-Sultamas são anéis de 4 membros que contém um grupo acil sulfonamida. 
Uma biblioteca de compostos baseada neste groupo reactivo foi sintetizada via química 
click. Ensaios bioqímicos de inibição enzimática utilizando a elastase neutrofílica 
humana como modelo revelaram valores de inibição submicromolares para os compostos 
com substituição 3-dietilo, com as ABPs a evidenciar que a adição de um elemento 
sinalizador volumoso não compromete a actividade dos compostos. A análise da 
reatividade destes compostos num proteoma complexo revelou que estes são dotados de 
alta reactividade, reagindo com uma elevada percentagem das proteinas identificadas nos 
ensaios de ABPP. As análises de espectrometria de massa revelaram que, apesar de 
identificarem várias enzimas da família das hidrolases de serina, as 3-Oxo-β-Sultamas 
fazem-no com baixa percetagem de ocupação de alvo, o que limita a sua aplicação como 
ABPs. O mecanismo de inibição de hidrolases de serina pelas 3-Oxo-β-Sultamas não se 
encontra bem definido. Estudos anteriores com a elastase porcina humana (PPE) levaram 
autores a sugerir que o mecanismo é a acilação, mas estes resultados basearam-se apenas 
em análise cinética da reacção e verificação da sua reversibilidade com o tempo. 
Utilizando técnicas de cristalografia demonstrámos, pela primeira vez, através de análise 
de raios X de complexos entre a PPE e a HNE, que o mecanismo de acção é a sulfonilação 
da serina catalítica das enzimas. Estes resultados são bastante promisores para a expansão 
da biblioteca de ferramentas de sulfonilação disponíveis na química biológica, um 
mecanismo sub-explorado de inibição enzimática. 
As 4-Oxo-β-Lactamas são derivados de β-Lactamas que contém um grupo carbonilo 
adicional na posição 4 do anel de 4 membros. A análise ABPP revelou um perfil selectivo 
de inibição de enzimas num proteoma complexo, que incluem a HNE, um alvo 
previamente conhecido, mas também novas proteínas anteriormente não identificadas 
como alvos deste grupo reactivo, que incluem enzimas das famílias domínio αβ-hidrolase 
(ABHD) e dipeptidil peptidase (DPP). Ao contrário do que acontece com as 3-Oxo-β-
Sultamas, estes alvos são inibidos com alta ocupação de alvo, o que sugere que a 4-Oxo-
β-Lactama é um bom grupo reactivo para aplicações ABPP. 
Uma biblioteca de inibidores baseados nas 4-Oxo-β-Lactamas com substituinte N-arilo 
foi sintetizada de modo a estudar as características estruturais que definem a preferência 
de inibição para as enzimas identificadas nos ensaios ABPP. Uma análise por ABPP 
competitivo revelou que a posição dos substituintes no grupo N-arilo parece influenciar 
a especificidade dos compostos, com compostos com substuintes em para a apresentar, 
em geral, maior afinidade para a HNE e ABHD6, e compostos com substituintes em meta 
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a apresentar maior especificidade para as DPPs. Compostos com substituintes em orto 
não apresentaram alvos relevantes nos ensaios em gel e não foram testados em 
espectrometria de massa. A validação dos alvos utilizando sobreexpressão de hidrolases 
de serina de interesse revelou que a maioria dos compostos inibe alguns destes alvos com 
IC50 submicromolar. Estes resultados enfatizam o potencial das 4-Oxo-β-Lactamas como 
grupo reactivo para aplicações ABPP e para o desenvolvimento de novos inibidores de 
hidrolases de serina. Uma ABP com um alcino terminal foi sintetizada para aplicações 
bioortogonais, demostrando alta selectividade para a HNE em ensaios ABPP em gel, 
tendo potencial para estudos futuros da HNE na doença pulmonar obstrutiva crónica. 
De entre os novos alvos identificados para as 4-Oxo-β-Lactamas são de salientar a DPP8 
e a DPP9. A procura de inibidores da DPP8 e da DPP9 é uma grande área de interesse 
actual na química medicinal. Estas duas enzimas possuem alta similaridade estrutural 
entre si e não possuem inibidores específicos, sendo frequentemente inibidas em 
conjunto. Os inibidores que apresentaram melhores resultados para estas duas enzimas 
foram estudados mais aprofundadamente com as DPP8 e DPP9. Os compostos revelaram 
ter um efeito modesto na indução da piroptose, uma consequência da inibição destas 
enzimas e estudos de similaridade confirmaram que este grupo reactivo é completamente 
diferente dos grupos reactivos previamente utilizados para a inibição destas enzimas. 
Análise de complexos de raio X entre um inibidor 4-Oxo-β-Lactama e a DPP8 revelou a 
formação de uma ligação covalente entre o composto e a serina catalítica da DPP8. A 
parte distal da molécula apresenta interacções com aminoácios vizinhos ao sítio activo e 
um mecanismo de inibição que nunca tinham sido reportados anteriormente para os 
inibidores conhecidos da DPP8. Esta informação será vital para o futuro desenho de 
inhibidores destas enzimas e a exploração desta nova interacção poderá ser a chave para 
a descoberta de inibidores específicos para as mesmas. 
Adicionalmente, reportamos a síntese de sondas contendo vinil sulfonas como grupo 
reactivo para a análise de proteases de cisteína, sondas sintetizadas por modificação da 
estrutura de ácidos biliares e a síntese de sondas e inibidores baseados em modificações 
da 4-Oxo-β-Lactama como actividades complementares ao projeto princial aqui descrito. 
Em resumo, a utilização de ABPP e técnicas cristalográficas revelou o potencial de grupos 
reactivos com anéis de 4-membos, com as 3-Oxo-β-Sultamas comportando uma alta 
reactividade associada a baixa ocupação de alvo, mas com um mecanismo de acção 
inesperado via sulfonilação do centro activo de enzimas como a HNE. Os resultados 
revelaram também o enorme potencial das 4-Oxo-β-Lactamas como ABPs e como grupo 
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reactivo para o desenvolvimento de inibidores, incluindo enzimas como a DPP8 e DPP9, 
para as quais a procura de inibidores é uma área de grande interesse actual. A descoberta 
de que os inibidores contendo 4-Oxo-β-Lactamas ibibem a DPP8 através de interacções 
previamente não conhecidas poderá resultar na descoberta dos primeiros inibidores 
específicos da DPP8 ou DPP9. 
 
Palavras-chave: Análise de proteínas baseada na actividade • sondas baseadas na 













































Chapter 1 – Introduction and General Concepts 
 
 
1.1. Activity-based Protein Profiling 
 
 
In the current scientific landscape, the complete genome sequences of several organisms 
have been determined, with the human genome project being completed in 2001.1 With 
the exception of cells that demonstrate genomic mosaicism, nearly all cells contain 
identical DNA.2,3 Despite this, complex organisms present vastly different cell types, 
mostly due to the expression of different proteins. Furthermore, through mechanisms like 
gene splicing and post-translational modifications, our genome, which contains around 
30000-40000 genes, can generate over 100000 structurally and functionally diverse 
protein entities.4 Many of these proteins remain unannotated regarding their biochemical 
activities.5 
The annotation of the human proteome is a colossal task which is complicated by the 
complex dynamics of proteins in the cell. The large-scale approaches to characterize the 
myriad of proteins expressed in biological systems are collectively termed proteomics 
and have been greatly assisted by the development of mass-spectrometry techniques, 
which have supported the study of the proteome for a long time.3,6,7 One of the goals of 
proteomics is to develop techniques capable of analyzing protein expression levels and 
assigning functional roles to proteins in normal and pathologic states.8 
Protein dynamics in biological systems depend on a variety of factors, including the wide 
range of abundances, compartmentalization of proteins in cellular organelles, different 
temporal expression, the possibility of diverse post-translational modifications affecting 
protein function and the existence of amino acid side-chain reactivity, which strongly 
varies, depending on the local microenvironment.6,9 Additionally, endogenous inhibitors 
and protein-protein interactions contribute to the modulation of protein activity, adding 
an additional layer of complexity to the system.10 These factors make it so that a certain 
protein’s abundance or expression levels are frequently not directly correlated with that 
protein’s activity. Traditional proteomic methods, including two-dimensional 
electrophoresis coupled with mass spectrometry, provide data focused on protein 
expression levels, with no information regarding the activity state of the proteins. These 
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methods also struggle with low abundance proteins and proteins with particular features 
like transmembrane domains.7,11,12 
The need of new platforms to analyze protein function and activity instead of abundance 
led to the development of ABPP, a group of chemoproteomic techniques that are able to 
quantify only the active fraction of total enzyme in complex proteomes and profile the 
functional dynamics of enzymes in complex systems (Figure 1).13-16 
The application of ABPP relies on ABPs, the molecular players that perform covalent 
tethering of single or multiple enzymes and provide a readable signal which can be 
analyzed as a measurement of protein function. The basic structure of an ABP contains a 
reactive group,17,18 responsible for binding to the active target enzyme; a tag, which 
provides a readable signal or a means of purifying the probe-target complex;8 and a linker, 
which separates the reactive group from the tag and can also contain additional elements 
that contribute to increased potency and selectivity by interacting with non-catalytic 
residues of the target enzymes (Figure 1).4 
A typical ABPP experiment involves the treatment of a protein sample, that can be a 
complete proteome, with an ABP. The reaction of ABPs with their target enzymes results 
in the formation of a covalent bond between them. Downstream analysis protocols vary 
depending on the experiment. Proteomes labeled with fluorescent tags can be analyzed 
by SDS-PAGE techniques and are commonly used for direct visualization of labeled 
proteins in-gel.4,19 Gel bands can then be excised for mass-spectrometry-based protein 
identification. If the probe is biotinylated, engaged targets can be directly enriched from 
the proteome using a streptavidin-coated solid surface and the enriched peptides can then 
be processed  and analyzed by LC-MS/MS, resulting in a list of engaged proteins after 
appropriate data processing.20 
ABPs can be applied in parallel to normal and diseased tissues to profile and compare 
enzymatic activities in both samples, resulting in a fingerprint of the key enzymes that 
are differently active between them and might be up or downregulated in the disease state. 
In an ideal situation, the readable signal is significantly and consistently different between 
tissues and allows the target enzyme or enzymatic profile to be classified as a potential 
biomarker of disease (Figure 2).21 The application of ABPs in different stages of disease 
can also provide insight into molecular mechanisms that promote disease progression and 







Figure 1 – General Structure of an ABP, comprising a reactive group, a linker and a tag, and general overview of an 
ABPP experiment, where an ABP is incubated with a complex proteome, labeling its targets that are in a catalytically 
active state. This is followed by analysis via gel-based methods or streptavidin enrichment of labeled proteins and 
analysis by mass spectrometry. 
 
 
ABPs can be directed to a single enzymatic target or have a broader scope of targets that 
share a certain substrate specificity or mechanistic machinery. Using ABPs with broad 
reactivity in non-directed approaches allows groups of enzymes to be analyzed together 
and different patterns of expression can be associated with different disease stages.22 
These probes can also react with previously uncharacterized enzymes, allowing the study 
of their reactivity, the search for specific inhibitors and the allocation of these enzymes 
into known enzyme families.23 Additionally, broad reactivity probes have been 
successfully used in competitive ABPP, where libraries of inhibitors compete with probe 
labeling, allowing preliminary information on potency and selectivity to be obtained for 
specific targets without the need of a specific ABP (see chapter 1.1.4.). The application 
of on-off fluorescent ABPs can also provide in vivo or in situ visualization of enzymatic 
activity and has been used for tumor border imaging in brain tissue, among other 
applications.24 
ABPP probes have been successfully developed for diverse classes of enzymes, including 
proteases,5,18,25-28 kinases,29-31 phosphatases,32,33 glycosidases,34,35 gluthatione-S-
transferases,36 among others. Application-wise, ABPs have been successfully used in the 
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identification of critical molecules in pathologic states,25,37 discovery of enzyme targets,38 
in vivo visualization of enzymatic activity,24,39,40 inhibitor discovery41 and biomarker 
discovery and validation,21 among other examples. 
Ideally, multiple probes of complementary specificity could potentially be used 
simultaneously to provide a universal platform for comprehensive analysis of enzymatic 





Figure 2 – Application of ABPs in the discovery of enzymatic activities potentially responsible for specific 
phenotypes. Different phenotypes can be incubated with the same ABP and analyzed by ABPP techniques to identify 
enzymatic activities that are upregulated or downregulated and can potentially be responsible for the phenotype. 
 
 
1.1.1. Designing Activity-based Probes 
 
The basic structure of an ABP contains a reactive group,17,18 which binds to the active 
target enzyme, a tag which provides a readable signal or a means of purifying the probe-
target complex,8 and a linker, which separates the reactive group from the tag and might 
contribute to increase potency and selectivity by interaction with non-catalytic residues.4 
For specific applications additional elements can be present, including fluorescence 
quenchers, recognition moieties, among others. In the following sections, specific details 
regarding these probe elements are discussed with relevant examples. Figure 3 depicts an 






Figure 3 – Example of an FP ABP commonly used for ABPP of serine hydrolases. The probe uses an FP reactive 
group, an alkyl linker containing an amide and a rhodamine tag. 
 
 
1.1.1.1. The Reactive Group 
 
The reactive group is the element of the ABP responsible for target engagement and 
covalent binding to the enzyme’s active site. It is usually based on an electrophilic 
chemotype (Figure 4). If the enzyme to be targeted has known covalent inhibitors, 
preliminary probe design can take advantage of adapting the inhibitor structure and 
modifying it to include an appropriate tag.43  
The choice of reactive group depends on the type of enzyme to be targeted, ease of 
synthesis and the desired selectivity/reactivity. A myriad of reactive groups is available 
to target diverse enzymatic families.43 Electrophiles that target enzymes that use cysteine, 
serine and threonine as catalytic residues are well established.17,18,43,44 Other enzymes like 
metalloproteases and aspartyl proteases don’t use a catalytic aminoacid and are usually 
targeted by reactive cross-linkers that activate with light exposure and establish a non-
specific covalent bond with a neighboring aminoacid. This is called affinity-based protein 
profiling and has allowed the application of ABPP techniques for enzymes that form no 
direct covalent bonds.5,45,46 Concerning selectivity and reactivity, care must be taken in 
choosing an adequate reactive group for each specific task. Absolute specificity is not a 
requirement for ABPs, as long as efficient separation of the labeled proteins by SDS-
PAGE or LC-MS/MS allows unequivocal detection and analysis of the target protein of 
interest. The simultaneous measurement of multiple enzymatic activities is often 
advantageous since it can provide a better understanding of proteome dynamics, where 
biologic or pathologic phenotypes are usually associated with multiple enzymatic 
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activities. Additionally, broad reactivity probes are essential in competitive variants of 
ABPP and allow profiling of potency and selectivity of large libraries of potential 





Figure 4 – Common reactive groups in ABPP. 
 
 
1.1.1.2. The Tag 
 
The tag is the element of the probe that provides either a readable signal or allows for 
affinity enrichment of labeled proteins. Choosing the tag depends on the analytical 
platform and the type of data desired. ABP imaging can be achieved by using 
fluorophores or radioactive tags, while mass-spectrometry-based identification of 
proteins requires biotin as the tag. Biotin makes it possible to enrich labeled proteins using 
avidin- or streptavidin-coated surfaces.8 Commonly used tags in ABPP are presented in 
Figure 5.  
125I tagging is an example of an isotopic tagging method. It can be easily achieved by 
iodination methods and has been incorporated in several ABPs. The probes provide 
highly sensitive signals with low background noise but require specialized equipment for 
manufacture and handling and have limited storage time due to the low half-life of 125I. 
The signal can be read by SDS-PAGE and allows discrimination of singular labeled 
proteins in complex mixtures. These probes have been used successfully in the labeling 
of cysteine proteases.18,47 Stable isotopes are frequently used in ABPP in techniques like 
Stable isotope labeling by amino acids in cell culture (SILAC) and have also been 
incorporated into ABPs.48,49 
Fluorophores are one of the most prevalent tagging strategies in ABPP. There is a 
multitude of available fluorophores, covering a broad range of absorption and emission 
wavelengths, containing varied structural properties and being commercially available in 
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diverse formats, including for example, alkyne and azide derivatives for click chemistry.50 
The most used fluorophores are rhodamine, fluorescein, nitrobenz-2-oxa-1,3-diazole 
(NBD), BODIPY and cyanine dyes. BODIPY and Cyanine dyes are more resistant to 
photobleaching than more classic fluorophores like rhodamine and fluorescein and 
present much better cell permeation due to their lipophilicity.8 However, most 





Figure 5 – Commonly used tags in ABPP. 
 
 
One of the biggest advantages of using fluorophores is the possibility of in-gel analysis 
of fluorescently labeled peptides, allowing for quick readout of labeled proteins 
immediately after running the SDS-PAGE gel and without requiring additional 
processing. Fluorophore-tagged ABPs can also be adapted into high-throughput screening 
protocols like Fluorescence Polarization (FluoPol) (see chapter 1.1.4.).51 Applications of 
fluorophores in real-time analysis are usually hindered by the need to remove the excess 
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of unlabeled probe. This can be solved by engineering a quencher into the ABP structure, 
which suffers an “activity-based displacement” upon engagement with the target enzyme, 
leading to generation of fluorescence only after reaction with a target enzyme.52 
Biotin is the tag of choice for affinity purification of labeled peptides for mass 
spectrometry applications. Its use is based on taking advantage of the strong bond that 
forms between biotin and avidin or streptavidin, which is one of the strongest non-
covalent bonds known, involving a complex network of polar and hydrophobic 
interactions and having an affinity constant of 1015 M-1.53 Binding of biotin to avidin 
seems to induce ordering of an avidin loop that locks biotin into its active site. Upon 
labeling of target proteins by a biotinylated probe, labeled proteins can be affinity-purified 
using avidin or streptavidin coated solid surfaces like beads.11,13 
The use of biotin is associated with some problems, including poor cell permeability, the 
existence of endogenously biotinylated proteins, which are enriched together with probe-
labeled proteins, and the strength of the biotin-avidin bond, which can make the elution 
of labeled peptides difficult without using harsh conditions.54,55 All these hindrances can 
be solved by simple protocol modifications and biotin remains the handle of choice for 
affinity purification of proteins for mass spectrometry analysis in ABPP. Alternatives to 
biotin usually involve the incorporation of peptide sequences that are specifically 
recognized by antibodies, oligonucleotide microarrays or resin-bound probes.56-58  
An additional tagging strategy is the use of small chemical handles to avoid problems 
associated with “true tags”. Biotin and some fluorophores significantly change ABP’s 
properties, making them unsuitable for cell permeation, which means they can’t be used 
in assays with whole cells. The cell is a complex system that cannot be accurately replaced 
by whole cell lysates, which makes it important to study whole cells whenever possible. 
To circumvent the permeability problem, ABPs can be modified with simple handles that 
have little to no effect on their properties like cellular permeability and that can be 
modified to add a fluorophore or affinity handle after incubation with whole cells. The 
most common tandem labeling strategy is appending an alkyne or an azide handle to the 
ABP structure. These ABPs can then be incubated with whole cells, labeling their targets, 
and an appropriate tag is attached by click chemistry after cell lysis using fluorophores or 
biotin with the complementary handle.54,55,59,60 
An additional variant in tagging consists in combining more than one type of tag in the 
ABP, creating the so-called “trifunctional” probes. These probes usually have a 
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fluorophore to provide an in-gel fluorescent signal and a biotin probe so that portions of 
the gel can be extracted, enriched and analyzed by mass spectrometry.61 
 
 
1.1.1.3. The Linker and/or Recognition Sequence 
 
The linker functions as a spacer between the reactive group and other probe elements. It 
can have a simple function of removing steric hindrance between other probe elements, 
but can also contribute to determine target specificity, in which case it can also be called 
a recognition sequence. Linkers can vary from simple alkyl chains to PEG polymers of 
varying lengths, peptidic chains and combinations of these elements (Figure 6). In some 
cases, the linker can be a protein domain or an entire substrate protein. However, in most 
cases where a peptidic sequence is used, a small peptide based on optimal protease 
substrate is sufficient.15 The incorporation of ubiquitin in ABP linkers has been used as a 
strategy to profile deubiquitinating enzymes, allowing isolation and identification of these 
enzymes, which are essential for the ubiquitin-proteasome pathway of protein turnover 






Figure 6 – Common linkers in ABPP: A. Alkyl linker; B. Peptidic linker (functions as a spacer but can also help 
define specificity of the probe); C. PEG linker. 
 
 
Focusing on the example of HNE, probe development has taken advantage of knowing 
the enzyme’s optimal substrates contain the peptide sequence Ala-Ala-Pro-Val.64 Target 
specificity can be hard to achieve even when knowing the optimal recognition sequences 
of specific enzymes since substrate preferences are often similar between related 
enzymes. The inclusion of non-natural aminoacids in peptidic linkers has proven to be 
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efficient in achieving selectivity between related enzymes. Kasperkiewicz and coworkers 
have established a protocol called Hybrid Combinatorial Substrate Library (HyCoSul) to 
determine protease substrate specificity for HNE, including more than 100 non-natural 
aminoacids in their library. Optimal aminoacid recognition for each position in the 
peptide sequence was determined and allowed the authors to obtain a substrate that was 
more selective for HNE when against related serine proteases like proteinase 3 (PR3).65 
A more functionalized strategy is the use of cleavable linkers. These linkers are stable in 
the conditions of proteome incubation but can be selectively cleaved by chemicals, light 
exposure, pH changes, enzymatic activity, among others.66,67 In standard ABPP 
experiments, after trypsin digestion, filtration of the tryptic peptides leads to the loss of 
the sequence that was directly labeled by the ABP, since it remains bound to the 
streptavidin beads. Cleavable linkers can be designed into ABPs and cleaved after avid-
enrichment of labeled proteins and trypsinization to release the ABP-modified peptides 
from the avidin beads. These can then be profiled to obtain direct information on the sites 
of probe binding.68 
A notable case is the incorporation of a tobacco etch virus (TEV) protease recognition 




Figure 7 – TEV-biotin linker/tag. The TEV cleavage site is labeled In red.7 
 
 
The incorporation of the TEV recognition sequence allows these peptides to be selectively 
eluted from the avidin beads and the LC-MS/MS analysis that follows provides 
information about the specific binding site of ABPs. Briefly, an alkynylated ABP is 
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incubated with the proteome and then click chemistry is used to append an azide with a 
biotin tag and the TEV cleavage site. Labeled proteins are subjected to the usual ABPP 
protocol involving enrichment and on-bead trypsin digestion. After elution of tryptic 
peptides by filtration the labeled peptides are eluted from the beads by incubating with 
TEV protease. This tandem orthogonal proteolysis (TOP) approach provides the identities 
of all probe-labeled proteins and their modification sites in a single experiment.7,69 
Weerapana and coworkers adapted this protocol into a quantitative analysis of cysteine 
reactivity, labeling 1,082 reactive cysteines, out of a total of 8,910 that existed on the 890 




1.1.2. Gel-based ABPP 
 
As previously noted, ABPP relies mostly on gel- and mass-spectrometry-based 
techniques for downstream analysis of probe-labeled proteins. Gel-based approaches are 
usually the first technique used to test labeling of proteins by ABPs. SDS-PAGE has been 
a standard technique in ABPP since its inception, allowing for rapid separation and 
visualization of ABP-labeled proteins.20,71  Application of SDS-PAGE allows up to 
hundreds of ABP-labeled proteomes to be quickly analyzed in a short period of time.42 
The necessary equipment to perform SDS-PAGE experiments is also more easily 
accessible and much less expensive than mass-spectrometry tools and equipment. 
Briefly, in a gel-based ABPP experiment using SDS-PAGE, a target proteome is labeled 
with a pre-determined concentration of ABP. A control where the proteome is incubated 
with an equivalent amount of DMSO is usually performed. After a set period of time, 
loading buffer is added to the sample, quenching the reaction and denaturing the proteins, 
while SDS non-specifically covers the surface of the peptides, assuring a constant charge 
to weight ratio, which guarantees that the proteins will be separated by molecular weight. 
The samples are loaded into the gel, together with a molecular weight marker, and run at 
constant voltage. After separation of proteins, several techniques can be used for analysis 
of the results. Analysis of in-gel fluorescence allows the direct readout of protein labeling 
as long as an appropriate fluorescently-labeled ABP was used. Other possibilities include 
coomassie staining and other protein staining methods, which result in total protein 
staining. Additionally, downstream analysis of specific proteins can be achieved by 
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western blot, and to identify labeled proteins gel bands can be excised, enriched with 
streptavidin, assuming a biotinylated probe was used, and analyzed by mass spectrometry 
for identification. The combination of gel-based techniques with mass-spectrometry-
based techniques, like Multidimensional Protein Identification Technology (MudPIT)-
ABPP, provides a very powerful platform for high-content functional proteomic 
analysis.42,72 
The limitations of SDS-PAGE are mostly associated with limited resolution and 
sensitivity. While the technique allows for a quick glimpse into proteome reactivity of a 
determined probe, proteins with similar molecular weight generate superimposed signals 
and low abundance proteins can provide signals below the method’s limit of detection or 
be occluded by higher abundance proteins that are also labeled.73 
Two-dimensional polyacrylamide gel electrophoresis is also a well-established technique 
in proteomics and allows proteins to be separated sequentially by their isoelectric point 
and molecular weight.19 
 
 
1.1.3. Mass Spectrometry-based ABPP 
 
Mass spectrometry is an essential technique in proteomics. It is unmatched in its ability 
to analyze complex mixtures of peptides and provide high-content quantitative 
information about complex biological samples. In mass-spectrometry based ABPP, 
peptide mixtures are usually obtained by proteolytic digestion of a protein mixture or 
proteome. Sample complexity can be simplified by running an SDS-PAGE of the mixture 
and fractioning the sample by excising different gel bands. As per ABPP definition, the 
complexity of the sample is usually reduced in the enrichment step of the protocol. The 
peptide sample is then fractioned in-line with the instrument by a one- or multi-
dimensional liquid chromatography separation system, commonly using a reverse-phase 
system that separates the peptide mixture by hydrophobicity prior to MS analysis. 
Introduction of the sample in the MS device is done by electrospray ionization and is 
concentration-dependent, meaning that peptides should be introduced in narrow peaks to 
improve detection limits. Application of a potential causes the sample solution to spray 
from the column into the mass spectrometer. Complex mixtures of peptides usually 
benefit from using a second dimension of separation to improve resolution. A strong 
cation exchange resin is a good choice to achieve this, since it can be packed together 
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with the reverse phase matrix and allows a two-dimensional separation to be achieved in 
a single column by using different buffers to gradually release fractions of peptides. The 
mass-to-charge ratios of the peptides are measured by MS and the molecular weight is 
determined on a first stage. The peptide ions are directed into a collision cell and 
fragmentation produces a tandem mass spectrum. These data are analyzed with an 
appropriate software, providing the peptide sequence, which is identified by comparison 
with a protein database.13,42,74 
In terms of protocol and sample preparation, a biotinylated probe is commonly used for 
labeling of the proteomes, but an alkynylated probe can also be used, with subsequent 
click reaction with biotin azide. Briefly, the technique involves the labeling of the target 
proteome with the probe for a predetermined time. The reactions are quenched by adding 
the mixture to cold methanol. The protein content of the samples is precipitated using a 
mixture of methanol, chloroform and PBS and the excess of probe is washed off. The 
proteins are denatured in the presence of urea and reduced using TCEP. Modification of 
reactive side chains is achieved by incubating with iodoacetamide. Labeled proteins are 
enriched with streptavidin and non-enriched proteins are washed off. The enriched 
proteins are trypsinized overnight. The tryptic peptides are sequenced in an LC-MS/MS 
equipment. A control should be prepared to be run simultaneously or separately, 
depending on the technique used. Processing of the data using appropriate software 
provides a list of engaged proteins. 
Quantitative mass spectrometry methods usually take advantage of analyzing multiple 
samples of differently labeled peptides, which allow relative quantification of one or 
several samples in comparison with a control sample. This can be achieved in a single 
experiment by using the so-called “heavy” and “light” samples. By modifying the 
peptides of either the experimental/treated sample or the control sample with heavy 
isotope-labeled reagents, one of them will present a consistent shift in the mass of all 
peptides, which will allow both samples to be run and analyzed simultaneously. Peptides 
coming from “heavy samples” will always have a mass shift when compared with the 
“light sample”, allowing for H/L or L/H ratios to be calculated, providing relative 
quantification data and eliminating the need for control probes or running the control 
separate to the treated sample. 
Several techniques are available to achieve this, including Isotope-coded affinity tag 




One of the first techniques introduced was ICAT, where identical tags with different mass 
are appended to peptides, allowing the differentiation of proteins from different samples 
at the MS1 level. Early ICAT tags had a iodoacetamide reactive group, a linker with light 
or heavy isotopes, and a biotin for affinity enrichment.75  
A different technique, ReDiMe, where labeling is performed by methylation of the N-
terminal of peptides using formaldehyde, leads to irreversible dimethylation of the 
peptide N-terminal, resulting in a molecular weight shift of +6 to all the peptides labeled 
with “heavy” formaldehyde (Figure 8 – A).76  
In SILAC, the isotopic labels are introduced during cell culture. Cells are grown in either 
heavy or light media, which contain “heavy” or “light” forms of specific aminoacids, 
which are incorporated into the cell’s proteins via the cell’s protein translation machinery, 
resulting in either heavy or light cells where all proteins contain these aminoacids. 
Peptides coming from the sample grown in “heavy media” will have a mass shift when 
compared with the ones grown in “light media” (Figure 8 – B).48 SILAC has advantages 
over ReDiMe, since the early introduction of the labels simplifies the protocol, reduces 
the number of samples and minimizes variability in sample preparation, despite requiring 
the preparation of SILAC cells, which is not possible in a lot of sample types.  
A more recent iteration of relative protein quantification in proteomics is TMT-labeling. 
The TMT-labeling procedure makes use of isobaric tags. These reagents are composed of 
a mass reporter, a mass normalizer and an amine-reactive group. The mass reporter and 
the mass normalizer have different distributions of stable isotopes, such that the mass of 
each tag is the same and the signal resulting from labeling of a protein with each different 
tag is the same in a MS1 spectrum, but able to be resolved in a MS2 spectrum. Since the 
different tags possess the same mass and similar chemical properties, it is ensured that 
peptides labeled with the same TMT tags will have similar chromatographic elution and 
ionization. This makes it so that multiple samples (up to 10 with 10plex TMT – Figure 8 
– C) can be labeled with different TMT-tags and analyzed in parallel in the same LC-
MS/MS run.77  
A detailed description of the methods of analysis of ABPP mass spectrometry data is out 
of the scope of this project. Nevertheless, a brief description of the process used for the 
processing of the proteomics data generated in this project is given here. After running 
the samples in the LC-MS/MS, protein identification and quantification and analysis were 
done with the Integrated Proteomics Pipeline-IP2. Spectrum raw files were extracted into 










A static modification to account for the isotopes introduced in SILAC or ReDiMe was 
specified. Quantification of light/heavy or heavy/light ratios was performed using 
software developed by the Cravatt Lab which reads raw chromatographic data in the 
mzXML format. Ion chromatograms are analyzed to identify target peptide m/z values 
for which both a light and heavy modification was identified. Candidate co-eluting pairs 
of MS1 peaks (light and heavy) are analyzed and the ratio of integrated peak area is 
calculated. The combined ratios for peptides belonging to a protein are grouped and the 
median value found is reported as the final ratio. A more detailed description of this 
process has been reported by Weerapana et al.9 
 
 
1.1.4. Competitive Activity-based Protein Profiling 
 
In many ABPP experiments where an alkyne derivative of a covalent inhibitor is used it 
is common to perform a competition experiment with the original inhibitor to demonstrate 
the blocking of probe labeling and prove that the probe and the inhibitor have similar 
reactivities. This approach has been adapted to the screening of libraries of compounds 
in a technique called competitive ABPP. The technique uses a broad reactivity probe for 
labeling of groups of enzymes, usually within the same family, and tests compounds for 
their ability to block labeling by the reactive probe.68 Briefly, whole cells or cell lysates 
are incubated with the compound and DMSO separately. After a pre-determined 
incubation time both samples are labeled with the same fluorescent or biotinylated probe. 
The samples are run in SDS-PAGE or LC-MS/MS and the protein profiles are compared 
between the control and the compound-treated sample. If a target enzyme’s active site is 
covalently inhibited by the tested compound, labeling by the probe is blocked and the 
specific signal for that protein will be absent when compared with the control (Figure 
9).78 In mass-spectrometry-based competitive ABPP, the labeled proteins can be directly 
identified and information regarding target occupancy can also be inferred. 
Competitive ABPP allows the application of ABPP techniques to non-probe compounds 
and can be performed for preliminary screening of large libraries, generating quick data 
on compound reactivity, potency, selectivity and allowing the calculation of parameters 
like IC50, even for uncharacterized enzymes. The pool of analyzable targets will, however, 






Figure 9 – Competitive ABPP Workflow. Separate samples are prepared for DMSO (control) and compound 
treatment. The compound will label its targets in the proteome. Both samples are then labeled with an appropriate 
broad reactivity ABP. The results can be read by SDS-PAGE (fluorescent ABP) or mass spectrometry (biotinylated 
ABP). If an enzyme is a target of the compound being tested the signal corresponding to this enzyme will be absent 
or attenuated when compared with the DMSO control. 
 
 
probes with good coverage of high occupancy targets are required. Commonly used ABPs 
for competitive ABPP include the FP probes for serine hydrolases17,79 and iodoacetamide 
probes for reactive cysteine residues.9,80 An ideal competitive ABPP assay should use a 
probe or a combination of probes that covers the largest percentage of engageable targets 
of interest possible.  
A derivative of the competitive ABPP platforms is Fluopol-ABPP which allows an 
enzyme to be screened in vitro for compounds that bind to it. ABPP-Fluopol provides a 
signal in the form of light polarization, which can be associated with the size of the 
complexes formed after the reaction of a fluorescent ABP and a target enzyme. In this 
technique, a target enzyme is incubated with a library of inhibitors for a pre-determined 
period and then the fluorescent probe is added to the reaction. When excited with plane-
polarized light, light emission from the fluorophore is parallel to the excitation plane, 
which can be altered by the rotation of the structure containing the fluorophore. A probe 
that reacted with an enzyme will have slower rotation and emit polarized light. On the 
other hand, if a library inhibitor is very potent and fully inhibits the enzyme, probe 
labeling will be blocked and the free probe will have faster rotation and emit depolarized 
light. Evaluation of light polarization can then be associated with inhibitor potency. The 
technique is compatible with high throughput screening and can be easily adapted to 
different enzyme classes, as long as the pure target enzyme is available. Bachovchin et 
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al. used ABPP-Fluopol to discover selective inhibitors for the enzymes retinoblastoma-
binding protein-9 and glutathione S-transferase omega 1.51 Knuckley and coworkers 
developed a high throughput screening based on Fluopol-ABPP to identify protein 
arginine deiminase isozyme-selective inhibitors, with 10 successful hits, including a 










The serine hydrolases are one of the most well-studied classes of enzymes by ABPP, 
comprising over 200 enzymes and 1% of the proteome. Approximately half of these are 
the serine proteases, with the other half being the “metabolic serine hydrolases”.82,83 
Among them we find several enzyme types, including lipases, esterases, thioesterases, 
amidases, peptidases and proteases.84 
They play vital roles in numerous processes in human biology, including digestion, 
coagulation, inflammation, peptide processing, immunoregulation, reproduction, among 
others.17,84 Disfunctions in their behavior are therefore responsible for numerous 
pathologies, including cancer, hemorrhagic disorders, chronic obstructive pulmonary 
disease (COPD) and many others, while also being involved in processes like pathogen 
infection and drug resistance.82 These factors make them attractive targets for the 
development of inhibitors and drugs, with some serine hydrolase inhibitors being 
approved for the treatment of diseases like Alzheimer’s (acetylcholinesterase), type 2 
diabetes (DPP4), obesity (pancreatic and gastric lipases) and thrombosis (thrombin and 
factor Xa).84 
The defining characteristic of this enzyme family is the catalytic serine residue that is 
used to cleave their substrates.82 The general mechanism involves the activation of the 
hydroxyl group in the serine residue, assisted by additional active site residues, typically 
histidine and aspartic acid, but with other possible variations. Additionally, the existence 
of an oxyanion hole, formed by other surrounding aminoacid side-chains, assists the 










hydroxyl attack on the substrate.85 The nucleophilic hydroxyl of the catalytic serine 
residue attacks an electrophilic moiety of the substrate, forming an acyl-enzyme 
intermediate. Water-induced saponification of the product regenerates the enzyme active 
site for the next catalytic cycle (Scheme 1).82 
Several chemotypes have been used for serine hydrolase labeling in ABPP.43 The shared 
catalytic mechanism dependent on a highly nucleophilic serine residue makes serine 
hydrolases susceptible to irreversible inhibition by reagents like fluorophosphonate (FP), 
the most common reactive group for serine hydrolase ABPP.17,83 Additional examples are 
presented in Figure 10 and include diphenyl phosphonates,86 diphenyl 
phosphoramidates,87 β-Lactams,88-90 β-Lactones,91,92 sulfonyl fluorides,93,94 coumarins 










FP probes have had broad application in ABPP experiments of the serine hydrolase family 
of enzymes and supported most of the ABPP studies performed for this family of enzymes 
in complex proteomes.99 Liu et al. reported the profiling of serine hydrolases using an 
FP-biotin probe (Figure 11). The FP-Biotin probe was first tested with fatty acid amide 
hydrolase (FAAH), behaving as a potent irreversible inhibitor of the enzyme and tagging 
only its active form. Overall, the FP probe was shown to efficiently label serine 
hydrolases in crude cell and tissue samples, allowing differences in the enzymes’ 
functional states to be identified, even when enzymatic activity varied with no correlation 





Figure 11 – FP-Biotin ABP. 
 
 
Kidd et al. showed that the nature of the linker between the FP reactive group and the 
biotin tag had little to no influence on the reaction of FP with serine hydrolases, except 
for select proteins like FAAH, which reacts faster with a FP probe containing an alkyl 
linker. The optimal concentrations of probe to achieve the best specific to nonspecific 
proteome reactivity were determined to be between 4 and 8 µM and the optimal pH was 
determined to be around 8, with significant increase of nonspecific reactivity at pH 9. The 
probes were shown to efficiently label membrane proteins, which are typically harder to 
profile by conventional methods.79 
Some of the first examples of the use of ABPP in the serine hydrolase superfamily were 
related to the study of cancer. Jessani et al. used FP probes to study the serine hydrolase 
dynamics across human breast and melanoma cell lines with differences in hormone 
responsiveness, invasiveness, and metastatic potential, fractioning the proteomes into 
secreted, membrane and soluble protein fractions. The resulting serine hydrolase activity 
profiles allowed different cancer types to be clustered into subtypes according to 
properties like tissue of origin and invasiveness.25 The authors also studied the enzymatic 
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activities of serine hydrolases in the process of breast tumor growth in vivo. The objective 
was to identify the differences between human breast cancer line MDA-MB-231 in vitro 
and in xenografts in immunodeficient mice. While several serine hydrolases were shown 
to be similarly expressed in both systems, several others were shown to be expressed 
exclusively in xenografts, potentially due to host factors, which induce alterations in the 
proteomic expression pattern, as confirmed by the identification of mouse serine 
hydrolases in the samples. This work supported the fact that experiments using human 
cancer cell lines provide results that are not always representative of in vivo tumor 
properties like proliferation, invasiveness, and drug sensitivity.100  
Nomura et al. used FP to perform a functional proteomic analysis of aggressive and 
nonaggressive human cancer cell lines, identifying neutral cholesterol ester hydrolase 
(1KIAA1363) and monoacylglycerol lipase (MAGL) to be consistently elevated in 
aggressive cancer cell lines, suggesting a role of these enzymes in cancer aggressiveness. 
The work unveiled a MAGL-dependent pathway that regulates free fatty acid levels in 
cancer cells, which is associated with migration, survival, and in vivo tumor growth.101 
These approaches focused mostly on gel-based assays, but ABPP truly excels at providing 
functional information on enzyme families when these are combined with mass-
spectrometry techniques. An integrated strategy for profiling of serine hydrolase activities 
in cancer was described by Jessani et al. On a first phase, 33 primary breast tumor samples 
were characterized and split into classes based on their serine hydrolase activity profiles 
obtained through one-dimensional electrophoresis. A second phase using ABPP-MudPIT 
provided a complete in-depth analysis of the serine hydrolase activities in these samples. 
Over 50 serine hydrolase activities were identified, including proteases, lipases, esterases 
and numerous uncharacterized enzymes. fibroblast activation protein (FAP), platelet-
activating factor acetylhydrolase 2 (PAFAH2) and KIAA1363 were found among the 
enzymes that were elevated in ER(-)/PR(-) cancers.42 Madsen et al. determined that 
urokinase-type plasminogen activator is a determinant enzyme in tumor cell entry into 
the vasculature, one of the earliest steps in metastasis, by applying serine hydrolase 
targeting probes in high disseminating and low disseminating human fibrosarcoma cell 
lines. The low disseminating cells were shown to contain abundant amounts of inactive 
enzyme, highlighting that the active enzyme state is necessary for the high disseminating 
characteristic.102 
ABPP was also applied in the characterization of brain enzymes responsible for the 
hydrolysis of 2-arachidonoylglycerol (2-AG), a ligand for cannabinoid receptors, after 
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the observation that upon FP probe treatment, the hydrolysis of this molecule was halted. 
Among the identified targets were MAGL, α/β hydrolase domain fold family protein 6 
(ABHD6) and α/β hydrolase domain fold family protein 12 (ABHD12).103 Viader and 
coworkers used ABPP to map serine hydrolase dynamics across different mouse brain 
cell types, detecting a large number of enzymatic activities that varied between cell types, 
including the enzymes that regulate 2-AG metabolism in microglia, ABHD12 and 
diacylglycerol lipase β.104 
ABPP has also been used to clarify the specific roles of some serine hydrolases. Diphenyl 
phosphonate ABPs were used to clarify the roles of granzymes A and B in cytotoxic 
lymphocyte-mediated cell death. The results suggested that granzyme B plays a major 
role in lymphocyte-mediated lysis of targeted cells. This study provided information that 
could not be obtained from conventional genetic or biochemical experiments.105 
In the field of infection and microbiology, ABPs based on 4-membered ring chemotypes 
like β-Lactams have been extensively used for the study of bacterial pathogenesis.106,107 
Even before the ABPP concept had been established, Dargis and Malouin developed the 
first biotinylated β-Lactams (Figure 12 – A), to more easily characterize and purify 
penicillin binding proteins (PBPs) in bacteria.108 PBP labeling was traditionally done with 
isotope-labeled penicillin. Zhao and coworkers introduced the use of Bocillin-FL (Figure 
12 – B), which consisted of penicillin V with an appended BODIPY tag, as a reagent for 
quick visualization of nanogram amounts of PBPs.109 
Staub and Sieber developed a library of alkyne probes based on the β-Lactam structure. 
The β-Lactam chemotype was appended with a short alkyne handle, different side chains 
and modifications of the amide by sulfonylation or acylation to provide chemical 
variability. Well-established antibiotics were also derivatized with an alkyne handle, 
including aztreonam, ampicillin and cephalosporin (Figure 12 – C). Labeling of P. putida 
with the antibiotic probes showed high specificity and significantly different target 
profiles. Target deconvolution by LC-MS revealed labeling of several PBPs. The 
synthetic β-Lactam probes did not label PBPs, but instead targeted other proteins like 
virulence factors. Targeting these molecules was envisaged as a potential new strategy 
for treatment of bacterial infections.89 In a follow-up work with S. aureus and methicillin-
Resistant S. Aureus (MRSA), a subset of the best compounds identified 5 enzymatic 
activities unique to MRSA, suggesting they may be relevant for resistance development.88 
β-Lactones have also been extensively studied in ABPP and found to be efficient 
inhibitors of crucial virulence factors. Examples of β-Lactone probes are showed in 
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Figure 12 – D. These experiments also guided the development of novel inhibitors which 
showed promise in the treatment of resistant strains and helped identifying enzymes that 
are active in dormant states of pathogens like Mycobacterium bovis.60,91,110-112 β-sultams 
were also studied in ABPP (Figure 12 – E), revealing the modification of internal 






Figure 12 – ABPs based on β-Lactam, β-Lactone and β-Sultam reactive groups. 
 
 
Another notable example of FP use was the characterization of active enzymes in both 
active and persistent Mycobacterium tuberculosis. The study identified enzymes that 
remain active in persistent states and that could potentially be therapeutically targeted to 
eliminate resistant forms of the disease.114 FP was also used in numerous other studies 
that helped characterize serine hydrolase dynamics in Mycobacterium tuberculosis.115-119 
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Additional examples include the use of ethyl-p-nitrophenyl phosphonates to profile 
lipolytic enzymes and esterases and FP probes for the study of rhomboid proteins.95,120-
124 
Competitive ABPP has also greatly contributed to the study of serine hydrolases and the 
discovery of new inhibitors. Li et al. used a competitive ABPP platform to develop 
inhibitors for the enzyme ABHD6, which was uncharacterized at the time. The ABPP 
approach allowed a small library of carbamate inhibitors to be screened for the enzyme 
and also guided the optimization of the best hit into a potent and selective ABHD6 
inhibitor.125 Competitive ABPP was also used to assess the targets of a compound 
containing a piperidine/piperazine urea group as the electrophilic reactive group, 
revealing that the compound is highly selective for FAAH, with no detectable activity 
against other serine hydrolases, a particular reactivity profile which was attributed to the 
high chemical stability of the urea and FAAH’s ability to hydrolyze C(O)-N bonds.126 In 
a follow up work a FP-based competitive ABPP protocol was used to guide medicinal 
chemistry optimization of dual FAAH/MAGL inhibitors based on the N-substituted 
piperazine carbamate scaffold, which resulted in inhibition of the hydrolysis of the 
substrates of these enzymes, anandamide and 2-AG, allowing the study of the impact of 
elevations in these endocannabinoids.127 
A modified approach where, instead of the blockade of probe labeling, the slowing down 
of the rate of probe reaction is measured at a kinetically relevant time point, has also 
allowed the competitive ABPP technique to be applied to reversible inhibitors and led to 
the discovery of inhibitors for enzymes like FAAH, triacylglycerol hydrolase and 
KIAA1363.128 The uncharacterized enzyme KIAA1363’s role in lipid signaling pathways 
was later uncovered through a multidimensional platform that included competitive 
ABPP.129 
Despite being one of the most well-studied families of enzymes by ABPP, it was reported 
in an excellent review by Simon and Cravatt in 2010 that nearly half of the human 
metabolic serine hydrolases remain uncharacterized in terms of their substrates and 
functions.83 Considering the importance of the currently annotated serine hydrolases and 
the magnitude of impactful discoveries made by ABPP of serine hydrolases that were 
described in this section, we can deduce that non-annotated serine hydrolase surely have 
similar vital roles in human biology and can be an important source of new targets for 




1.2.1. Target Enzymes for Present Work 
 
In this work we focused our attention on a small group of serine hydrolases, which 
included known targets of our 4-membered ring chemotypes, like HNE, and additional 
serine hydrolase families like α/β hydrolase domain fold (ABHD) and dipeptidyl 
peptidase (DPP) enzymes that were discovered as targets of 4-Oxo-β-Lactams by ABPP-
MudPIT through the course of the project. Herein we describe relevant information 
regarding these enzymes, focusing on HNE, the model enzyme for the development of 
our libraries, and members of the DPP and ABHD families of serine hydrolases. 
 
 
1.2.1.1. Human Neutrophil Elastase and Chronic Obstructive Pulmonary Disease 
 
HNE is a neutrophil serine protease. Neutrophils are important effectors of the immune 
system and participate in the first line of host defense against invading pathogens using a 
combination of oxidative and non-oxidative mechanisms and mediating the link between 
the innate and adaptive arms of the immune response. Microorganisms are engulfed by 
neutrophils via phagocytosis, a process which activates the membrane-bound NADPH 
oxidase system. This system produces reactive oxygen species (ROS), which directly kill 
microorganisms, constituting the oxidative mechanism of neutrophil action. The non-
oxidative pathway involves fusion of neutrophil granules with the phagolysosome, 
releasing antimicrobial peptides and neutrophil proteases into it.130 The most commonly 
described neutrophil serine proteases are HNE, PR3 and cathepsin G. More recently, an 
additional member, neutrophil serine proteinase 4, has been described.131,132 
HNE is a basic single-chain glycoprotein with 218 aminoacids and approximately 25 kDa 
in size. It contains four intramolecular disulfide bridges and two asparaginyl N-linked 
carbohydrate side chains, resulting in different isoforms. The catalytic triad is composed 
of serine, histidine and aspartate, which come together at the catalytic center. Like for 
other serine hydrolases, catalysis involves proton transfer between the catalytic triad and 
allows serine to become a highly reactive nucleophile and attack an electrophilic moiety 
in the target.133 
HNE’s activity is tightly regulated both at the synthetic level during transcription and at 
and at the post-translational level before being stored in the azurophilic granules of 
neutrophils in its active form due to its destructive potential for biological tissues.134 HNE 
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also associates with the nuclear envelope. Activation of neutrophils leads to mobilization 
of neutrophil serine proteases and secretion into the extracellular medium. A fraction of 
the expelled serine proteases associates with the cellular membrane.135,136 Neutrophil 
activation leads to a significant increase of membrane-bound HNE.137 Previous studies 
have shown that structures of high HNE concentration upon neutrophil activation can 
contain HNE that is mostly in an inactive state.65 
The S1 pocket in HNE is hemispherical and hydrophobic and its substrate preference has 
been well studied.65 The pocket preferentially accommodates small hydrophobic residues, 
with the same happening for PR3, which has a smaller active site.64,138-140 The preferences 
for the additional subsites of HNE using both natural and non-natural aminoacids have 
also been determined and are discussed in more detail in section 1.2.1.1.1.65 
The proteolytic activity of HNE is tightly controlled by several endogenous inhibitors to 
avoid excessive destruction of connective tissue proteins like elastin, collagen and 
proteoglycans. The most commonly referenced inhibitor is alpha-1-antitrypsin. Its 
primary function is to protect lung parenchyma against destruction by neutrophil serine 
proteases. It acts by irreversible inhibition using a suicide substrate inhibition mechanism 
that alters HNE’s active site into a non-functional state. Other HNE endogenous inhibitors 
include SerpinB1, the recombinant form of PI9, elafin and secretory leukocyte protease 
inhibitor (SLPI), which acts by a reversible mechanism.134,141 
HNE-associated pathogenesis is usually related with an imbalance between protease and 
antiprotease activity, which is required for lung tissue homeostasis. In persistent 
inflammatory states, the balance is shifted towards the protease side and the inflammatory 
process becomes self-sustained, leading to tissue injury.  
Our main interest in studying HNE is its role in the development of COPD.142 Other HNE-
related lung pathologies include cystic fibrosis, acute lung injury and acute respiratory 
distress syndrome which are mostly caused by trauma, sepsis and pneumonia, and are 
associated with massive accumulation of neutrophils in the lung.143 HNE’s role in cancer 
development is also well established.144,145 
COPD describes a broad syndrome that encompasses a group of diseases, including 
chronic bronchitis and emphysema, that cause progressive and non-reversible limitation 
of lung airflow. The chronic bronchitis component is associated with persistent 
productive cough and obstruction of small airways, while emphysema stems from loss of 
lung elasticity, destruction of lung parenchyma and enlargement of air spaces.146,147 
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The disease is mainly caused by prolonged exposure to cigarette smoke but other factors 
include occupational and environmental toxins and air pollutants, recurrent 
bronchopulmonary infections, history of tuberculosis and asthma, airway hyper-
responsiveness and genetic factors like deficiency in alpha-1-antitrypsin.148-151  
Neutrophil migrate to the site of inflammation to neutralize the external aggression and 
externalize serine proteases like HNE.149,150 These enzymes are clinically relevant for 
disease initiation and progress.142,152 When the external aggression is persistent the 
inflammatory process becomes self-sustained and an imbalance between HNE and its 
endogenous inhibitors may occur. The excessive activity of HNE leads to an increase in 
elastin degradation, which causes loss of elasticity of lung tissue and limitations in the 
tissue’s ability to expand and contract. Furthermore, the sustained inflammation, 
associated with T cell release of granzyme B and perforins, leads to an increase in 
pneumocyte apoptosis. The replacement of these native lung tissues with fibrous tissue 
hinders the breathing process and eventually causes emphysema when small airway walls 
collapse for not being able to withstand lung expansion during inhalation. The chronic 
bronchitis component is associated with chronic irritation that leads to failure of the 
mucociliary system due to cellular atrophy and decrease in ciliated cell number and 
length. Furthermore, alterations in the number and function of secretory cells, including 
enlargement of mucous glands and hyperplasia of goblet cells in the airways lead to 
overproduction of mucus. The failure of clearance mechanisms leads to accumulation of 
the secretions, which cause airway obstruction and potentiate the development of bacteria 








1.2.1.1.1. Human Neutrophil Elastase Inhibitors 
 
Despite the high amount of research put into developing HNE inhibitors, Sivelestat or 
ONO-5046 (Scheme 2) is the only elastase inhibitor to ever reach the market (Ono 
Pharmaceutical).160,161 
HNE inhibitors usually fall into 4 categories: acylating-enzyme inhibitors, mechanism-
based inhibitors, transition-state analogs, and noncovalent inhibitors.142 
The mechanism of HNE inhibitors usually involves taking advantage of the nucleophilic 
character of the active site serine and inducing its attack on a substrate which results in a 
stable adduct. The attack of the serine on a nucleophilic moiety of the inhibitor leads to 
the formation of a tetrahedral intermediate. This intermediate can be stabilized by 
hydrogen bonding with NH groups of the enzyme’s oxyanion hole to promote a more 
stable inhibition or be hydrolyzed and regenerate the enzyme’s active site. The 
intermediate can also collapse, displacing a leaving group and resulting in a covalently 
modified active site. Furthermore, bulky hydrophobic substituents can help prevent 
hydrolysis of the inhibitor from the active site. These factors influence the reversibility 
of the inhibition process and if the tetrahedral intermediate is stable enough the enzyme 
can be considered irreversibly inhibited.142 
ONO-5046 is an example of an acylating agent, with an IC50 of 44 nM and Ki of 0.2 µM. 
Its mechanism is reversible, which could account for its higher safety when compared to 
other inhibitors (Scheme 2). 
Among the acylating agents we find several types of inhibitors based on 4-membered 
rings. β-Lactams have been extensively used in Medicinal Chemistry, particularly due to 
their importance in antibiotic development.106,162,163 β-Lactams were first derivatized into 
HNE inhibitors by Merck in 1986, with the major modification from a traditional 
cephalosporin antibiotic being the conversion of the ionizable carboxylate group from 
position 4 into an amide or ester. This preference for non-ionic moieties is consistent with 
the function of HNE in cleaving peptide linkages between non-ionic aminoacids.164 
Inhibition was shown to depend on the attack of the serine to the β-Lactam ring and 
formation of a tetrahedral intermediate. The collapse of the intermediate is facilitated by 
the presence of a leaving group and leads to the opening of the β-Lactam ring, potentially 
generating a secondary electrophilic moiety that would allow for a suicidal inhibition 





Scheme 2 – ONO-5046 (Sivelestat) and its mechanism of HNE inhibition. Adapted from Lucas et al.142 
 
 
functionally irreversible inhibitors, since the recovery of HNE activity after inactivation 
is slow.165 Additional experiments found monocyclic β-Lactams to be remarkably potent, 
selective and orally active as HNE inhibitors (Figure 14 – A).166 Moreira’s group also 
developed β-Lactams as suicide inhibitors of HNE. Clemente et al. reasoned that adapting 
the leaving group strategy to β-Lactams could lead to development of suicide inhibitors 
of HNE and developed C-3 and C-4 substituted N-acyloxymethyl and N-
aminocarbonyloxymethyl-2-azetidinones (Figure 14 – B).167 Since β-Lactam reactivity is 
dependent on how good the amine leaving group formed from tetrahedral intermediate 
decomposition is, the group performed additional testing, obtaining good results with a 
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oxazolidin-2,4-dione moiety on the leaving group and with electron withdrawing 
substituents at position 4 (Figure 14 – C).168  
Other 4-membered rings that were developed for HNE inhibition include β-sultams. 
Inhibition by β-sultams is hindered by the fact that sulfonyl derivatives are less reactive 
than their acyl counterpart, but efficient inhibitors were developed from N-aryl β-
sultams.169 Additional 4-membered ring scaffolds include the 3-Oxo-β-Sultams, 
developed as HNE inhibitors by the Page Lab,170 and 4-Oxo-β-Lactams developed by 
Moreira’s Lab.171,172 These scaffolds will be the basis for our project and will be discussed 
in detail in the following sections (see section 1.3.1. for 3-Oxo-β-Sultams and section 





Figure 14 – Examples of HNE Inhibitors based on the β-Lactam scaffold. 
 
 
Bicyclic pyrrolidine trans-lactams were also developed, with some compounds being 
reported to be potent, selective, and to have prolonged pharmacodynamic and acceptable 
clearance rates in animal models.173 
The concept of transition-state analogs involves the replication of van der Waals 
interactions and molecular electrostatic potential surfaces as close as possible to those 
that stabilize the transition state of a given enzyme.174 An example of these compounds 
is ONO-6818 (Figure 15 – A), disclosed as a promising therapeutic agent to treat HNE-
related inflammation. The compound was shown to react with the catalytic serine of 
porcine pancreatic elastase (PPE) and result in a stable, tetrahedral, hemiketal adduct, 
with the oxygen anion stabilized by hydrogen bonds to the backbone amide N-H of both 
Ser-195 and Gly-193. An alternative strategy to increase inhibitor residence time in the 
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lungs was developed by Guarnieri et al., who linked an HNE inhibitor to a fragment of a 
lung surfactant molecule.175 
Mechanism-based inhibitors are designed to take advantage of the nucleophilic attack of 
the catalytic machinery of the target enzyme to induce a structural change in the inhibitor 
that generates a highly reactive electrophilic group, which is able to react with the enzyme 
a second time, rendering the enzyme irreversibly inhibited. Upon formation of the 
tetrahedral intermediate after attack of the catalytic serine, the intermediate can either be 
hydrolyzed and regenerate the active enzyme or the suicidal mechanism occurs.176 Some 
mechanism-based HNE inhibitors were based on the saccharin moiety. In the example 
shown in Scheme 3, attack of the serine to the acyl center of the saccharin core leads to 
formation of a tetrahedral intermediate that, upon collapsing, induces the departure of a 
leaving group and formation of a sulfonyl imine, which is subsequently engaged via 
Michael addition by an active site histidine residue. The Groutas lab has done extensive 
work with 1,2,5-thiadiazolidin-3-one 1,1-dioxide compounds (Figure 15 – B), achieving 
potent and selective HNE inhibitors.177,178 
Natural products are an important source for therapeutic molecules and have been 
explored to develop HNE inhibitors. Most reported inhibitors usually don’t go below 
micromolar potency and a better use of natural products for HNE inhibitor development 










An example is the discovery of cyclic peptidic inhibitors, lyngbyastatins (Figure 15 – C), 
isolated from marine cyanobacteria which showed low nanomolar IC50s against PPE.
179 
Non-covalent inhibitors are also described for HNE, including the C-shaped aurones 
(Figure 15 – D) developed in our lab, for which the c-shape seems to promote an induced 





Figure 15 – HNE Inhibitors; A. ONO-6818, a transition state analog; B. 1,2,5-thiadiazolidin-3-one 1,1-dioxide 
compounds, mechanism-based inhibitors; C. Lyngbyastatin 7, a natural product-derived HNE inhibitor; D. “C-
shaped” aurones, non-covalent inhibitor. 
 
 
1.2.1.1.2. Activity-based Probes targeting Human Neutrophil Elastase 
 
Our proposal for ABP synthesis and application was driven towards the targeting of HNE. 
In this section a summary of the currently existing HNE-targeting ABPs is presented, 
together with examples of their applications. 
One of the first reports of the applications of ABPs in HNE was done by Gilmore et al., 
who described the solid-phase synthesis of diphosphonate probes for serine proteases, 
including elastase-like enzymes. The ABPs comprised a diphenyl phosphonate reactive 
group attached to either a fluorophore or biotin via a linker like PEG (Figure 16 – A). The 
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probes detected HNE down to a 32 ng amount of enzyme. The labeling was shown to be 
dependent on the active state of the catalytic serine residue.86 
One of the limits of ABP synthesis for a particular enzyme is the fact that a lot of times 
probe interaction with the target is limited to a strong P1 interaction, while other exosites, 
when existent, might be hard to reach.181 Exploiting distant exosites in HNE could result 
in inhibitors with improved potency and selectivity. Kasperkiewicz et al. designed an 
ultrasensitive ABP for HNE based on the development of optimal and highly selective 
HNE substrates, which include non-natural aminoacids, by a process the authors call 
HyCoSuL. This strategy uses the tetrapeptide Ala-Ala-Pro-Val, which is routinely used 
for HNE, as a starting point. The optimal aminoacids for each subsite P1-P4 are then 
individually determined, in order to establish the best tetrapeptide for HNE inhibition. 
The optimal aminoacids were found to be Abu for P1, octahydro-1H-indole-2-carboxylic 
acid (Oic) for P2, methionine dioxide for P3 and 6-benzyloxy-L-norleucine at P4. The 
optimal peptide Ac-Nle(O-Bzl)-Met(O)2-Oic-Abu-ACC was determined to be more than 
7000 times better hydrolyzed by HNE than the commonly used commercial peptide Ac-
Ala-Ala-Pro-Val-ACC. Cleavage of the optimal tetrapeptide by HNE is also 900 times 
more efficient than cleavage by PR3, a closely related serine protease with similar 
substrate preference which is frequently also potently inhibited by HNE inhibitors. The 
optimal tetrapeptide was adapted with a PEG linker, a biotin tag and a phosphonate 
reactive group to generate an ABP (Figure 16 – B). The ABP labeled both HNE and PR3, 
with preference for HNE. The ABP was tested on induced neutrophil extracellular traps 
(NETs), showing that proteolytic activity was concentrated in perinuclear punctate 
structures and not in induced NETs. Overall, this work helped determine key features of 
substrate recognition by HNE that can provide selectivity against related enzymes for 
which selectivity is usually hard to achieve. Furthermore, the results concerning HNE 
inactivity in neutrophil NETs also created new questions concerning HNE’s role in the 
inflammatory process associated with these structures and emphasize the importance of 
developing new HNE ABPs.181 
Grzywa et al. also took advantage of peptidic linkers to design HNE-directed ABPs, 
containing aromatic esters of 1-aminophosphonic acids as reactive groups, which are well 
known potent and selective inhibitors of serine proteases. Kinetic studies showed that an 
ABP with the peptidyl chain Val-Pro-Ala (Figure 16 – C) is selective for elastase, being 
inactive against PR3 and cathepsin G. When used as ABPs however, most compounds 
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didn’t show good specificity or selectivity, providing similar signals for HNE, PR3 and 
CatG.182 
Preliminary work was made with 4-Oxo-β-Lactam ABPs to probe HNE related 
proteomes. The 4-Oxo-β-Lactam was derivatized through copper-catalyzed azide-alkyne 
cyclocondensation (CuAAC) (Figure 16 – D) and the resulting compounds showed low 
nanomolar IC50 values. Despite the small and highly reactive group, the compounds 
showed a good biochemical selectivity profile against related proteases. An alkyne 
derivative presented an IC50 of 82 nM, which makes it potentially suitable for 
biorthogonal experiments. Incubation with neutrophils and fluorescence microscopy 
revealed probe internalization, a possible advantage over the use of some peptide-based 
ABPs.183 
Edington-Mitchel and co-workers designed fluorescent diphenylphosphonate-based 
probes (Figure 16 – E), Cy5-PK-DPhPh and Cy5-Val-DPhPh, to detect serine proteases. 
Cy5-V-DPhPh strongly labeled HNE and, to a lesser extent, PR3. When applied in mouse 
bone-marrow cells, Cy5-V-DPhPh labeled HNE at 10 µM concentration, while 
simultaneously binding an additional high molecular weight protein.184 Schulz-Fincke 
and coworkers developed an HNE ABP using a α-aminoalkylphosphonate reactive group 
with two aryloxy groups. A peptidic backbone linker, Val-Pro-Val, was used as a 
recognition sequence (Figure 16 – F). Application of the compound with HNE and 
analysis by SDS-PAGE revealed labeling of characteristic HNE bands around 29kDa and 
a competition experiment with sivelestat showed that the mechanism is dependent on the 
enzyme’s active site.185 In a follow-up work, the authors developed an HNE ABP based 
on the sulfonyloxyphthalimide reactive group (Figure 16 – G). Upon engagement of the 
reactive group by the enzyme and opening of the heterocyclic ring, a Lossen 
rearrangement leads to the formation of an isocyanate, which can also be engaged by the 
enzyme, leaving it permanently inhibited. The inhibitors were highly potent, with low 
nanomolar Ki values. Selectivity assays showed strong preference of the ABP for HNE 
inhibition.186 
Liu and coworkers sought to improve HNE detection in living systems to better 
understand the pathways involved with HNE’s destructive role in lung diseases by 
developing a small-molecule-based near-infrared fluorogenic probe for HNE (Figure 16 







Figure 16 – ABPs for HNE (reactive groups are highlighted in red): A. Diphenyl phosphonate ABP developed by 
Gilmore et al.; B. ABPs based on the optimized tetrapeptides generated by the HyCoSul strategy by Kasperkiewicz et 
al.; C. Peptidic ABP developed by Grzywa et al.; D. 4-Oxo-β-Lactam ABPs developed by Ruivo et a; E. 
Diphenylphosphonate ABPs developed by Edington-Mitchel et al.; F. Peptidic ABP developed by Schulz-Fincke et 
al. G. ABP developed by Schulz-Fincke and coworkers based on a suicide inhibition mechanism dependent on a 




Overall, these existing studies have provided valuable ABPs which seem to be suited for 
HNE labeling, some of them even when in the presence of a complete proteome. Despite 
this, the application of these ABPs was limited to gel-based assays for all the described 
studies, with no mass-spectrometry-based ABPP experiments performed in any of the 
studies. Target identification with mass spectrometry techniques should be used to 
support gel-based assays whenever possible since, among other reasons, in the case of 
HNE, co-migration of the enzyme is expected to happen with related enzymes like PR3, 
which shares a very similar molecular weight and substrate specificity. 
 
 
1.2.1.2. DPP Family of Serine Hydrolases – DPP4, DPP8, DPP9, FAP and PREP 
 
 
The members of the DPP family are N-terminal dipeptide postproline-cleaving serine 
proteases. Among them we find dipeptidyl peptidase 4 (DPP4), dipeptidyl peptidase 7 
(DPP7), dipeptidyl peptidase 8 (DPP8), dipeptidyl peptidase 9 (DPP9), FAP and prolyl 
endopeptidase (PREP) (Figure 17).188 The DPP family proteins have a crucial role in the 
cytoplasmic degradation of proline containing peptides due to their ability to cleave N-
terminal dipeptides from peptides containing proline at the second to last position (Xaa-
Pro). The proteasome is the entity responsible for the degradation of most cellular proteins 
but the outcome of the process results in short peptides, which are then degraded by 
cytosolic peptidases for general cell housekeeping, aminoacid recycling and for antigen 
presentation by the major histocompatibility complex (MHC) class I.189 These peptidases 
struggle with proline containing peptides due to the conformational rigidity of proline’s 
pyrrolidine ring. Among the DPP family members capable of cleaving these problematic 
peptides we find DPP4, FAP, DPP8 and DPP9. These enzymes are also associated with 
cell-extracellular matrix interaction, cell adhesion, migration and apoptosis.190 
The DPP family of serine hydrolases gained notoriety due to the emergence of DPP4 
inhibitors as an oral treatment for type 2 diabetes.191 DPP4 plays an important role in 
glucose homeostasis by controlling gastrointestinal incretin hormones. The enzyme 
regulates the endogenous levels of glucagon-like peptide-1 (GLP-1), a gastrointestinal 
hormone which increases its levels in plasma after food intake. GLP-1 promotes insulin 
secretion, insulin sensitivity and β-cell proliferation. DPP4 is also described to inhibit an 
additional incretin hormone, glucose-dependent insulinotropic polypeptide.192 The GLP-






Figure 17 – Overview of selected DPP serine hydrolases and their main localization and functions. Adapted from 
Waumans et al.188 
 
 
The enzyme is a well-established drug target for type 2 diabetes, with multiple FDA 
approved drugs currently in the market, including sitagliptin, saxagliptin, linagliptin, and 
alogliptin.193 Diabetic patients treated with DPP4 inhibitors have shown a significant 
decrease in glycated hemoglobin, in glucose levels after meals and in circulating 
triglycerides. DPP4 has also been studied in the lung. Meyerholz and coworkers have 
shown an increased immunostaining of DPP4 in chronic lung diseases including COPD. 
Increased staining was mostly observed in areas of tissue remodeling. The authors found 
areas of enhanced immunostaining in tissues like airway epithelia, type II cells, pleural 
mesothelia, and alveolar macrophages.194 Additionally, Schade et al. showed that the 
induction of asthma in a F344 mouse model is associated with increased DPP4 enzymatic 
activity in the bronchoalveolar lavage fluid and lung parenchyma, which is associated 
with T-cell recruitment and activation.195 
FAP shares 50% homology with DPP4. It is mainly expressed during development, while 
being rarely expressed in healthy adult tissues. It is highly upregulated at sites of tissue 
remodeling like wounds, fibrosis and cancer, especially in fibroblasts. Besides the 
exopeptidase activity common to the DPP family, FAP also has gelatinase activity. FAP 
activity is intimately associated with cancer due to its pro-tumorigenic nature and has also 
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gained notoriety as a marker of cancer-associated fibroblasts. Inhibition of FAP is 
pursued as an anti-cancer therapy and FAP expression is of prognostic value in some 
tumors.196,197 Pharmacological inhibition of FAP has been shown to lead to a decrease in 
tumor growth in mouse models.198 FAP was found to be increased in lung cancers, while 
being absent in the normal lung. Despite this, it has been considered an indicator of 
positive outcome in non-small cell lung cancer (NSCLC)-squamous cell carcinoma.199 
PREP is involved in regulation of bioactive peptides and regulation of protein-protein 
interactions with particular emphasis on brain functions and has been associated with 
neuropsychiatric disorders like autism, schizophrenia and bipolar affective disorder.200-
202 PREP was found to be highly expressed in neutrophils, macrophages and epithelial 
cells found in lung tissues of COPD patients and in the lungs of mice exposed to cigarette 
smoke. PREP activity was also found to be increased in patients with cystic 
fibrosis.199,203,204 
DPP8 and DPP9 were first described by Abbott et al. as dipeptidyl peptidases related to 
DPP4 and FAP.205 The authors also worked on the cloning, recombinant expression, 
biochemistry and tissue expression of DPP8.205 DPP9 was later studied by Olsen and 
Wagtmann, who identified it as a novel DPP4-like protease and showed that it is 
ubiquitously expressed, with the highest expression in skeletal muscle, heart, and liver.206 
DPP8 and DPP9 are intracellular, mainly localized to the cytoplasm and nucleus, but can 
also be found associated with the plasma membrane. DPP8 has been described to be 
approximately 10-fold less abundant than DPP9 in some cell lines.207 Crystallographic 
structures of both DPP8 and DPP9 were only very recently described.208 
DPP8 and DPP9 share an overall identity of 58% and an identity of 92% of essential 
active-site residues.209 These enzymes also share enzymatic specificity, but growing 
evidence suggests they may have separate physiological roles and potentially interfere in 
processes that were previously attributed to DPP4. The independent functions of DPP8 
and DPP9 remain mostly undefined, in part due to the unavailability of specific 
inhibitors.210 Despite this, these serine hydrolases have been implicated in apoptosis, 
adipogenesis, ROS sensing, spermatogenesis, inflammation, among other functions.211-
213 
There is a conserved general structure between DPP4, DPP8 and DPP9, with all three 
enzymes having two domains, a C-terminal α/β globular domain, which encompasses the 
catalytic triad and is the most conserved region between the three enzymes, and an N-
terminal β-propeller domain, where most ligand-binding elements are present, and where 
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extensive variations from DPP4 were found, including additional secondary structures, 
strand exchanges, and loop alterations. The active sites have a conserved S1 subsite, but 
the S2 subsite diverges significantly, being larger in DPP8 and DPP9 when compared 
with DPP4 and showing a preference for voluminous hydrophobic groups. Furthermore, 
the small differences between catalytic site aminoacids have little impact in terms of 
reactivity since the different aminoacids have analogous structures; lysine 174 in DPP8 
is replaced with arginine in DPP9 and isoleucine in DPP8 is replaced with valine in 
DPP9.210 Unlike what happens in DPP4, ligand binding in DPP8 induces rearrangement 
of a region called the R-helix, which participates in the shaping of the substrate binding 
site, suggesting an induced fit mechanism. When comparing DPP8 and DPP9 structurally, 
a key difference seems to be a region contained in the R-segment, a solvent exposed loop 
with two consecutive histidines in DPP9 and aspartic acid and tyrosine in DPP8 in those 
positions. Regarding the interaction with the protein small ubiquitin-related modifier 1 
(SUMO1), the R-segment and R-helix seem to undergo significant structural changes 
upon ligand binding that disrupt the association of DPP8 or DPP9 with it.208 
Some DPP8 or DPP9 specific roles have been identified, like the importance of DPP9 in 
the cytosolic degradation of proline-containing peptides, in a paper published by Geiss-
Friedlander et al. The pyrrolidine ring-containing peptides seem to pose a problem for the 
normal protein turnover mechanisms due to structural constraints. Of the few peptidases 
known to be able to cleave these peptides, which include PREP, DPP8 and DPP9, only 
DPP9 seems to be the rate-limiting enzyme in the process. The turnover of substrates 
containing a proline in the second position was significantly decreased when DPP9 was 
depleted using siRNAs, but not when the same was done for DPP8 or PREP. This role of 
DPP9 was also associated with regulation of the presentation of proline-containing 
peptides by the MHC class I system.207 DPP9 also seems to have a role in cell adhesion 
and movement. In a study by Zhang et al. it was demonstrated that this function is 
associated with the focal adhesion proteins integrin-β1 and talin. DPP9 was shown to 
accumulate with these proteins near the membrane at the edge of migrating cells.214 
Furthermore, the importance of DPP9 in neonatal mice was demonstrated by the 
generation of gene knock-in mice where the catalytic serine was replaced with an alanine, 
leading to the production of an inactive form of the enzyme. The homozygote embryos 
were morphologically indistinguishable from wild type embryos, but died within the first 
24 hours of life. These results suggest that the other DPP enzymes are not capable of 
fulfilling an essential function of DPP9 in the first hours of life.215 Additional studies 
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suggested that lethality could be due to metabolic impairment. The lack of functional 
DPP9 was associated with major metabolic challenges mainly related with lipid and 
glucose metabolism.216 More recently, it was shown that neonatal lethality is avoided by 
manual feeding. The lack of DPP9 seems to be associated with deficient tongue 
development and a suckling defect.217 
There is therapeutic potential in inhibiting DPP8 and DPP9. While inhibition of both 
DPP8 and DPP9 was first thought to be associated with toxicity, continued research with 
strong and selective DPP8 and DPP9 inhibitors resulted in no toxicity, highlighting that 
the previously identified effects were probably due to other properties of the compounds 
and not related with inhibition of DPP8 and DPP9.218-220 These enzymes have been shown 
to mediate diverse cancer-related functions like cell migration, tumor cell invasion and 
metastasis.221 Smebye et al. described two instances of gene fusions involving DPP9 loss-
of-function that seemed to be associated with ovarian carcinoma. The tumorigenic effect 
of these gene fusions seems to be associated with the disruption of DPP9-associated cell 
signaling pathways that are involved with tumor suppressing.222 Inhibition of DPP8 and 
DPP9 has been shown to activate the immune system and trigger a proinflammatory type 
of cell death called pyroptosis via activation of the inflammasome sensor protein 
Nlrp1b.211,223 Johnson et al. have shown that selective DPP8 and DPP9 inhibition can be 
used for treatment of acute myeloid leukemia in a process dependent on the induction of 
this type of cell death.224 Additionally, DPP8 and DPP9 inhibition was also shown to have 
a role in chemosensitivity of leukemia cells to parthenolide.212 Han et al. showed that the 
inhibition of DPP8 and DPP9 blocked adipogenesis, a function not observed for DPP4 
and FAP inhibition. The mechanism involved inhibition of the expression of PPARγ 
during preadipocyte differentiation.225 DPP9 has been Shown by Gabrilovac et al. to be 
enzymatically active in fibroblasts and keratinocytes and to positively regulate adhesion 
and migration of these cells. Inhibition of DPP9 in these cells led to decrease in survival 
and proliferative capacity.226 
The roles of DPP8 and DPP9 in lung diseases have also been recently described.197 DPP8 
and DPP9 mRNA levels have been shown to be upregulated during asthma and the 
localization of their activity in the bronchi suggested the enzymes are responsive to the 
inflammatory stimulus.195 Tang et al. showed that DPP9 is associated with non-small cell 
lung cancer. DPP9 expression is increased in NSCLC cells when compared with adjacent 
non-tumor tissues and promotes proliferation, migration, and invasion of NSCLC cells.227 
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Overall, the inhibition of DPP8 and DPP9 is a hot topic due to the inexistence of selective 
inhibitors for each of the two enzymes and due to their involvement in several relevant 
diseases, for which new therapeutic options are sought. The study of the effects of DPP8 
and DPP9 inhibition have been crucial to discern the specific functions of these serine 
hydrolases in the cell. Previous competitive ABPP endeavors with large libraries of 
compounds that targeted several serine hydrolases failed to hit any of the DPPs, meaning 
the search for new reactive group for their inhibition is an ongoing task.228 
 
 
1.2.1.2.1. Inhibitors and Activity-based Probes of DPPs  
 
Inhibition of DPP enzymes is an important research field. As previously mentioned, 
inhibition of DPP4 is a therapeutic strategy for treatment of type 2 diabetes, with several 
approved drugs in the market. Both FAP and PREP have known selective inhibitors 
reported, namely N-(4-quinolinoyl)-glycyl-(2-cyanopyrrolidine) derivatives229,230 and 
xanthine derivatives231 for FAP, and prolylsulfonylfluoride for PREP.232 ABPP studies of 
DPPs have been generally carried out using FP probes.233,234 Nevertheless, ABPs have 
been developed to specifically hit selected DPPs, like the case of dipeptidyl phosphonate 
ABPs for PREP.235 In this section the focus will be on describing inhibitors of DPP8 and 
DPP9 since one of the aims of our project was the pursuit of selective inhibition of these 
enzymes, a topic of high interest in current medicinal chemistry. Selective inhibition of 
DPP8 or DPP9 remains elusive mostly due to the high similarity between these two 
enzymes and also significant similarity with related members of the DPP family.236 
While DPP8 and DPP9 inhibition is important due to the relevance of these enzymes in 
immune response and cancer,211,223,224 the lack of knockout models or crystallographic 
structures has hindered the knowledge available regarding the specific functions of the 
individual enzymes and the development of selective inhibitors for them. Most projects 
that aimed for specific substrates of either DPP8 or DPP9 resulted in dual inhibition of 
the enzymes, with varying degrees of concomitant DPP4 and DPP7 inhibition.237,238 The 
description of the molecular structures of both DPP8 and DPP9 is a valuable piece of 
information to guide the design of inhibitors for these enzymes. DPP4 has been 
extensively studied in the past using X-ray crystallographic methods in unliganded and 
liganded forms, establishing that the enzyme has two characteristic domains, one α/β 
catalytic and a β-propeller domain, with the active site located between these structures.239 
43 
 
DPP8 and DPP9 have similar structures, but their crystallographic data was only very 
recently published.208 
Val-BoroPro (Figure 18 – A) is a non-selective inhibitor of post-proline-cleaving serine 
proteases, including DPP4, DPP7, DPP8, DPP9 and FAP, with low nanomolar inhibition 
for DPP4, DPP8 and DPP9. The compound acts through mediation of the immune system 
but, until recently, the exact mechanisms of immune activation by Val-BoroPro have not 
been completely established. Okondo et al. showed that the compound induces pyroptosis 
selectively in monocytes and macrophages via inhibition of DPP8 and DPP9. Canonical 
pyroptosis involves the formation of cytosolic multiprotein complexes called 
inflammasomes, which are triggered by pathogen-associated molecular patterns, leading 
to recruitment and promotion of the proximity-induced autoproteolytic maturation and 
activation of pro-caspase-1, which leads to the induction of this type of cell death. 
Inhibition of DPP8 and DPP9 was shown to lead to the activation of the pro-protein form 
of pro-caspase-1 without autoproteolysis, which then cleaves gasdermin D, the key 
executor of pyroptosis.240 Upon cleavage, gasdermin D releases its N-terminal region to 
form pores in the cell membrane, inducing a lytic type of cell death. The activation of 
pro-caspase-1 has been shown to be dependent on the inflammasome sensor protein 
Nlrp1b and also dependent on the proteasome. When associated with DPP8 and DPP9 
inhibition, this process results in the induction of pyroptosis in monocytes and 
macrophages and activation of the immune system.211,223 
A small molecule inhibitor, 1G244 (Figure 18 – B), has been shown to inhibit DPP8 and 
DPP9 specifically, while showing no activity against DPP4.241 Analysis of 
crystallographic data has shown that the isoindoline group fits in the S1 pocket of DPP9, 
with the amino group interacting with specific side chains (removal of the free amino 
group is detrimental for inhibitory potency) and the 1-(4-4’-difluorbenzhydryl)-
piperazine substituent not being defined in electron density.208 Extensive optimization of 
this inhibitor, with the synthesis of numerous variants, has been attempted, with the goal 
of improving the selectivity for one of the two targets. These studies failed to achieve 
significant selectivity between both enzymes, highlighting the difficulty in achieving 
selectivity for either DPP8 or DPP9.210,236 
SUMO1 is a small ubiquitin-like protein that has been identified as interaction partner 
with DPP8 and DPP9. It has been shown that interaction between DPP9 and SUMO1 
activates peptidase activity and mutations of the DPP9 arm-like structure responsible for 





Figure 18 – A. Val-boroPro; B.1G244. 
 
 
interaction has been mapped, while mutations of this motif have resulted in loss of 
interaction with DPP8 and DPP9 and used to develop a sequence of aminoacids, 
SLRFLYEG, that functioned as a strong allosteric inhibitor of DPP8 and DPP9, but not 
DPP4.242,243 When the proteins were incubated with the SUMO1 derived peptide 
SLRFLYEG, the interaction was revealed to happen with the active site and showed tight 
interaction at P1’, P2’ and P3’. The phenylalanine seems to have a role in defining 
specificity for the enzymes, by fitting in pocket that is absent in DPP4. These results were 
surprising since the peptide was expected to react through binding with the binding site 
of SUMO1 and not as a competitive inhibitor.208 
 
 
1.2.1.3. ABHD Family Enzymes, overview, inhibitors and Activity-based probes 
 
The mammalian ABHD proteins are a group of at least 19 proteins that are potential 
regulators of lipid metabolism and signal transduction. A common feature of the ABHD 
family is the ability to hydrolyze or synthesize glycerophospholipid species. These act as 
key structural elements for the cell membrane and as intermediates in signaling pathways. 
They can contain serine, cysteine or asparagine as the nucleophilic catalytic aminoacid.244 
Here we focus on ABHD2, ABHD6 and α/β hydrolase domain fold family protein 16A 
(ABHD16A), including relevant examples of their inhibitors and ABPs. 
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ABHD2 seems to be involved with suppression of smooth muscle cell migration and 
chronic diseases that involve monocyte and macrophage recruitment like atherosclerosis. 
ABHD2 has triacylglycerol lipase and ester hydrolase activity and has been implicated in 
the breakdown of lipids to support the proliferation of cancer cells, suggesting that it is a 
potential target for cancer therapy.245 The ABHD2 gene expression has been shown to be 
upregulated in prostate cancer and associated with cancer growth and resistance to 
docetaxel chemotherapy.246 It seems to have a protective role in the lung since deletion 
of ABHD2 by gene trapping in aged mice has been shown to result in reduction of type 
II cells in alveolar tissues. Alveolar type II cells produce pulmonary surfactant, a complex 
mixture of lipids and proteins which regulates lung surface tension during the 
inflation/deflation cycle. The outcome of ABHD2 deletion involves accumulation of 
macrophages, increase in cytokines, enhanced apoptosis, reduced pulmonary surfactant 
and a protease/anti-protease imbalance, which progressively leads to the development of 
emphysema. This suggests a role for ABHD2 in the protection of lung structural 
integrity.244,247 ABHD2 gene polymorphisms have been described to contribute to COPD 
susceptibility.247,248 Competitive ABPP experiments using KT195, a known non-selective 
inhibitor of ABHD6, and an alkynylated version of the same compound identified 
ABHD2 as the enzyme responsible for the compound’s effect on cell death inhibition via 
regulation of cytoplasmic calcium concentration.249 
ABHD6 is a serine hydrolase known to have lipase activity in the central nervous system, 
where it participates in the hydrolysis of endocannabinoid 2-AG, a function shared with 
MAGL  and ABHD12.103,250 Outside of the nervous system, ABHD6 has been implicated 
in glycerophospholipid metabolism and lipid signal transduction, having a prominent role 
in the development of the metabolic syndrome.251 ABHD6 has recently been found to 
negatively regulate the trafficking of postsynaptic glutamate receptors in neurons.252 
ABHD6 inhibitors have potential as therapeutics for obesity, diabetes and non-alcoholic 
fatty liver disease. Potent and selective inhibitors of ABHD6 have been developed by the 
Cravatt lab using ABPP tools, including the carbamate derivative 51 (Figure 19 – A),125 
piperidyl-1,2,3-triazole ureas (Figure 19 – B).253 
ABHD16A possesses both an esterase catalytic triad and an acyltransferase domain. The 
enzyme is involved in the conversion of phosphatidylserine to lyso-PS in the brain. Lyso-
PS are signaling lipids that regulate macrophage activation and clearance of apoptotic 






Figure 19 – Carbamate (A) and urea (B) selective inhibitors of ABHD6 developed by the Cravatt lab. C. β-lactone-
based inhibitor of ABHD16a. 
 
 
inflammation. The enzyme is considered a potential target of inflammation-associated 
pain. ABHD16A and ABHD12 jointly regulate lyso-PS levels, with lyso-PS being 
hydrolyzed by ABHD12 into glycerophosphoserine. Therefore, inhibitors of ABHD16A 
should avoid concomitant inhibition of ABHD12.254,255 ABHD12 accounts for ~9% of 
total hydrolase activity towards 2-AG in the brain. Mutations in ABHD12 have been 
associated with the progressive neurologic disorder PHARC (polyneuropathy, hearing 
loss, ataxia, retinitis pigmentosa and cataract) in humans. The derivatization of α-
methylene-β-lactones by the Cravatt lab led to the development of an ABHD16a inhibitor 






1.3. Expanding the ABPP Toolbox of 4-membered ring Reactive Groups 
 
 
4-membered ring heterocyclic compounds are very prominent in medicinal chemistry and 
include chemotypes like β-Lactams, β-Lactones and β-Sultams. These scaffolds have 
been applied in ABPP experiments to determine their extent of target engagement. 
In this work we aimed to expand the knowledge on two underexplored 4-member ring 
chemotypes, the 3-Oxo-β-Sultam and the 4-Oxo-β-Lactam. These chemotypes are 
derivatives of β-Lactams, which contain an additional sulfone or carbonyl group, 
respectively, incorporated into the 4-membered ring structure of the β-Lactam ring.  
These reactive groups have been used in chemical biology for inhibitor development and 






3-Oxo-β-Sultams (Scheme 4 – A) are 4-membered rings containing an acyl sulfonamide 
reactive group. They are both β-Sultams and β-Lactams and have been described to 
inactivate PPE as acylating agents.170 Inhibition was suggested to involve the formation 
of an enzyme-inhibitor adduct with transient stability by acylation of the active-site serine 
of PPE.257 
The 3-Oxo-β-Sultam reactive group has been described to be too chemically reactive for 
therapeutic applications, since its alkaline hydrolysis occurs at a rate much greater than 
that of clinically useful β-Lactams and the compounds have short half-lives in water. 3-
Oxo-β-Sultam-based compounds have found use as scaffolds for poly(acylsulfonamide) 
polymer formation,258 ring-enlargement reactions,259 intermediates in synthetic 
pathways,260 and as serine hydrolase inhibitors.257 
One of our main interests in exploring the 3-Oxo-β-Sultam scaffold is the study of its 
mechanism of serine hydrolase inhibition. In theory, enzymatic inhibition by 3-Oxo-β-
Sultams could involve nucleophilic attack of the enzyme at either the acyl or sulfonyl 
centers, displacing either a sulfonamide or an amide leaving group, respectively (Scheme 









Tsang et al. have described that the hydrolysis of the 3-Oxo-β-Sultam reactive group and 
the reaction with the target enzyme occur at different reaction centers, with the enzyme 
reaction taking place at the carbonyl center and the alkaline hydrolysis occurring at the 
sulfonyl side.257,261  
Assuming the attack happens in the carbonyl center, the incoming nucleophile approaches 
at approximately the tetrahedral angle, while in the sulfonyl attack there is a 
pentacoordinate trigonal bipyramidal geometry, with the nucleophile taking the apical 
position. These differences suggest that the nature of the substituents could have an 
influence in the chemical reactivity of 3-Oxo-β-Sultam inhibitors.257 
The mechanism for acylation of serine hydrolase enzymes is usually described as a two-
step process, with the attack of the nucleophilic serine in the first step forming a 
tetrahedral intermediate and a second step with the collapse of the intermediate state and 
displacement of a leaving group.44 Sulfonylations on the other hand are usually described 
with a concerted mechanism.261 Even though the attack at the acyl center displaces a better 
leaving group, the sulfonamide anion, the nature of the leaving group does not seem to 
have a drastic effect on reactivity.262 
Inhibition of serine proteases by sulfonylation is a potential strategy as an alternative to 
the commonly reported acylation mechanism. However, sulfonyl inhibitors are usually 
less reactive that their acyl counterparts and sulfonylation of serine hydrolases remains 
an underexplored strategy. Tsang et al. have reported on β-Sultams, which are unusual in 
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that they undergo sulfonyl transfer faster than the corresponding acylation reaction. X-
ray crystallography has shown that an N-benzoyl β-Sultam inhibits elastase by 
sulfonation of the active site, an irreversible process. N-acylsulfonamides are commonly 
used to inhibit serine proteases, but the attack of the enzyme occurs in the acyl group, 
with displacement of a sulfonamide leaving group.176,263 
Mass spectrometry-based studies have been used to analyze the reaction of 3-Oxo-β-
Sultams with PPE. This, however, does not provide distinction between acylation and 
sulfonylation, since the products resulting from the attack at either position have the same 
molecular weight.  
In a study of enzymatic inhibition of PPE using 3-Oxo-β-Sultams it was shown that the 
enzymatic reaction occurs with a 1:1 ratio. The second order rate constant (ki) for the 
inactivation of PPE was shown to be nearly 1000 times greater than the inhibition by an 
N-benzoyl-β-Sultam, which inhibits HNE by a sulfonylation process. The authors 
concluded that such difference suggests a different inhibition mechanism is taking place, 
inferring that the acylation of the active site is the probable mechanism of action.257 On 
the other hand, NMR studies of the hydrolysis product have shown a cross-peak between 
the carbonyl carbon and the protons from the methylene group of the N-benzyl 
substituent, supporting that hydrolysis of the 3-Oxo-β-Sultam ring occurs through attack 
of the hydroxyl ion at the sulfonyl center.262 
After inhibition of HNE with a 3-Oxo-β-Sultam there is recovery of enzyme activity 
within a few hours of 3-Oxo-β-Sultam inhibition, suggesting acylation and formation of 
a labile ester rather than sulfonylation.264  
The rate of enzyme inactivation by an N-benzyl 3-Oxo-β-Sultam when compared with a 
N-benzoyl β-sultam, together with the observed recovery of enzymatic activity suggests 
different mechanisms for the two processes, leading the authors to conclude that 3-Oxo-
β-Sultams inhibit elastase enzymes by forming a reversible acyl enzyme of intermediate 
stability.257  
The requirements for attack at sulfonyl centers are inherently different from those at acyl 
centers. Sulfonyl transfer reactions catalyzed by proteases may offer interesting insights 
about the flexibility of enzymes, inhibition requirements and information concerning 
enzyme specificity and selectivity profiles. These characteristics make the 3-Oxo-β-
Sultam reactive group an interesting scaffold to study since it might have different 
selectivity characteristics when compared with related structures.261 
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While the rate of hydrolysis of a β-Lactam is similar to that of its acyclic amide analogs, 
for the sulfonyl counterparts the rate of hydrolysis of a β-Sultam is estimated to be 107-
fold higher than that of a sulfonamide.265 β-Sultams are also hydrolyzed faster than β-
Lactams. The alkaline hydrolysis of N-benzoyl β-Sultam occurs exclusively through 
attack on the sulfur atom with displacement of an amide leaving group, as demonstrated 
by 1H NMR and MS analysis.266 
A theoretical study on the alcoholysis of N-benzyl 3-Oxo-β-Sultam confirmed that the S-
N bond cleavage has a slightly lower energy barrier than C-N bond cleavage, suggesting 
the attack at the sulfonyl center is preferential. This seems to involve a stepwise 
mechanism, with the attack of the alcohol to the sulfur atom as the rate-limiting step.267 
Even with the added strain in the 3-Oxo-β-Sultam ring, a N-benzyl 4,4-dimethyl 3-Oxo-
β-Sultam is only 10-fold more reactive toward alkaline hydrolysis than the corresponding 
β-Sultam with an exocyclic acyl center (Scheme 5).266,268 Alkaline hydrolysis of the 3-
Oxo-β-Sultam occurs exclusively by attack on the sulfonyl center with a second-order 
rate constant of kOH = 1.83 x 10
5 M-1 s-1, which is consistent with the 103-fold greater 
reactivity of β-Sultams compared with β-Lactams towards alkaline hydrolysis.170 The 
preference for nucleophilic attack at the sulfonyl group was demonstrated by negative ion 
ESI-MS, 1H and 13C HMBC NMR. The nature of the leaving group doesn’t seem to have 





Scheme 5 – Difference in the hydrolysis of an N-benzoyl β-Sultam and a 3-Oxo-β-Sultam. 
 
 
Modifications to the basic 3-Oxo-β-Sultam structure can be done either at the 4- position 
or at the nitrogen of the acylsulfonamide group. Modification in the α-substituents and in 
the nitrogen atom of the 3-Oxo-β-Sultam structure have been shown to result in inhibitors 
with improved chemical stability, which retain inhibitory activity. Increasing the bulk of 
the substituent at the 4 position has been shown to decrease the rate of alkaline hydrolysis. 
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Changing the groups from dimethyl to diethyl diminishes hydrolysis 10-fold. A spiro-
cyclohexil is 30-fold less reactive. The dimethyl groups show the highest enzymatic 
inhibition, which decreases 3-fold when changing to diethyl and 100-fold when changing 
to spiro-cyclohexil. When taking in consideration both the inhibitory activity and the 
tendency to hydrolyze, the diethyl substitution is the most favorable, since despite being 
slightly less active than the dimethyl compounds, it possesses greater hydrolytic stability. 
It has also been shown that a carboxylic acid in the α-position of the nitrogen reduces 
chemical reactivity 10-fold, which was attributed to the electrostatic repulsion between 
the incoming nucleophile and the carboxylate group. The enzymatic inhibition is also 
reduced 25-fold. Overall, a diethyl 3-Oxo-β-Sultam with a carboxylic acid α to the 
nitrogen, followed by a phenyl group gave the best reactivity/stability ratio and a valine 
nitrogen leaving group gave the most stable 3-Oxo-β-Sultam, which was still too unstable 
to be considered therapeutically useful (kOH of 1.74 x 10
3 M-1 s-1), proved to be also the 
less reactive one towards the enzyme, highlighting that the intrinsic reactivity of the 3-






4-Oxo-β-Lactams (Scheme 6 – A) are 4-membered ring compounds containing a β-
Lactam with an additional carbonyl group at the 4-position. 4-Oxo-β-Lactams are 
isosteric analogs of 3-Oxo-β-Sultams. They retain the necessary elements for PPE and 
HNE recognition but have increased stability against hydrolysis. The mechanism of serine 
hydrolase inhibition by 4-Oxo-β-Lactams involves the attack of the nucleophilic serine 
residue to one of the carbonyl groups of the 4-Oxo-β-Lactam, forming a tetrahedral 
intermediate, which is stabilized in the oxyanion hole of the enzyme. The collapse of this 
intermediate leads to opening of the 4-Oxo-β-Lactam ring, rendering the enzyme inactive 
by acylation (Scheme 6 – B). The reversibility of this process depends on the stability of 
the acyl-enzyme complex. 
The 4-Oxo-β-Lactam core is synthesized by reaction of an appropriate amine with 2,2-
disubstituted malonic acid chlorides. Yields are low to moderate due the formation of the 
diamide side-product, which is easily removed by chromatography techniques.171 
Mulchande et al. first described the 4-Oxo-β-Lactam scaffold as a promising structure for 
the development of HNE inhibitors.171 The authors designed a small library of 4-Oxo-β-
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Lactam inhibitors, varying the substituents at the 3-position and at the nitrogen atom, in 
an effort to establish a basic SAR of common substituents. 
 
   
 




The compounds were tested against PPE. The rate of acylation of PPE decreased and the 
rate of deacylation increased when compared with 3-Oxo-β-Sultam inhibitors. Analysis 
of the second-order rate constants for the alkaline hydrolysis showed that the process is 
only 7-fold greater than for the corresponding N-benzoyl-β-Lactam. Comparison of the 
reactivity of 4-Oxo-β-Lactams with similar reactive groups showed that there is no 
significant rate enhancement caused by the increased ring strain. When a N-benzyl 
substituent was replaced with a N-phenyl group the change of leaving group decreased 
hydrolytic stability, with electron-withdrawing groups in the aromatic ring decreasing it 
even more and electron-donating groups having the opposite effect. As for the 
substituents at the 3-position, PPE inhibition is improved by small hydrophobic 
substituents, with dimethyl substitution being the most favorable one and 20-fold more 
active than diethyl. The most potent compounds contained a N-aryl substituent and two 
ethyl groups at C-3, with N-alkyl inhibitors being inactive or weak inhibitors. Electron-
donating groups in the aromatic ring increase inhibitory activity, with the most potent 
compound having a 4-CN substituent (Figure 20 – A). This compound was also tested 
against HNE and proved to be very potent and a promising scaffold for the development 
of HNE inhibitors. 
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Following the encouraging results for PPE, the authors created a library of inhibitors to 
test against HNE. Inhibitory activity was shown to be strongly dependent on the nature 
of C-3 substituents. The diethyl substitution at C-3 seems to be ideal to fit in the small S1 
pocket of the enzyme and substituting one of the ethyl groups by a bulkier group like 
benzyl causes a sharp decrease in activity. There is room for variability, given the fact 
that one of the most potent inhibitors obtained had an ethyl and a n-butyl group as 
substituents. Replacing an N-benzyl group with N-phenyl increases the rate of enzymatic 
inhibition, given the effect of the better leaving group that is generated upon enzyme 
engagement. Substituents in the ring should be at the para position to have a positive 
effect in activity. Inhibitors with a thioether substituent in this position present improved 
inhibitory activity when compared with unfunctionalized counterparts. It seems that the 
presence of 2-mercaptobenzoxazole is benefic for activity so it might be associated with 
improved enzyme recognition. A computational study where some inhibitors were 
modeled with HNE showed that the 3-diethyl substituents are accommodated in the S1 
pocket, there are enhanced van der walls interactions between benzothiazole with Leu-99 
and His-57 and the carbonyl in close proximity to Ser-195 is involved in H-bonds with 
the oxyanion hole of the enzyme, which promotes stability of the intermediate tetrahedral 
state. An inverted binding pose which is detrimental for activity was identified for some 
compounds and was predominant for compounds with the worst inhibitory activity. As 
for selectivity, all tested compounds were found to be time-dependent inhibitors of PR3, 
although with much lower activity than HNE. Most inhibitors were inactive or only 
weakly active against cathepsin G. This pattern of selectivity might benefit the 
development of therapeutic molecules since both HNE and PR3 participate in similar 
pathways of disease and their action is intimately associated. All compounds were 
inactive against papain, suggesting good selectivity for serine proteases against cysteine 
proteases. Compounds were reasonably stable in PBS at 37°C but quickly hydrolyzed in 
80% plasma.270 
Having revealed the great potential of these compounds for the development of HNE 
inhibitors the authors sought to develop an inhibitor with improved pharmacokinetic 
properties and that inhibits HNE through a suicide mechanism based on the 4-Oxo-β-
Lactam scaffold (Figure 20 – B). A sulfone group was added to improve 
pharmacokinetics and promote the suicide mechanism by inducing departure of 
phenylsulphinate after attack by Ser-195. An extremely rapid inactivation of HNE by the 
compound was observed. The compound also inhibited PR3 and CatG with lower potency 
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but didn’t show any inhibitory effect against papain. The compound’s half-life in PBS 
was found to be 1.04 ± 0.25 h and in 80% human plasma 0.11 ± 0.03 h at 37°C, suggesting 
high susceptibility to plasma esterases. Ex vivo studies in mice showed that the compound 
distributes to the lungs and spleen, but is not detected in the liver, suggesting high degree 




Figure 20 – 4-Oxo-β-Lactam HNE inhibitors developed by Mulchande et al. 
 
 
Ruivo et al. designed a library of 4-Oxo-β-Lactam inhibitors by derivatization of an 
alkynylated 4-Oxo-β-Lactam. The compounds resulted in low nanomolar HNE inhibition, 
including an 82 nM IC50 for HNE for the alkynylated compound. Derivatization of this 
compound by CuAAC afforded fluorescent and biotinylated ABPs with nanomolar 
potency inhibition against HNE and the application of the fluorescent ABPs in gel-based 
assays showed HNE labeling, confirming HNE as a target of the compounds. 
Furthermore, the fluorescent compounds were shown to permeate the cell membrane and 
allowed for visualization of probe accumulation in cells.183 
Chavan et al. have recently reported an alternative synthesis of 4-Oxo-β-Lactams, 
specifically for late stage functionalization of the position 3 of the ring. The methodology 
involves a Sn(II)-catalyzed one-pot reaction via a reaction sequence involving 
condensation, hydration and cyclization (Scheme 7 – A).271 The proposed mechanism 
involves the condensation of an aromatic aldehyde with ethyl cyanoacetate in the 
presence of Sn(II), generating an Sn adduct. The adduct suffers hydrolysis and is 
stabilized by the Sn catalyst. The carbonyl group of the ester moiety is activated by Sn(II), 
which favors the cyclization to give a 4-membered ring intermediate, which tautomerizes 
into the final compound (Scheme 7 – B). This alternative method could provide a versatile 






Scheme 7 – A. Synthesis of 4-Oxo-β-Lactams described by Chavan et al.; B. Proposed mechanism for the alternative 







The main objective of this project was the evaluation of the 4-member ring chemotypes 
3-Oxo-β-Sultam and 4-Oxo-β-Lactam as chemoproteomic tools in chemical biology. 
These reactive groups were developed into libraries of compounds and ABPs for 
application within a selected group of enzymes from the serine hydrolase family. Inhibitor 
and probe design was focused on HNE as a target, but engagement of additional serine 
hydrolase targets was evaluated and pursued. 
 
The project involved a multi-disciplinary and collaborative approach between Moreira’s 
group at iMed.ULisboa, Penque’s group at Instituto Nacional de Saúde Dr. Ricardo Jorge 
and the Cravatt Group at The Scripps Research Institute, comprising a fully integrated 
Medicinal Chemistry/Chemical Biology/Proteomics program to streamline the 
generation, design process and evaluation of novel ABPs with the ultimate goal of 
establishing target profiles of underexplored 4-membered ring chemotypes for serine 





Figure 21 – Overview of the project.  
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Moreira’s group has vast experience on medicinal chemistry, including computer-aided 
drug design of enzyme inhibitors, while Penque has optimized experimental sets for 
proteomic studies using state-of-the-art mass-spectrometry platforms. The Cravatt Lab at 
The Scripps Research Institute in La Jolla, California, is the leading lab in the 
development and application of ABPs using proteomics approaches. Evaluation of the 
compound libraries was performed at the Cravatt lab and supported by a Fulbright grant. 
 
A collaboration with the Archer Lab at Instituto de Tecnologia Química e Biológica 
António Xavier was pursued for crystallography studies of the interactions of serine 
hydrolases with some of the developed molecules. Additional collaborations were 
pursued for validation of the identified probe targets and evaluation of new inhibitors for 
specific serine hydrolases. 
 
The results obtained in this project are reported herein and are divided into five main 
chapters. The first two are associated with the study of the two chemotypes used in this 
project, the 3-Oxo-β-Sultams and the 4-Oxo-β-Lactams, including synthetic work and 
proteomics applications. Additional chapters are devoted to the pursuit of novel inhibitors 
of the enzymes DPP8 and DPP9, two targets that emerged in competitive ABPP 
experiments with 4-Oxo-β-Lactam ABPs, and the synthesis and application of other 
probes to target different enzyme classes associated with some outreaching projects and 
collaborations. A final chapter presents an overview of the work and the main conclusions 
and future perspectives. 
 
The main objectives were: 
 
- Synthesis and Evaluation of libraries of inhibitors and ABPs based on the 3-Oxo-
β-Sultam and the 4-Oxo-β-Lactam chemotypes, focusing on serine hydrolase as 
targets and using HNE as the model enzyme; 
- Evaluation of HNE inhibition and biochemical selectivity against related serine 
hydrolases; 
- Determination of the HNE and PPE inhibition mechanisms by 3-Oxo-β-Sultams 
via crystallographic analysis of protein-inhibitor complexes; 
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- Evaluation of the compounds in a proteomics platform, focusing on gel-based 
assays and mass-spectrometry based assays to determine compound selectivity, 
potency and target profile; 
- Development of new inhibitors for selected serine hydrolases identified in the 
ABPP-MudPIT assays and validation via competitive ABPP; 
- Study of the 4-Oxo-β-Lactam structure as a novel chemotype for DPP8 and DPP9 
inhibition; 
 
Overall, the project will provide unprecedented knowledge on unexplored 4-member 
rings in ABPP, contributing to the current toolbox of available probes in chemical biology 
and potentially leading to the establishment of new biomarkers of disease. 
Proteomics tools have become indispensable in the evaluation of potential new drugs for 
the identification of the full extent of target engagement of candidate compounds to 
prevent potential pitfalls down the pipeline of drug development. This project will mark 
the first time that proteomics tools are intimately associated with drug development at the 
Medicinal Chemistry group of iMed.ULisboa and will provide the foundation for future 












Chapter 2 – 3-Oxo-β-Sultams 
 
 
The experimental part of our project started with the development and evaluation of a 
library of compounds based on the 3-Oxo-β-Sultam structure. In this chapter we present 
the optimization and synthesis of 3-Oxo-β-Sultams using CuAAC, the evaluation of these 
compounds in biochemical assays against HNE and other serine hydrolases and the 
unprecedented evaluation of these compounds in gel-based and mass-spectrometry-based 
assays. Furthermore, we attempt to clarify the existing questions regarding the 
compound’s mechanism of action by providing the first crystallographic structures of 3-
Oxo-β-Sultams co-crystallized with the serine hydrolases HNE and PPE. 
We show that 3-Oxo-β-Sultams are potent inhibitors of HNE, with limited selectivity due 
to their high reactivity, and demonstrate that inhibition of PPE and HNE proceeds through 
a sulfonylation mechanism. 
 
 
2.1. Synthetic Procedures 
 
2.1.1. Synthesis of the 3-Oxo-β-Sultam Reactive group 
 
 
3-Oxo-β-Sultams were prepared by ring closure of a (chlorosulfonyl)acetyl chloride, 62, 
with a substituted amine.257 Scheme 8 depicts an example of the synthesis of a benzylated 
3-Oxo-β-Sultam (56), which was used to optimize the cyclization reaction. 
In this work we varied the 3-Oxo-β-Sultam substituents at the 2-position and on the 
nitrogen atom of the acylsulfonamide. The substituents at the 2-position were introduced 
prior to the cyclization step, while the N-substitution pattern is determined by varying the 
amine used for cyclization. We used dimethyl and diethyl substituents at the 2-position, 
based on previous data of HNE inhibition by 3-Oxo-β-Sultams and related compounds. 
Bulkier and more varied substitutions have generally resulted in worse activity/stability 







Scheme 8 – Synthesis of a benzylated 4,4-dimethyl 3-Oxo-β-Sultam. 
 
 
The synthesis of 3-Oxo-β-Sultams started with the introduction of the sulfonyl group in 
an appropriate anhydride. While the synthesis of the dimethyl derivatives was pursued 
starting with the commercially available isobutyric anhydride 67, dimethyl derivatives 
required 2-ethylbutanoic anhydride 66, which was synthesized from 2-ethylbutanoic acid 
(scheme 9). A sodium carboxylate salt and an acyl chloride derivative were prepared from 
2-ethylbutanoic acid by reacting the acid with sodium ethoxide and thionyl chloride, 






Scheme 9 – Synthesis of 2-ethylbutanoic anhydride from 2-ethylbutanoic acid. 
 
 
With the appropriate anhydrides in hand, we pursued the synthesis of the 3-Oxo-β-Sultam 
ring. Scheme 10 depicts an example of the synthesis of compound 70. The sulfonyl group 
was introduced in the molecules by reaction of the anhydride with sulfuric acid overnight 
at 90°C. The product was precipitated as a sodium salt with ethanol from water in 
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quantitative yield. The disodium salt was derivatized into the dichloride by refluxing in 
thionyl chloride. The cyclization step to form the 3-Oxo-β-Sultam ring was then 
performed by reacting the dichloride with an appropriate amine. Slow addition of the 
amine into the reaction was essential to promote cyclization instead of the secondary 
product that results from the attack of one amine molecule into each of the chlorides.  
The 3-Oxo-β-Sultam compound library was developed by taking advantage of CuAAC 
click chemistry.50 For this purpose, we prepared derivatives of the 3-Oxo-β-Sultam core, 
compounds 69 and 92, by using propargylamine in the cyclization reaction. The 
alkynylated 3-Oxo-β-Sultams were obtained in good yield by crystallization in the case 
of the dimethyl derivative 69 and by column chromatography in the case of the diethyl 





Scheme 10 – Synthesis of a 4,4-diethyl 3-Oxo-β-Sultam alkyne and derivatization by CuAAC. 
 
 
An alternative strategy for the derivatization of 3-Oxo-β-Sultams was the direct alkylation 
of a non N-substituted 3-Oxo-β-Sultam, described by Glasl et al. (Scheme 11).260 The 
non-substituted 4-membered-ring core 71 was easily obtained by cyclization with liquid 
ammonia at -78°C in a mechanism analogous to the other described 3-Oxo-β-Sultams. A 
simple extraction-based work-up from the reaction yielded the desired product in decent 
yield. 
Alkylation of this type of compound was described by using sodium hydride to 
deprotonate the acylsulfonamide and then adding an appropriate halogenated compound 
for alkylation (Scheme 11). The proof-of-concept and optimization of this reaction was 
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attempted with benzyl chloride and with 4-nitrobenzylbromide. When analyzing these 
reactions, no products were obtained. In NMR analysis, only vestigial amounts of the 
desired product were identified. This strategy was abandoned for this project, but an 
optimization is envisaged in the future as a way of increasing N-substitution variability 










2.1.2. Synthesis of Azide Building Blocks 
 
For the derivatization of the 3-Oxo-β-Sultam chemotype into a library of compounds click 
chemistry was used.50 Click reactions are extremely useful in the fast generation of 
libraries of compounds. In ABPP the CuAAC click chemistry reaction is very commonly 
used to attach tags to reactive groups, generating a triazole linker, which is also associated 
with favorable properties in the final compounds.272 
The azides used in this work were either purchased from commercial sources (phenyl 
azide derivatives 72-76 and biotin azide 77 – Figure 22 – A) or synthesized prior to the 
CuAAC reaction (benzyl azide derivatives 78-84 – Figure 22 – B), carbohydrate-based 
azides 85 (Figure 22 – C) and fluorophore azides 88 and 91 (Scheme 12 and Scheme 13).  
For the synthesis of benzyl azide building blocks, halogenated benzyl derivatives were 
stirred overnight with sodium azide in DMSO and the azide derivatives were obtained by 
extraction from the reaction using diethyl ether and stored as DMSO stocks. The 







Figure 22 – Azides used in the CuAAC derivatization of 3-Oxo-β-Sultams. 
 
 
Introducing click chemistry handles in complex molecules like fluorophores is less 
straightforward since the complex structures of most fluorophores make them 
intrinsically challenging to derivatize and the fluorescent properties of the fluorophore 
must not be negatively affected. Commercially available azide and alkyne derivatives of 
a very large number of different fluorophores and affinity-based tags are plentiful but 
frequently expensive, making the optimization of their synthesis in the lab important for 
them to be readily available to use in significant amounts. For fluorescent ABP synthesis 
we derivatized NBD and Rhodamine.  
NBD was purchased as a halogenated derivative (86). Derivatization of NBD-Cl has been 
performed by adding a linker arm with 3-bromopropylamine hydrobromide, which is then 
converted into an azide by using sodium azide (Scheme 12 – A). In this synthesis, the 
reaction of the intermediate bromine derivative into the azide derivative was usually 
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incomplete, even after adding an excess of sodium azide into the reaction and prolonging 
its course through several days. Furthermore, the bromine and the azide derivatives have 
almost identical Rfs, which makes their chromatographic purification problematic. Given 
the low overall yield (40% over two steps), an optimization of the reaction was done. 
We hypothesized that by synthesizing the azide of the 3-bromopropylamine arm first and 
then adding NBD-Cl, we could avoid formation of the bromine intermediate and simplify 
product purification (Scheme 12 – B). A new experiment was made where 3-
bromopropylamine was stirred with sodium azide in DMSO overnight and then, without 
intermediate purification, NBD-Cl and triethylamine were added to the reaction. As 
predicted, this avoided formation of the bromine derivative and made the final NBD-azide 
product easier to purify by column chromatography, resulting in a yield of 46%. Despite 
obtaining only slightly better yield, the new strategy made the product much easier and 





Scheme 12 – Synthesis of an NBD azide. 
 
 
For rhodamine B (8), the general strategy was to take advantage of the carboxyl group to 
create an amide bond using different amines that could then be derivatized to include an 
azide. Rhodamine B was stirred with HOBt, TBTU and DIPEA in DCM for 30 minutes 
and then 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-amine and DIPEA were added 
and the reaction was stirred overnight at 45°C (Scheme 12). TLC analysis suggested that 
there was total consumption of rhodamine B and formation of a new product. After work-
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up extractions with water and DCM and a chromatographic purification by preparative 





Scheme 13 – Derivatization of Rhodamine B with 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-amine. 
 
 
2.1.3. Synthesis of 3-Oxo-β-Sultam derivatives by Click Chemistry 
 
 
The click chemistry reaction between the 3-Oxo-β-Sultam alkynes 69 and 92 and the 
library of azides had to be optimized. The CuAAC reaction, a click reaction, is usually 
reliable and provides the desired products in excellent yield with no need for 
chromatographic purification steps. The first attempts of clicking our 3-Oxo-β-Sultam 
with different azides failed and no products were obtained. We suspected that the 
presence of water in the reaction or the extraction-based workup could induce ring-
opening of the 3-Oxo-β-Sultam and be responsible for the poor results. An optimization 
of the synthesis was done, varying reaction times, solvent, sodium ascorbate amounts, 
copper-ligand and work-up procedure. Additionally, purification of the compounds 
proved to be complicated, with no elution of the final compounds in silica-based solid 
media, unless methanol was used, a solvent which can potentially react with the 3-Oxo-
β-Sultam ring. 
After testing different conditions we concluded that the best results could be obtained by 
using DMSO and water as solvents; a concentration of sodium ascorbate double to the 
copper sulfate concentration seemed to improve yields, while the use of a copper ligand 
(bathophenanthrolinedisulfonic acid disodium salt hydrate or TBTA273) resulted in no 
apparent improvement. The reaction time was minimized to avoid hydrolysis due to 
prolonged exposure to aqueous conditions. Using these optimized conditions, dimethyl 
compounds were easily obtained by precipitation from the reaction by adding water, while 
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diethyl compounds, which did not precipitate via the addition of water, were extracted 
from the reaction using ethyl acetate and precipitated by washing the resulting crude oil 
with diethyl ether. The yields were mostly moderate but allowed sufficient amounts of 





Figure 23 – 3-Oxo-β-Sultam library of compounds. 
 
 
3-Oxo-β-Sultam ABPs were synthesized using the same methodology with the 
fluorophore and biotin azides. Fluorophore containing ABPs (106-108) were synthesized 
with the previously described NBD and Rhodamine azides. The biotinylated ABP 109 
was synthesized for mass-spectrometry applications. 
Overall, the synthetic route chosen for the synthesis of our library was efficient, with the 
dimethyl derivatives requiring no chromatographic purification in any of the steps, and 
the diethyl derivatives requiring only a simple chromatographic step after the cyclization 
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reaction with propargylamine. The yields of most of the steps were good, making it easy 
to obtain a varied library of 3-Oxo-β-Sultams for testing. The complete library of 
compounds is presented in Figure 23. 
 
 
2.2. Enzymatic Inhibition Studies 
 
The 3-Oxo-β-Sultam compound library was tested for the inhibition of HNE and for 
additional serine hydrolases, to establish potency and biochemical selectivity. 
HNE studies used commercially available pure HNE and an HNE fluorogenic substrate. 
Briefly, the assays were based on measuring the conversion of a fluorogenic substrate by 
the tested enzymes after incubation with the compounds. The resulting fluorescent signal 
increase is inversely proportional to the compound’s potency.  
 
 
2.2.1. Inhibition of Human Neutrophil Elastase by 3-Oxo-β-Sultams 
 
To test the ability of the 3-Oxo-β-Sultam library to inhibit HNE, a biochemical inhibition 
assay was performed. Briefly, decreasing concentrations of 3-Oxo-β-Sultam compounds 
were plated, commercially purchased HNE was added and an incubation of 30 minutes 
was done. After this, an HNE fluorogenic substrate is added and the fluorescence 
generation was measured for 30 minutes. If inhibition is efficient, no HNE remains active 
and there is no increase in fluorescence for the duration of the assay due to no substrate 
cleavage. As compound concentration decreases, the remaining active HNE in each 
reaction cleaves the fluorogenic substrate, generating fluorescence. The remaining HNE 
activity when compared to a control was plotted against the logarithm of compound 
concentration for each experimental dataset and the IC50 was calculated from the obtained 
curve. An example of a dose-response curve for compound 101 is presented in Figure 24. 
The calculated IC50 values for the 3-Oxo-β-Sultam library are presented in Table 1.  
The compounds are potent HNE inhibitors, with some having IC50 values in the 
nanomolar region. A significant difference was observed between dimethyl and diethyl 
derivatives. When changing from dimethyl to diethyl substitution there was, in general, a 
ten-fold increase in activity. For example, compound 95, a dimethyl derivative, had an 
IC50 of 1.791 µM, while its diethyl counterpart, compound 102, had an IC50 of 156 nM. 
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This was most likely due to a better recognition of the compounds by HNE since it has 
been shown that the 2-diethyl substitution is a better fit for HNE’s S1 pocket. 
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Table 1 – IC50, LE and LLE values for HNE inhibition by 3-Oxo-β-Sultams (N.D. = Not determined).  
 
 IC50 (µM) LE LLE   IC50 (µM) LE LLE 
         
69 3.271 ± 1.09  0.64 5.64  100 0.184 ± 0.034 0.39 3.58 
70 3.104 ± 0.043 0.35 4.9  101 0.292 ± 0.028 0.37 4.15 
71 10.031 ± 1.90 0.78 6.13  102 0.156 ± 0.041 0.38 4.28 
92 0.873 ± 0.16 0.61 5.16  103 0.199 ± 0.042 0.35 5.29 
93 N.D.    104 0.309 ± 0.072 0.35 4.92 
94 1.523 ± 0.21 0.35 4.5  105 1.040 ± 0.47 0.21 5.08 
95 1.791 ± 0.25 0.35 4.27  106 0.528 ± 0.13 0.28 5.04 
96 4.391 ± 0.87 0.3 5.01  107 0.188 ± 0.077 0.29 4.43 
97 1.539 ± 0.28 0.33 5.46  108 0.011 ± 0.002 0.18 6.95 
98 1.833 ± 0.079 0.32 5.46  109 0.603 ± 0.24 0.2 7.12 





A diethyl substitution has been shown to be favorable in 3-Oxo-β-Sultams due to a better 
ki/kOH ratio, when compared, for example, with dimethyl or spiro-cyclohexil derivatives. 
Tsang and coworkers have established the ki/kOH ratio as a good measurement to evaluate 
3-Oxo-β-Sultams since it encompasses both the enzymatic inhibition value and the 
tendency for alkaline hydrolysis, giving an overall better metric of compound potential.257 
The most potent compound was the Rhodamine ABP 108, with an 11 nM IC50. 
Additionally, the biotinylated ABP 109 presented a good IC50 of 603 nM. These results 
were very promising since they showed that the addition of fluorophore and biotin tags 
did not negatively affect compound potency, supporting our concept of using these probes 
for proteomics applications. The alkyne derivatives 69 and 92 also showed good IC50 
values, of 3.271 µM and 0.873 nM, respectively, an encouraging result since these probes 
can be used for biorthogonal labeling experiments. 
Additionally, ligand efficiency (LE – Equation 1) and ligand-lipophilicity efficiency 
(LLE – Equation 2) values were calculated and are presented in Table 1.   
 
 
𝐿𝐸 =  
1.37
𝐻𝐴𝐶
 . 𝑝𝐼𝐶50 
 
Equation 1 – LE calculation. 
 
 
𝐿𝐿𝐸 = 𝑝𝐼𝐶50 − 𝑐𝐿𝑜𝑔𝑃 
 
Equation 2 – LLE calculation. 
 
 
LE and LLE are used in drug discovery to guide inhibitor development by providing a 
simultaneous measurement of both potency and lipophilicity to estimate druglikeness. 
According to these concepts, compounds should display an LE > 0.3 kcal mol-1 per heavy 
atom and an LLE > 5.274 The analysis of the LE and LLE values of the 3-Oxo-β-Sultam 
compounds revealed a promising outlook, with most compounds fulfilling the 
recommended values. Practically all the small inhibitors have an LE above 0.3, with most 
also presenting an LLE above 5 or slightly below this value. Interestingly, all the 3-Oxo-
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β-Sultam ABPs have an LE below 0.3, clearly reflecting the significant increase in size 
by inclusion of the bulky tags, which pertain to probe functions and do not necessarily 
contribute to target engagement, but which also contribute to the excellent LLE values 
for most of them. 
 
 
2.2.2. Biochemical Selectivity against Selected Serine Hydrolases 
 
An analogous approach was taken with a group of selected serine hydrolases to determine 
biochemical selectivity. The tested enzymes were thrombin, urokinase, trypsin, kallikrein 
and chymotrypsin. The obtained IC50 values are presented in Table 2. 
 
 
Table 2 – Biochemical selectivity against selected serine hydrolases (n = 3). 
 
           
  Thrombin  Urokinase  Trypsin  Kallikrein  Chymotrypsin 
  IC50 SD  IC50 SD  IC50 SD  IC50 SD  IC50 SD 
  µM  µM  µM  µM  µM 
             
92  6.2 1.2  2.6 1.1  >100  >100  >100 
107  2.0 1.1  1.7 1.1  >100  2.5 1.1  4.8 1.1 
109  6.8 1.2  >100  >100  >100  >100 
108  4.4 1.1  4.1 1.2  >100  >100  >100 
102  1.4 1.1  4.2 1.2  >100  >100  8.1 1.2 
 
 
The compounds were reasonably selective for HNE when compared with the other 
studied enzymes. For almost all the tested compounds, micromolar inhibition was 
measured for thrombin and urokinase. No activity was observed for trypsin. Kallikrein 
was only inhibited by 107 at micromolar levels and chymotrypsin was inhibited by 107 
and 102. These results reinforce our suspicions that the 3-Oxo-β-Sultam is able to inhibit 
other hydrolases other than HNE due to its high reactivity, however, there seems to be 
some degree of selectivity, since some of the tested serine hydrolases were not inhibited 
by any of the selected compounds in the biochemical selectivity assay and HNE’s 
inhibition is associated with much lower IC50s. A more in-depth analysis of the protein 
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engagement by the 3-Oxo-β-Sultams was performed using mass spectrometry and the 
biotinylated 3-Oxo-β-Sultam 109. 
 
 
2.3. Proteomic studies of 3-Oxo-β-Sultams 
 
With the biochemical results in hand, we next engaged in a proteomic study to understand 
the potential of 3-Oxo-β-Sultams as ABPs. The 3-Oxo-β-Sultam library was tested 
against purified HNE protein, revealing that the compounds are potent HNE inhibitors, 
with IC50 values ranging from low nanomolar to low micromolar values. This was an 
encouraging result, since it shows that the compounds possess enough stability to engage 
the targets in aqueous media and can potentially be used in biological applications as 
probes. Additionally, the most potent compound was the rhodamine derivative 108, 
reinforcing the potency of the ABP derivatives and suggesting this compound could be 
efficiently used in gel-based assays. Biochemical inhibition assays provide preliminary 
information regarding inhibitory properties and allow us to quickly compare between 
compounds of the same library but fail to mimic the more complex native environment 
where proteins are encountered in vivo. In our biochemical assays, there is a limited and 
controlled number of entities present, the target enzyme and the inhibitor, which increases 
the chances of inhibition if no relevant constraints for active site engagement are present 
and potentially overestimates the activity of some compounds. Additionally, the 
selectivity assays were limited to a selected group of related enzymes, making any claim 
of compound selectivity inherently flawed due to the small number of enzymatic entities 
tested when compared to the complexity of the proteome. For these reasons, we employed 
ABPP techniques to establish, for the first time, the full extent of target engagement and 




2.3.1. Gel Evaluation of 3-Oxo-β-Sultams 
 
Gel-based experiments are one of the pillars of proteomics and ABPP, providing 
preliminary information regarding proteome reactivity, potency and selectivity of the 
compounds against specific targets. Several experiments were done with 3-Oxo-β-
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Sultams, using different conditions and ABPs. Preliminary studies showed that the signal 
provided by the rhodamine derivative 108 was much stronger than the signals provided 
by the NBD ABPs 106 and 107. Additionally, the diethyl alkynylated derivative 92 
unsurprisingly provided a much better signal than the dimethyl counterpart 69. For these 
reasons, we performed the gel studies exclusively with compounds 92 and 108. 
We started by testing the general reactivity of the 3-Oxo-β-Sultam compounds by 
performing incubations of the alkynylated and rhodamine-derivatized ABPs with 
complete proteomes of selected cell lines. Compound 92 was incubated for 30 minutes in 
concentrations ranging from 0.1 to 100 µM with whole cell lysates from the cell lines 
HEK293T and U937. After incubation, a click reaction with rhodamine-azide was 
performed to allow visualization of the labeled proteins. FP-rhodamine 1 µM labeling 
was used for comparison (Figure 25). Concentration-dependent labeling of proteins was 





Figure 25 – Concentration range tests for 3-Oxo-β-Sultam ABP 92 in two different whole cell lysates of HEK293T 
and U937. Labeling of proteins is clearly visible around 5-10 µM and background labeling seems to increase 
significantly at high concentrations 75-100 µM. FP-Rhodamine (1 µM) labeling is shown for comparison. 
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selective, with only a few visible bands, but for higher concentrations, background 
labeling became significant, suggesting non-specific binding. These results suggested the 
alkynylated 3-Oxo-β-Sultam 92 was able to label proteins in a biological sample 
containing a full proteome, but did so with limited selectivity, especially at high 
concentrations. 
In a similar experimental setting, the rhodamine probe 108 was tested in increasing 
concentrations (0.1 to 100 µM) in THP-1 and HEK293T whole cell lysates. Like for the 
alkynylated ABP, concentration-dependent labeling of proteins was observed, with a 
good degree of apparent selectivity for lower concentrations, but significant background 






Figure 26 – Labeling of THP-1 and HEK293T whole cell lysates (1 mg/mL) with increasing concentrations of 3-Oxo-





To evaluate the ability of the compounds to label HNE, experiments were done where 
commercially purchased pure HNE was used in PBS as the sample (Figure 27). Both 
compounds 92 and 108 were incubated at 50 µM with decreasing concentrations of HNE, 
from 500 nM to 31.25 nM. The alkyne ABP 92 was clicked with rhodamine azide after 
incubation. For the rhodamine derivative 108, HNE labeling was observed for all 
concentrations of enzyme, down to 31.25 nM.  In the case of compound 92 a signal was 
only observed for the highest concentration, meaning the compound might not be suitable 
for tandem-labeling strategies for HNE. These results are consistent with the previously 
obtained IC50 values for these two compounds, where the rhodamine derivative 108 





Figure 27 – Labeling of decreasing concentrations of pure HNE by 3-Oxo-β-Sultams 92 and 108 at 50 µM. 
Compound 92 was clicked with Rhodamine azide after incubation with the proteome. While labeling is clearly 
observed with the Rhodamine probe, the alkyne probe provides a weak signal, only visible at 500 nM of HNE. 
 
 
We then spiked a full HEK293T proteome with HNE in decreasing concentrations to test 
HNE labeling in the presence of a full proteome. Compound 108 was incubated with these 
mixtures at 50 µM of compound concentration. HNE was clearly labeled by 108 down to 
a concentration of 75 nM, but concomitant labeling of additional proteins was also 
observed. These results showed that the probe was able to label HNE when in the presence 
of a complete proteome, but not with absolute specificity. Some bands were observed to 
increase in labeling as HNE’s concentration decreased, suggesting they could be HNE 





Figure 28 – HNE spiking experiments in HEK293T cells. 3-Oxo-β-Sultam-Rhodamine 108 labeling of pure HNE 
(first lane) and spiking of pure HNE in decreasing concentrations into HEK293T whole cell lysates (1mg/mL). 
Labeling of HNE is observed even in the presence of a complete proteome but not completely selective. As spiked 
HNE concentration decreases, labeling of some proteins clearly increases, indicating these might be HNE substrates. 
 
 
An additional experiment was done where HNE labeling was tested in three different 
situations: pure protein, pure protein spiked into a HEK293T whole cell lysate, and HNE 
natively expressed in a U937 proteome (whole cell lysate), a cell line which expresses 
active HNE.275 Additionally, in all three experimental conditions a pre-incubation with 
an HNE-specific active site-dependent inhibitor, ONO-6818,276 was done to attempt to 
block HNE labeling and confirm that 3-Oxo-β-Sultam inhibition of HNE was active site 
dependent. The results are presented in Figure 29. 
As expected from previous tests, the labeling of pure HNE by probe 108 was efficient 
and clearly visible as a group of three bands corresponding to different carbohydrate 
content, a known feature of HNE.134 Pre-incubation with ONO-6818 blocked labeling, 





Figure 29 – Testing of HNE labeling in a pure form, spiked into a complete proteome and in a cell line that expresses 
active HNE with compound 108. Labeling is clearly visible in all three types of experiments, being suppressed by 




Labeling of HNE when spiked into a full HEK293T proteome was also efficient and 
inhibited by ONO-6818. In U937 cell lines, labeling of a small band around the molecular 
weight of HNE was detected. Pre-incubation with ONO-6818 blocked labeling of the 
protein, confirming it was HNE and that labeling was active site-dependent. These results 
showed that compound 108 was capable of labeling HNE in a complex proteome at native 
concentrations with enough intensity to be visualized by gel-based ABPP techniques and 
suggested that the 3-Oxo-β-Sultam ABPs might be suitable for HNE studies in complex 
proteomes. 
To complement these gel studies, we performed competitive ABPP experiments using 
selected 3-Oxo-β-Sultam compounds. Briefly, compounds 92, 102 and 109 were 
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incubated with U937 whole cell lysates in different concentrations (0.1, 1.0 and 10 µM) 
for 30 minutes and then the FP or iodoacetamide probe was added and incubated for 30 
minutes. The samples were run in SDS-PAGE and compared with a control where DMSO 
was used as the competitor. The results are presented in Figure 30. 
Overall, there was no clear strong inhibition of any bands that were labeled by the FP or 
iodoacetamide probes, suggesting that either the compounds have a very selective target 









competition, when the highest concentrations of compound were tested, there seemed to 
be partial inhibition of specific targets (band above 50 kDa for compounds 109 and 92 
and bands around 25 kDa for compounds 92 and 102). This may suggest that inhibition 
of some serine hydrolase targets was incomplete or occurred with limited target 
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occupancy. In the case of the compound 102, there seemed to be a general non-specific 
reduction of FP labeling, which could indicate a general reactivity for serine hydrolases 
with low stoichiometry inhibition. In the iodoacetamide competition gel, there were no 
clear observable targets with the exception of a couple of bands at the highest 
concentration of compound 102, suggesting the compounds may have limited reactivity 
with cysteine residues. 
Overall, the gel-based assays performed with 3-Oxo-β-Sultam ABPs 92 and 108 indicated 
that these compounds seem to be able to efficiently label HNE, even in the presence of a 
complex proteome, and to do so in a process dependent on the active catalytic site of the 
enzyme. However, the results also suggested that selectivity and the stoichiometry of 
inhibition are limited, which could hinder their applicability as ABPs. 
 
 
2.3.2. Mass Spectrometry Evaluation of 3-Oxo-β-Sultams 
 
While gel-based experiments are a useful tool to quickly evaluate potency and selectivity 
of chemical compounds, a more in-depth analysis can be achieved using mass 
spectrometry. Gel experiments showed us that 3-Oxo-β-Sultam ABPs were able not only 
to label HNE in complex proteomes, but also additional enzymes. Mass spectrometry-
based ABPP techniques are extremely powerful and are able to provide a comprehensive 
list of engaged targets by the tested compounds and additional information like target 
occupancy by using competitive assays.13,42,72 
For these experiments we used the 3-Oxo-β-Sultam biotinylated derivative 109, since 
labeling of HNE by the alkynylated probe seemed to not be efficient in gel-based assays. 
Probe versus DMSO control and probe versus competitor experiments were done. A brief 
explanation of the relevance of this distinction is given here. In probe versus DMSO 
experiments, a proteome is incubated with an ABP and the labeled proteins are enriched 
and compared with a control sample where no probe was added. Proteins enriched in the 
sample containing ABP, but not in the control are deemed hits of the experiment and the 
hit proteins are considered “engageable” by the tested probe. This type of experiment is 
important to establish the scope of targets a probe can hit, but provides no information 
regarding the extent of inhibition and target occupancy of those targets, since even if only 
a small fraction of a certain protein is enriched by the probe and not by the DMSO, that 
protein will be classified as a hit.  
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To circumvent these limitations and provide a better target profile of the ABP, probe 
versus competitor experiments should be done. In this case, two separate samples are 
treated with either DMSO vehicle or a competitor, a molecule that should be as close as 
possible to the probe being tested, but without the alkyne or biotin handle. This competitor 
will engage its targets with varying levels of target occupancy. After this, both samples 
are separately incubated with the biotinylated probe and the profiles of enriched proteins 
are compared. Unlike the probe versus DMSO experiments, hits will be considered when 
successful competition is verified between the ABP and the competitor molecule, 
meaning proteins that were enriched in the DMSO experiment but not in the sample where 
competitor was used. The extent of inhibition can be calculated by comparing the 
enrichment of specific proteins between both samples, providing data on target 
occupancy. In practice, these assays can be used with any non-biotinylated molecule as 
competitor against a broad reactivity probe to study the target profiles of compounds. In 
our work with 3-Oxo-β-Sultams, the rhodamine derivative was used as a competitor since 
we had previous data confirming its ability to label HNE and other proteins in gel-based 
assays.  
The ABP was first tested in a quantitative protocol using ReDiMe in U937 cell lines.76 
Whole cell lysates originated from this cell line where normalized for protein content and 
treated with the ABPs or DMSO. Hit proteins were enriched using streptavidin-coated 
agarose beads and analyzed by mass spectrometry. A summary of the results with the 
proteins filtered for the serine hydrolase enzyme family is presented in Figure 31. 
The results showed labeling of HNE in the probe versus DMSO experiments only for the 
higher concentration of 50 µM of probe. Among the other targets there was clear labeling 
of several members of the DPP family, including FAP, DPP8 and DPP7, as well other 
enzymes like acyl-protein thioesterase 2 (LYPLA2), acylamino-acid-releasing enzyme 
(APEH) and carboxylesterase 1 (CES1), among others. In a separate experiment, HNE 
was spiked into a HEK293T whole cell lysate, providing more consistent results, with 
HNE being labeled in both concentrations of probe, 10 µM and 50 µM. Among the other 
targets we found PREP, fatty acid synthase (FASN), acyl-protein thioesterase 1 
(LYPLA1), LYPLA2, retinoid-inducible serine carboxypeptidase (SCPEP1), lysosomal 
Pro-X carboxypeptidase (PRCP), carboxypeptidase (CPVL), ABHD10, among others. 
The detection of some of these proteins was consistent with the results of the U937 cell 
line experiments, potentially reinforcing them as targets of our compounds.  
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To validate these results and determine target occupancy we performed probe versus 
competitor experiments using the rhodamine ABP as competitor. Surprisingly, the results 
were very variable and none of the labeled proteins was efficiently competed, suggesting 
low target occupancy of the targets identified in the probe versus DMSO experiments 





Figure 31 – ReDiMe results for 3-Oxo-β-Sultams. A ratio higher than 3 is considered a hit. The results were filtered 
to show only the serine hydrolase family of proteins. Each line represents one experiment. 
 
 
After running the samples and analyzing the data we weren’t completely satisfied with 
the consistency of the results. For this reason, we decided to change our approach to a 
protocol using SILAC-MudPIT going forward. In SILAC, the control and the tested 
samples are combined in the beginning of the process after probe labeling and user 
interference is minimized, which could improve our results. A summary of the obtained 
results filtered for the serine hydrolase family of enzymes is presented in Figure 32. 
The results from the experiments using SILAC were more consistent. In probe versus 
DMSO experiments a large group of serine hydrolases was labeled. HNE was labeled 
with maximum ratio in all experiments, reinforcing that our compounds are good HNE 
inhibitors. PREP, FASN, FAP, SCPEP1, LYPLA1, PRCP, CPVL and cytosolic acyl 
coenzyme A thioester hydrolase (ACOT7) were also consistently labeled in all replicates. 
Other proteins like CES1, APEH, LYPLA1, DPP7, DPP8, DPP9, PRTN3 were labeled, 
but not consistently between replicates. When validating these targets in a competitive 
protocol against compound 108 there were no high occupancy targets identified 







Figure 32 – ABPP-SILAC results for 3-Oxo-β-Sultams. The results were filtered for the serine hydrolase family. Hits 
were considered when the protein is enriched with a ratio of at least 3 when compared with a DMSO control in at 
least two experiments. A.109 [10 µM (Probe VS. DMSO)]; B.109 [50 µM (Probe VS. DMSO)]; C. [108 (100µM) 
VS. DMSO], then 109 (10 µM); D. [(108 (100µM) VS. DMSO)], then 109 (50 µM). 
 
 
high number of proteins identified and our interest in profiling serine hydrolase 
engagement (Figure 32). 
When analyzing the pool of enriched proteins identified in the assay, we see that 
approximately 70% were identified as hits of the 3-Oxo-β-Sultam in the 10 µM 
concentration. Increasing the concentration to 50 µM increases this number to 90%. This 
shows that the reactive group is very reactive and presents low selectivity, which could 
hinder its applicability in ABPP. When analyzing the results for the probe versus 
competitor experiments the number of targets with a high ratio decreases significantly for 
both tested concentrations. (Figure 33). When analyzing the complete list of high ratio 
hit, these were found to have no relevance. 
The analysis of the results shows that while 3-Oxo-β-Sultams hit a diverse group of serine 
hydrolases and could potentially function as an interesting broad reactivity probe, akin to 
the FP probes, the target occupancy was very low in virtually all proteins of interest, with 
very low SILAC ratios in the competitive assays, indicating that inhibition is not 
complete. Only PREP and FAP presented ratios higher than 3 and those ratios were 
inconsistent between replicates. When the analysis of the results was expanded to the full 
proteome we identified several proteasome subunits being inhibited with high target 
occupancy (data not shown).  
Overall, 3-Oxo-β-Sultams seem to not be suitable for use as ABPs since even though they 
labeled a high number of proteins of interest, inhibition is very incomplete for these 
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targets. These results also highlighted the importance of using a probe vs. probe 






Figure 33 - Example of the peptide count plotted against observed ratios for: A. 109, 10 µM vs. DMSO experiment; 
B. 109, 50 µM vs. DMSO experiment; C. Probe vs. probe experiment. Pre-incubation with 108, 10 µM or DMSO, 









2.4. Crystallography Studies 
 
The exact mechanism of inhibition of serine hydrolases by 3-Oxo-β-Sultam compounds 
remains unknown. Several experiments performed by the Page group have led to the 
conclusion that these compounds inhibit serine hydrolases like PPE by acylation of the 
active site serine. This, however, was based mostly on kinetic assays and the analysis of 
reaction reversibility.170,257 
The mechanism of target inhibition by a 3-Oxo-β-Sultam could, in theory, involve attack 
at either the acyl or the sulfonyl groups, resulting in opening of the ring and displacement 
of either a sulfonamide or an amide leaving group, respectively (Scheme 14).257  
To the best of our knowledge, a crystal structure of the complex resulting from the 
reaction of a 3-Oxo-β-Sultam compound with PPE, HNE or other serine hydrolases has 
never been generated or published. To unequivocally clarify the mechanism of action of 
3-Oxo-β-Sultams in serine hydrolase inhibition we performed crystallography 
experiments between PPE, HNE and selected compounds from the 3-Oxo-β-Sultam 
library. Our study was focused on PPE and HNE since HNE was our model target when 
developing the 3-Oxo-β-Sultams and PPE’s inhibition by 3-Oxo-β-Sultams is well-






Scheme 14 – Mechanism of inhibition of a putative Serine hydrolase by a 3-Oxo-β-Sultam Compound. Inhibition can 





The work started with the optimization of the conditions for PPE crystallization (Figure 
34). Co-crystallization of the compounds with the enzyme was attempted by two 
techniques, soaking of pre-formed PPE crystals with 3-Oxo-β-Sultam compounds and co-
crystallization of 3-Oxo-β-Sultam compounds with PPE. Only the second technique 
yielded the desired crystals where a positive density corresponding to a 3-Oxo-β-Sultam 





Figure 34 – Native PPE crystals obtained when screening different conditions for PPE crystallization. 
 
 
One of the first compounds to be successfully co-crystallized with PPE was 94 (Figure 
35). The compound structure was clearly defined, with the open-ring form after reacting 
with the catalytic serine from PPE. Surprisingly, the density map showed that PPE was 
inhibited by sulfonylation of the active site, a result which directly challenged previously 
published data.170 
The crystallization process was optimized, and an improved electronic density map 
technique was developed after refinement of the previous results. Compounds 106, 94, 
95 and 96 were co-crystallized with PPE. The open 3-Oxo-β-Sultam ring was visibly 
bound to the active site serine for all enzyme-compound pairs. In all co-crystallization 
experiments the protein had a positive density corresponding to the density of the ligand 
in the protein’s catalytic center. In all the refined models obtained the electron density 
suggested that the enzymes were being inhibited by sulfonylation. This was observed due 
to the presence of two density spheres near the catalytic serine which clearly correspond 
to the oxygens of the sulfonyl group. The crystallographic structures were refined and are 





Figure 35 – Reaction of compound 94 with PPE via attack of the catalytic serine to the sulfonyl group of 94. Active 
site zoomed view of the complexes between PPE and compounds 94, 95 and 96 with PPE. 
 
 
The results clearly showed that the mechanism involves formation of a bond between the 
catalytic serine oxygen and the sulfur from the 3-Oxo-β-Sultam, displacing an amide 
leaving group and leaving the enzyme sulfonylated. This was a surprising and promising 
result since it showed an unexpected mechanism of reaction between a serine hydrolase 
and the 3-Oxo-β-Sultam structure. Inhibition of serine hydrolases by sulfonylation is an 
underexplored strategy and these results might uncover some of the requirements and 
mechanisms underlying the inhibition of this type of enzyme. 
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For larger compounds like 106, electronic density was only well-defined at the catalytic 
center. This is probably explained by the flexibility and mobility of the distal part of the 






Figure 36 – Electron density map around the covalently bound 95 (A) and 96 (B) ligands of PPE, |2Fo-Fc| map is 
depicted in blue mesh and contoured at 1σ level. Color code: carbon in yellow, oxygen in red, nitrogen in blue, sulfur 
in green, and Br atoms in dark red. 
 
 
Using the COOT program, structures of native HNE were superimposed with the obtained 
structures for PPE-3-Oxo-β-Sultam crystals. The inhibitors were fitted into HNEs active 
site and bound to Ser-195, after which an energy minimized model for this complex was 
obtained. The results suggested that orientation of the ligand in the HNE-inhibitor 
complexes should be similar to the ones obtained for the PPE-inhibitor complexes. 
After the exciting results obtained with PPE, the same experiments were performed for 
HNE. This enzyme proved to be significantly more difficult to co-crystallize with the 3-
Oxo-β-Sultam compounds and only one crystal was obtained, for the complex of 
compound 102 with HNE. An X-ray structure of the complex at 2.6 Å resolution with 
Rcryst of 20.8 % was obtained. The open-ring compound was clearly defined in HNE’s 
active site, covalently bound to the catalytic serine via the sulfur atom, which was 
consistent with the mechanism found for PPE. The results showed that the sulfonyl 
moiety participates in hydrogen bonding with Gly-193, Ser-195 and His-63, contributing 
to complex stabilization, along with the expected accommodation of the two ethyl groups 





Figure 37 - Surface representation of HNE:102 (A) and PPE:94 (B) with ligands depicted in sticks (carbon in yellow, 
oxygen in red, nitrogen in blue, sulfur in green, and halide atoms in dark red (C) or light blue (D)); catalytic serine is 
colored in orange. Zoomed view of active site of HNE:102 (C) and PPE:94 (D) with |2Fo-Fc| electron density map 
drawn in blue mesh (at 1σ contour) around the covalently bound 3-Oxo-β-Sultam ligands.  
 
 
Comparison of the results for PPE and HNE showed that 94 seemed to interact more 
extensively with the surface of PPE than 102 interacted with the surface of HNE, which 
instead extended towards the solvent and showed greater structural flexibility (Figures 37 
and 38). 
Overall, for all tested compound-enzyme pairs, the mechanism of inhibition of PPE and 
HNE was shown to be sulfonylation of the active site serine. The three compounds 
crystallized with PPE showed similar crystal structures, with stabilization of the sulfone 
moiety by hydrogen bonding with neighboring aminoacids. These results suggest a 
unified mechanism for hydrolysis and serine hydrolase inhibition by 3-Oxo-β-Sultams. 
Sulfonylation is an underexplored strategy in enzymatic inhibition and drug discovery, 
with the β-sultams as the only sulfur (VI)-nitrogen-based reactive groups to successfully 





Figure 38 – Atomic interactions around the ligands in HNE:102 (A) and PPE:94 (B). Hydrophobic interactions are 
displayed in green. 
 
 
The covalent modification of proteins using sulfur-based reactive groups has focused on 
sulfur (VI) fluoride exchange chemistry, including sulfonyl fluorides and aryl 
fluorosulfates.280-282 The unanticipated preference of a catalytic serine to react with the 
sulfonyl center of the 3-Oxo-β-Sultam when a theoretically more reactive neighboring 
acyl center is present, which upon ring opening could expel the better sulfonamide anion 
leaving group, strongly suggests that the nature of the leaving group does not have a large 
effect on reactivity. The discovery that 3-Oxo-β-Sultams inhibit serine hydrolases by 
sulfonylation could provide an opportunity to expand the available pool of sulfonylating 
reactive groups in chemical biology and uncover new enzymatic mechanisms that could 





The work with 3-Oxo-β-Sultam compounds showed these highly reactive compounds 
engage a number of targets in complex proteomes, including serine hydrolases, doing so 
via a sulfonylation mechanism in the case of elastase enzymes. 
The synthesis of the compounds was straightforward, allowing some of the inhibitors to 
be efficiently obtained without relying on any chromatographic purification steps. The 
compounds also provided good results in biochemical enzymatic assays, showing 
efficient inhibition of HNE and some selectivity against a panel of related serine 
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hydrolases. More importantly, these assays showed that the compounds presented enough 
stability for biological experiments. 
Gel- and mass-spectrometry-based proteomic assays confirmed the compound’s potential 
for labeling of HNE, but also showed significant detrimental reactivity, which resulted in 
low stoichiometry engagement of a large portion of the enriched proteome and suggested 
the compounds have limited application as ABPs. 
On the other hand, our co-crystallization studies unveiled an unprecedented mechanism 
of inhibition by the 3-Oxo-β-Sultam compounds, via sulfonylation of the active sites of 
PPE and HNE. This data directly contradicted the results published by other groups that 
studied the same process in the past and could provide relevant information regarding the 
mechanisms of serine hydrolase sulfonylation and the selectivity of the nucleophilic 
attack of serine hydrolases when in the presence of multiple chemical groups of distinct 
reactivity. 
Medicinal chemistry endeavors by the Page group that focused on the 3-Oxo-β-Sultams 
have yielded derivatives with improved stability and lower reactivity, which could be 
suitable for further exploration as serine hydrolase inhibitors. While these contain a 
carboxylate alpha to the nitrogen atom of the 3-Oxo-β-Sultam, which will hinder HNE 











Chapter 3 – 4-Oxo-β-Lactams 
 
 
The 4-Oxo-β-Lactam chemotype has been discovered and studied by Moreira’s group at 
iMed.ULisboa as an inhibitor of serine hydrolases, namely HNE, and has been developed 
into libraries of potent enzymatic inhibitors.171,172,270 The full extent of protein 
engagement by the 4-Oxo-β-Lactam scaffold remains to be established by proteomics 
methods. Preliminary work with 4-Oxo-β-Lactam ABPs was done in the group but with 
no mass spectrometry-based ABPP experiments.183 In this chapter we sought to identify 
the full extent of targets of the 4-Oxo-β-Lactam chemotype in selected proteomes using 
fluorophore- and biotin-derivatized 4-Oxo-β-Lactams and to evaluate the scaffold’s 


















3.1. Synthesis of 4-Oxo-β-Lactam ABPs 
 
4-Oxo-β-Lactams were synthesized by slow addition of an appropriate amine to a 
dichloride derivative of a malonic acid.171,172,270 An alkyne derivative of the 4-Oxo-β-
Lactam (111) was synthesized via cyclization of diethyl malonyl dichloride with 
propargylamine (Scheme 15 – A). The 4-Oxo-β-Lactam-alkyne 111 was derivatized into  
Rhodamine and Biotin ABPs, 112 and 113, respectively, using CuAAC click chemistry 
(Scheme 15 – B, C).54 The Rhodamine ABP was used for gel experiments and the biotin 






Scheme 15. A. Synthesis of an alkynylated 4-Oxo-β-Lactam; B. Synthesis of a biotinylated 4-Oxo-β-Lactam ABP; C. 






3.2. Proteomic studies of 4-Oxo-β-Lactams 
 
Despite having been used to develop potent HNE inhibitors in the past,183 no proper 
proteomics approach has been taken to establish the full extent of target engagement by 
4-Oxo-β-Lactams. In this work we developed both fluorescent and biotinylated 4-Oxo-β-
Lactam ABPs for application in gels and mass spectrometry. Our goal was to validate our 
previous work with HNE inhibitor development by confirming it as a target of 4-Oxo-β-
Lactams and to potentially uncover new targets of interest that would allow us to 
repurpose the 4-Oxo-β-Lactam chemotype to develop inhibitors for other targets. For this 
purpose, we used the U937 cell line since it natively expresses HNE and had shown to 




3.2.1. Gel Evaluation of 4-Oxo-β-Lactams 
 
We started by evaluating the 4-Oxo-β-Lactam ABPs in gel-based assays. The proteome 
reactivity of the alkynylated 4-Oxo-β-Lactam 111, which could potentially be used for 
tandem-labeling experiments, was tested by labeling HEK293T and U937 whole cell 
lysates with increasing concentrations of probe, from 0.1 to 100 µM.  After incubation, a 
click chemistry reaction was performed with rhodamine-azide to append a fluorophore to 
the alkynylated probe. FP-Rhodamine labeling was used as a control reaction (Figure 40). 
Concentration-dependent labeling of proteins was clearly seen, down to 0.1 µM 
concentration in HEK293T cells. Unlike the 3-Oxo-β-Sultams, increasing the 
concentrations up to 100 µM doesn’t seem to significantly increase non-specific 
interactions, with no excessive increase in intensity of labeling and number of apparent 
labeled entities, suggesting that these compounds are more selective. The labeling pattern 
was also significantly different from FP-rhodamine labeling, suggesting the 4-Oxo-β-
Lactam chemotype could offer complementary coverage to the FP probes. 
Knowing the reactivity of the alkyne ABP we proceeded to test the rhodamine derivative 
113 in similar conditions for both cell lines HEK293T and U937 and in the same 






Figure 40 – Concentration range tests for 4-Oxo-β-Lactam-alkyne 111 in HEK293T and U937 whole cell lysates. The 
ABPs were clicked with Rhodamine-azide after incubation with the proteomes for 30 minutes. Labeling of proteins is 
clearly visible starting at low concentrations 0.1-1 µM and appears to be concentration-dependent, with little to no 




Comparable results to the alkyne probe were obtained. Labeling was observed even at the 
low concentrations of 0.1 and 1 µM. At high concentrations, between 50 and 100 µM, 
background labeling didn’t seem to increase excessively and the protein target profile 
seemed to be consistent as concentration increases, a promising result, which suggested 
that 4-Oxo-β-Lactams were much more selective in terms of target engagement when 
compared with the 3-Oxo-β-Sultams. 
Following the gel experiments it seemed that a concentration between 1 and 10 µM was 
ideal to achieve good protein labeling with minimum non-specific background labeling. 










Figure 41 – Concentration range tests for 4-Oxo-β-Lactam-rhodamine 113 in HEK293T and U937 whole cell lysates. 
The ABPs were incubated with the proteomes for 30 minutes. Labeling of proteins is clearly visible starting at low 





The biotinylated 4-Oxo-β-Lactam 112 was tested in a competitive ABPP approach 
(Figure 42). The compound was incubated at three different concentrations (0.1, 1.0 and 
10.0 µM) in U937 whole cell lysates and fractioned U937 lysates. The proteomes were 
then labeled with FP-Rhodamine and the samples were run in SDS-PAGE. Only a few 
proteins were observed to be inhibited by the compound, like the band at approximately 






Figure 42 – Competitive ABPP for the biotinylated 4-Oxo-β-Lactam 112 compound in U937 whole cell lysates, 




3.2.2. Mass Spectrometry Evaluation of 4-Oxo-β-Lactams 
 
Gel-based experiments with the alkynylated and the rhodamine derivatives of the 4-Oxo-
β-Lactam showed a reasonably selective profile of proteome labeling at low 
concentrations. We followed these results by performing mass-spectrometry-based ABPP 
to identify the labeled proteins. 
We started by performing probe vs. DMSO control experiments with the 4-Oxo-β-Lactam 
biotinylated probe in U937 whole cell lysates using ReDiMe. The results, which were 
filtered for serine hydrolases, are presented in Figure 43.  
The target profile for 4-Oxo-β-Lactams was moderately selective. Approximately 20 
potential targets were identified, including HNE, PREP, APEH, LYPLA1, LYPLA2, and 






Figure 43 – ReDiMe results for 4-Oxo-β-Lactams. Probe vs. DMSO and competitive experiments. The results were 
filtered for serine hydrolases. Preliminary results, only one replicate was performed. 
 
 
To validate these targets, we performed probe versus competitor experiments using a 
rhodamine 4-Oxo-β-Lactam ABP (113) as competitor (Figure 43). The number of targets 
with high ratio was reduced significantly, indicating that only a few proteins were true 
high occupancy hits. The target list showed efficient labeling of DPP family members, 
with DPP8, DPP9 and FAP returning maximum hit ratios. ABHD6, carboxylesterase 2 
(CES2), carboxylesterase 3 (CES3), PRCP and SCPEP1 were also identified as hits. 
Surprisingly, HNE was not identified in these complementary experiments, suggesting it 
could be a low target occupancy hit for this compound at the tested concentrations. These 
results showed that the 4-Oxo-β-Lactam reactive group is very promising for the 
development of ABPs for a selected group of serine hydrolases. However, these 
experiments were merely exploratory and only one replicate was done. A more in-depth 
study was done using SILAC, which previously showed more reliable results when 
working with the 3-Oxo-β-Sultams. 
The experiments were repeated using SILAC U937 cells. Probe versus DMSO 
experiments with 1 µM of biotinylated 4-Oxo-β-Lactam 112 were performed (Figure 44). 
The results between three replicates were consistent and mostly agreed with the results 
found in the ReDiMe experiments. Targets like APEH, PRCP, the members of the DPP 
family and the LYPLAs were once again identified. DPP8 was only identified in one of 
the three experiments. HNE was not identified in any of the replicates, consistent with the 
ReDiMe results. Increasing probe concentration to 10 µM led to identification of a few 
additional targets, including FASN, HNE, CPVL, lysosomal protective protein (CTSA), 
ABHD6 and CES3, but this was based in only one replicate. 
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Competition experiments (Figure 44) confirmed that 4-Oxo-β-Lactams inhibited DPP7, 
DPP8, DPP9 and FAP from the DPP family with high target occupancy, as well as 
ABHD6 and the CES enzymes. Unlike what the ReDiMe experiments showed, HNE 
presented a ratio of 20, which confirmed the serine protease as a target of 4-Oxo-β-
Lactams and is consistent with previous work from our group. Other identified enzymes 
included PR3, PREP and SCPEP1. The SILAC results supported the preliminary results 
obtained with ReDiMe, revealing a surprisingly selective profile of targets, especially 
when compared with the results obtained for 3-Oxo-β-Sultams. The identification of 
several targets as true high occupancy hits showed that the 4-Oxo-β-Lactam reactive 
group is suitable for ABPP applications. These compounds were originally envisaged for 
the inhibition of HNE, so the identification of additional serine hydrolase targets that are 
strongly inhibited was surprising and an exciting prospect for the potential of the 
chemotype in developing enzymatic inhibitors for these targets.  
 




Figure 44 – SILAC-MudPIT results for 4-Oxo-β-Lactams. Results were filtered for serine hydrolases. The results 
present an average ratio of at least 2 replicates and only when the target was identified in at least two experiments is 
the target shown. 
 
 
The output of the LC-MS/MS experiments performed with the biotinylated 4-Oxo-β-
Lactam ABP 112 identified several unexpected serine hydrolases as targets, including 
multiple members of the DPP and ABHD families of serine hydrolases.  Our biotinylated 
probe was a simple 4-Oxo-β-Lactam ring separated from biotin with a PEG3 linker. 
Inhibitors with maximum activity for specific targets could potentially be developed by 
taking advantage of not only molecular recognition of the 4-Oxo-β-Lactam by the 
catalytic apparatus of the enzyme, but also by exploring favorable noncovalent 
interactions at the various subsites of the enzymes.  
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Most of the identified proteins have therapeutic potential, like FAP, whose inhibition is 
pursued as an anti-cancer therapy.196,198 DPP8 and DPP9 inhibition is also a hot topic, 
since these are usually concomitantly inhibited and no selective inhibitors for each have 
ever been described.188,210,220,224 Enzymes of the ABHD family are also associated with 
important pathways, including ABHD2, which could be associated with COPD 
development.247 
Given the potential of the 4-Oxo-β-Lactam reactive group target profile and the myriad 
of targets that these compounds could potentially hit, it was decided to pursue the 
development of inhibitors of the newly identified enzymes focusing on the 4-Oxo-β-




3.3. Synthesis of a Library of 4-Oxo-β-Lactam Inhibitors 
 
The yields for 4-Oxo-β-Lactam ring cyclization reaction have been historically low, 
mostly due to the dominant formation of a diamide side-product. For the quick 
derivatization of the 4-Oxo-β-Lactam scaffold into a varied library of compounds, it was 
important to optimize the synthetic route to allow a significant amount of 4-Oxo-β-
Lactam starting material to be generated and easily derivatized. The synthetic route 
described in our group’s published research consists in performing the reaction in dioxane 
at room temperature while approximately 1 equivalent of the amine is slowly added to 
the dichloride malonate derivative (Scheme 16 – A). These procedures usually resulted 
in yields of less than 10% for the cyclization reaction.171,172,183,270 We performed an 
optimization of the synthesis of the 4-Oxo-β-Lactam in which the major factor was 
changing the reaction solvent from dioxane to DCM, allowing it to be performed at 0°C, 
instead of room temperature, which was previously required due to dioxane’s high 
melting point. The stoichiometry of the reagents was also adjusted to promote formation 
of the compound instead of the side-product. Our optimized conditions dramatically 
increased the yields of the cyclization reaction to near quantitative values. Specifically, 
this method resulted in yields of approximately 80, 90 and 100% for cyclization reactions 
with o-, m- and p- toluidine, respectively, after one chromatographic purification step 
(Scheme 16 – B). This strategy allowed gram amounts of 4-Oxo-β-Lactam starting 
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Scheme 16 – Optimization of the synthesis of the 4-Oxo-β-Lactam scaffold using the example of compound 114: A. 
the classic synthesis of 4OBLs, which resulted in the unwanted diamide as the major product; B. Optimized synthesis 
of 4-Oxo-β-Lactams, which results in near-quantitative yields in selected cases. 
 
 
For this project, a diethyl substitution on the 3-position was used, since this motif has 
been shown to adequately fit the catalytic sites of specific serine hydrolases and the 
starting material was commercially available. An N-aryl substitution was chosen for most 
compounds, since it results in a better leaving group upon opening of the ring when 
compared to N-alkyl or N-benzyl groups, resulting in increased compound potency.270 To 
achieve these structural motifs, (-p, -m or -o) toluidines were used as the amines for 
cyclization of the commercially available diethyl malonyl dichloride. The methyl group 
of the toluidine scaffold was then brominated using N-bromosuccinimide in the presence 
of benzoyl peroxide and a nucleophilic substitution reaction with a diverse library of 
amines, mostly piperazine derivatives, was used to obtain the final compounds. Scheme 












N-benzyl, but also N-aryl substituents were chosen, containing both electron withdrawing 
and electron donating groups. Additional variety was introduced with pyridine and 
piperonal substituents and to achieve geometrical diversity, bulkier and less linear 
substituents like dibenzylamine and 1-(bis(4-fluorophenyl)methyl)piperazine and other 
heterocycles were used. 
Two additional compounds were prepared by cyclization with benzyl 4-
(aminomethyl)benzoate, resulting in the corresponding 4-Oxo-β-Lactam 119 (Scheme 18 
– A). The benzyl group was deprotected by hydrogenation with triethylsilane and 
palladium in activated charcoal to generate a compound with a free carboxylic acid, 120 
(Scheme 18 – B). Both the benzylated and the deprotected compounds, 119 and 120, 
respectively, were tested in the competitive experiments. These two compounds allowed 
us to evaluate how critical the N-aryl substitution is for activity and if the presence of a 
free carboxylic acid significantly changes reactivity and selectivity. The complete library 








Scheme. 18 – Synthesis of 4-Oxo-β-Lactam compounds 119  and 120. A. Synthesis of a 4-Oxo-β-Lactam with N-
benzyl substituent, 119, from benzyl 4-(aminomethyl)benzoate; B. Synthesis of a 4-Oxo-β-Lactam with a free 





3.4. Competitive ABPP 
 
With the new library of 4-Oxo-β-Lactams in hand we performed preliminary studies of 
potency and selectivity by gel-based competitive ABPP against the well-established 
serine hydrolase-reactive FP probes in U937 cells (Figure 39).283 Briefly, compounds 
were incubated with U937 whole cell lysates for 30 minutes at 3 different concentrations, 
0.1 µM, 1 µM and 10 µM. After 30 minutes, 1 µM of FP-Rhodamine was added. 30 
minutes later the reaction was quenched with loading buffer and the mixture was analyzed 
by SDS-PAGE. Compound reactions were compared against a control sample pre-
incubated with DMSO for 30 minutes and then FP-Rhodamine. Inhibition of an enzyme 
by the 4-Oxo-β-Lactam compounds resulted in total or partial blocking of FP-rhodamine 
labeling, leading to disappearance of a band when compared with the DMSO control. 












Figure 46 – Example of a competitive ABPP experiment for selected para-substituted 4-Oxo-β-Lactam compounds 
(117, 121, 122, 123, 124, 125) compounds in U937 whole cell lysates against FP-Rhodamine (1 µM). The region 
between 75 and 150 kDa is reproduced on the right with higher contrast. 
 
 
Figure 47 – Example of a competitive ABPP experiments for selected para-substituted 4-Oxo-β-Lactam compounds 
(132, 133, 134, 135, 136, 137) compounds in U937 whole cell lysates against FP-Rhodamine (1 µM). The region 
between 75 and 150 kDa is reproduced on the right with higher contrast. 
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for the entire 4-Oxo-β-Lactam library are presented in the attachments section. The 
analysis of the gel showed selective blocking of some targets of the FP probe.  
These gels offered a preliminary glimpse into the reactivity of our compounds, showing 
a surprisingly selective profile of inhibition, in some cases also with good potency. The 
para-substituted compounds showed very efficient labeling of a protein at 25 kDa 
(compounds 117, 121-125), which could potentially be HNE or PR3. Some of the meta-
substituted compounds also inhibited this band, but generally with less potency 
(compounds 132-137). The area between 75 kDa and 150 kDa, where most DPP family 
members fall was difficult to analyze due to the lower abundance of some proteins but 
seemed to suggest there was more efficient inhibition of these enzymes by the meta-
substituted compounds, with compounds 132 and 135 showing inhibition of a band at 100 
kDa, which could potentially be either DPP8 or DPP9. Overall, the results seemed to be 
hindered by the lack of resolution in the ~30 kDa section, where a lot of proteins overlap. 
For these reasons, the experiments were repeated using fractioned cell lysates, with 
separated soluble and membrane fractions of proteins, which usually provide better 
resolution. 
The inhibitors were incubated with membrane and soluble lysate fractions of U937 cells 
for 30 minutes at 3 different concentrations, 0.1 µM, 1 µM and 10 µM. After 30 minutes 
1 µM of FP-Rhodamine was added. 30 minutes later the reaction was quenched with 
loading buffer and the mixture was analyzed by SDS-PAGE. Compound reactions were 
compared against a control sample pre-incubated with DMSO for 30 minutes and then 
FP-Rhodamine. The gel of fractioned lysates offered a much more readable profile of 
protein labeling than before. The gels for selected compounds are presented in Figure 48. 
The full results for the entire 4-Oxo-β-Lactam library are presented in the attachments. 
The results suggested that the compounds are potent and selective inhibitors of a selected 
group of serine hydrolases. A band at approximately 25 kDa in the membrane fraction 
(potentially HNE) was strongly inhibited by several compounds (for example compounds 
117, 121 and 124), even at low concentrations of 100 nM. Bands at approximately 100 
kDa in the soluble fraction (likely to be DPP8, DPP9 and/or FAP) seemed to also be 
strongly inhibited by some compounds (for example 132, 135 and 139). Bands lower than 
25 kDa in the soluble fraction also showed some inhibition (probable LYPLA1 and 
LYPLA2) for most tested compounds.  
Other bands which were harder to identify with confidence also show inhibition when 
compared with the DMSO control, suggesting additional enzymes are being hit by the 
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compounds. These identifications were suggested by a combination of previous 
knowledge of the expected targets of 4-Oxo-β-Lactams and known labeling patterns of 
FP-probes. 
A significant number of bands increased in labeling intensity when compared to the 
DMSO control. This can be explained by inhibition of serine proteases, which led to an 
increase in their substrates, suggesting the increasing bands could potentially be proteins 
that are usually cleaved by serine hydrolases that were inhibited by the 4-Oxo-β-Lactams. 
Overall the results suggested that para-substituted compounds result in a remarkably 
potent inhibition of the band at 25 kDa in the membrane fraction, while the meta-
substituted compounds seemed to have a much higher potency against the bands around 
100 kDa in the soluble fraction, with some compounds, like 135, showing significant 
inhibition at 100 nM and seemingly complete inhibition at the two higher concentrations. 
This suggested potential SAR dynamics involving positioning of the substituents in the 
aromatic ring attached to the 4-Oxo-β-Lactam core. This had previously been observed 
in work of our group with HNE inhibition, where compounds with substituents at the 
para-position showed higher potency.270  
Ortho-substituted compounds showed almost no blocking of relevant FP-labeled bands 
and were not presented here, with only some minor bands being partially inhibited at the 
highest concentration of 4-Oxo-β-Lactam compound (gels for these compounds are 
presented in the attachments). Compounds 119 and 120 showed inhibition of some bands, 
but no unique features that warranted further study. 
The data presented above was obtained when the compounds were tested in U937 whole 
cell lysates. To evaluate the capacity of selected compounds to cross the cell membrane 
and inhibit serine hydrolases we performed a competitive ABPP assay in whole U937 
cells. Briefly, U937 cells were diluted to 1 million cells/mL in serum-free media and 
incubated with selected compounds of the 4-Oxo-β-Lactam library at 1 and 10 µM of 
concentration. DMSO controls were also performed. The mixtures were incubated at 
37°C for one hour. The reactions were stopped by centrifugation, removal of media and 
PBS wash, followed by resuspension and lysis in PBS. Protein content was normalized 
to 1 mg/mL and the samples were labeled with FP-Rhodamine for 30 minutes. The results 





Figure 48 – Competitive ABPP gels with soluble and membrane fractions of U937 cells for selected compounds. 
Disappearance of a band when compared with DMSO control indicates that band is a target of the compound. Clear 
inhibition of some targets is observed. Analysis of the molecular weights seems to suggest that the compounds are 
inhibitors of DPP8 and/or DPP9 (soluble fraction, ~100 kDa), PREP (soluble fraction, ~75 kDa) and HNE 





Figure 49 – Competitive ABPP in U937 whole cells using selected compounds from the 4-Oxo-β-Lactam library. The 




The gel profiles suggested that 4-Oxo-β-Lactam compounds were generally able to cross 
the cell membrane. This was suggested by the different FP labeling profiles observed 
when compared with the DMSO control for nearly all compounds at different points in 
the gels. Some particular bands that were identified in the whole cell lysate assays seem 
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to also be inhibited in these assays, including the band at approximately 25 kDa for 
compounds 117, 121 and 126, for example. Interestingly, multiple bands that are not 
visible in the DMSO-treated sample are being strongly stained by FP in compound-treated 
samples, particularly, bands above 150 kDa, which are visible in samples treated with 
compounds 117, 122, 123, 126, 128 and 135. Additional bands present this pattern across 
the gel. This phenomenon might be the result of inhibition of serine proteases, with the 
proteins corresponding to bands of increased labeling being potential substrates of these 
enzymes. Overall, a significant change in the profile of serine hydrolase labeling by FP 
was observed, suggesting that 4-Oxo-β-Lactams efficiently cross the cell membrane, in 
sufficient concentrations to cause changes in enzymatic behavior that are visible by SDS-




3.5. Competitive ABPP-MudPIT 
 
The gel-based assays showed us that the compounds have a selective profile of targets 
within the pool of FP-labeled proteins. The identification of these proteins cannot be made 
with complete confidence based solely on gel data since proteins with similar molecular 
weight co-migrate in the gel. In our case for example, inhibition of HNE could be 
mistaken with inhibition of PR3. Other enzymes like DPP8, DPP9 and FAP also have 
similar molecular weights. Mass-spectrometry-based techniques can be applied to 
confidently identify the targets of our compounds, either by extracting bands from gels 
or simply by analyzing the full proteome via LC-MS/MS. In this work we took the second 
approach, adapted to a competitive ABPP protocol. 
Based on the competitive ABPP gel profile, six compounds were selected for analysis by 
competitive ABPP-MudPIT, including three para-substituted compounds, 117, 124 and 
126, and three meta-substituted compounds, 135, 138 and 139. SILAC U937 cells were 
employed; heavy cells were treated with DMSO while light cells were treated with 
selected compounds at 10 µM concentration for 30 minutes. After this, 5 µM of FP-biotin 
was added to each sample and incubation was done at room temperature for 1h. Samples 
were combined and enriched with streptavidin beads for 2.5h, followed by overnight 
trypsinization. Samples were run in duplicate on an LC-MS/MS experiment and 





Figure 50 – Overview of a competitive SILAC-ABPP-MudPIT Protocol for 4-Oxo-β-Lactam compounds. The 
proteomes of SILAC “light” cells and SILAC “heavy” cells are incubated with either 4-Oxo-β-Lactam compound or 
DMSO. Both samples are then treated with FP-Biotin to label the serine hydrolases that are not inhibited by the 4-
Oxo-β-Lactam compound. The reaction is quenched, the samples are combined, enriched with streptavidin, and 
processed for LC-MS/MS analysis. Determination of heavy/light ratios gives the IDs of serine hydrolases inhibited 
by the 4-Oxo-β-Lactam compound. 
 
The results of the mass-spectrometry-based competitive ABPP supported the results of 
the gel-based assays by presenting a relatively selective target profile for all the tested 
compounds. Meta-substituted compounds seemed to be more selective than para-
substituted compounds. HNE and PR3 showed maximum ratios for all para-substituted 
compounds. Meta-substituted compounds, especially compound 138, showed efficient 
inhibition of HNE and no hit for PR3, suggesting the meta-substitution pattern in the 
aromatic ring could be exploited to selectively target HNE and not PR3. The DPP family 
seemed to not be significantly inhibited by compounds 117, 124 and 126, with the 
exception of FAP. Meta-substituted compounds inhibited FAP and DPP9, while DPP8 
returned minimal ratios to be considered a hit for compounds 138 and 139. This could 
suggest some degree of selectivity between DPP9 and DPP8, a desirable characteristic, 







Figure 51 – Competitive ABPP-MudPIT experiments for selected compounds of the 4-Oxo-β-Lactam library. 
Heavy/light ratios are presented. Values higher than 3 are considered a hit. The results were filtered for serine 
hydrolases (n = 2). 
 
 
The ABHD family of enzymes was represented by 4 members. All compounds seemed 
to hit ABHD16A and para-substituted compounds hit ABHD6 and ABHD3, while 
ABHD2 is hit by compounds 117, 124 and 138. PARL was hit by all para-substituted 
compounds with maximum ratio and, to a lesser extent, by compound 135. Additional 
hits included CES3 by compound 135, PAFAH2 by all para-substituted compounds and 
APEH, LYPLA2, AFMID, LIPA and DDHD2 were all hit by compound 117. 
Following these results, we performed target validation for selected enzymes identified 
in the competitive mass spectrometry assays, namely HNE, DPP8, DPP9, FAP, ABHD6, 







3.6. Target Validation and IC50 calculation 
 
Following the mass spectrometry experiments it was necessary to validate the main 
proteins identified in the assays as targets of the 4-Oxo-β-Lactam compounds. For this 
purpose, a competitive ABPP protocol was employed with overexpressed serine 
hydrolases and IC50s for selected compound-target pairs were calculated.  
Given the extensive work of the Cravatt Lab with Serine Hydrolases, a library containing 
plasmid genes in cloning vectors for most of the existing serine hydrolases was readily 
available. We overexpressed selected targets of interest to test the compounds and 
calculate IC50s, including DPP4, DPP7, DPP8, DPP9, FAP, PREP, ABHD2, ABHD3, 
ABHD6, ABHD16A, SCPEP, CES1, HNE, LYPLA1, LYPLA2, APEH and PAFAH2. 
Overexpression of METTL7A was used a as mock transfection. 
Briefly, the plasmid DNA for each serine hydrolase was transformed into E. coli for 
amplification and the DNA was obtained using an appropriate DNA extraction miniprep 
kit. The plasmid DNA was transiently transfected into HEK293T cells using 
polyethyleneimine (PEI) as the transfection agent (Figure 52).284 The cells were incubated 
for approximately 48h, after which they were collected and lysed. The protein 
concentration was normalized to 1 mg/mL. Appropriate overexpression of the serine 
hydrolases was confirmed by FP-rhodamine labeling (Figure 53) and by western blotting 
using an anti-FLAG tag antibody for selected enzymes.  
Most of the overexpressed serine hydrolases resulted in clear overexpression of the 
protein, which was confirmed by labeling with FP-Rhodamine. HNE overexpression did 
not result in the active protease being overexpressed. A western blot analysis using an 
anti-FLAG tag primary antibody (all overexpressed proteins contained the FLAG tag) 
confirmed that the protein was overexpressed, but in the inactive form (Figure 54). 
Additionally, APEH and ABHD3 seemed to not have been efficiently overexpressed in 
our assay. 
We decided to test the possibility of measuring HNE in the proteome of U937 cells. This 
cell line was originally chosen due to its native expression of HNE. For this purpose, a 
western blot analysis was done with an anti-HNE antibody to confirm where HNE located 
in fractioned U937 cell lysates (Figure 55). The results showed HNE was only identified 
in the membrane fraction of U937 lysates. This is consistent with HNE being described 






Figure 52 – Overexpression of Serine Hydrolases via PEI-mediated transient transfection of plasmid DNA containing 
a selected serine hydrolase gene. The PEI/DNA complex is internalized, and the DNA is released in the cell. 





















Figure 55 – Western blot of HNE in U937 membrane and soluble fractions using an anti-HNE antibody. The 




A preliminary inhibition test with the overexpressed serine hydrolases was done using 
compounds 117 (para-substituted) and 135 (meta-substituted) to help determine the 
adequate concentration ranges for the following studies. A range of compound 
concentrations between 50 nM and 50 µM was tested for a series of overexpressed serine 
hydrolases. After pre-incubation with the compounds for 30 minutes FP-Rhodamine was 
used to label the proteins. The results are presented in Figure 56. 
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Selected compound-target pairs were tested for IC50 determination by competitive ABPP. 
Compounds were incubated with whole cell lysate proteomes of HEK293T cells with the 
individually overexpressed serine hydrolases. HNE was tested in the U937 cell line. 
Increasing concentrations of compound were incubated with the proteomes for 30 
minutes and then labeled with FP-Rhodamine. The samples were run in SDS-PAGE 
experiments and band intensity of the selected targets was quantified using appropriate 
software. All samples were run in at least triplicates. In select cases additional 
experiments were performed to cover a wider range of concentrations. The results were 
plotted as log [4-Oxo-β-Lactam inhibitor] vs. normalized response and IC50s were 
calculated. Selected examples are presented in Figure 57 (the complete results are 

















Figure 57 – Examples of determination of the IC50 for selected compound-protein pairs: 132-HNE; 135-DPP8; 139-
DPP9. FP-labeling blocking is analyzed by SDS-PAGE and gel band intensity is quantified and plotted, allowing the 






For some serine hydrolases that were not our main interest of study, a preliminary test of 
inhibition was done where the overexpressed serine hydrolases were incubated with the 
compounds at 1 µM concentration (Figure 58). If inhibition at this concentration was 
significant, further assays were performed in a range of concentrations. Significant 
inhibition was only observed for ABHD2 with compounds 117, 124, 132, 138 and 139, 
with visible competition of FP-Rhodamine labeling. Additional tests were done for 
compounds 124, 132 and 139, which showed the best ABHD2 inhibition. A summary of 




Figure 58 – Preliminary testing for selected serine hydrolase-compound pairs at 1 µM concentration. 
 
 
Table 3 – Summary of the IC50 values (nM) determined by competitive ABPP for the tested compound-target pairs. 
 
 
117 121 124 126 132 135 138 139 
         
HNE 29 6 19 226 246 553 25 483 
DPP8 1140 - 404 - 137 392 292 34 
DPP9 5171 - 603 - 409 950 1033 92 
FAP 219 680 652 2755 147 - > 10000 - 
ABHD6 7 - 253 - > 10000 320 > 10000 44 
DPP4 3446 - 646 - 1398 1182 2699 47 
DPP7 > 10000 - > 10000 - > 10000 > 10000 > 10000 > 10000 




The results revealed significant differences between the para-substituted compounds, 
117, 121, 124 and 126, and the meta-substituted compounds, 132, 135, 138 and 139. All 
compounds showed sub-micromolar inhibition of HNE, with compounds 117, 121, 124 
and 138 having an IC50 below 30 nM. Inhibition of DPP8 and DPP9 was also efficient 
and seems to be stronger for meta-substituted compounds, as suggested by the 
competitive gel-based assays. Compound 139 is especially potent, having IC50s of 34 nM 
and 92 nM for DPP8 and DPP9, respectively. This compound also strongly inhibits DPP4, 
while most other tested compounds show micromolar inhibition. FAP is overall 
efficiently inhibited, at varying levels across the tested compounds, with the best IC50 
corresponding to compound 132. ABHD6 is very efficiently inhibited at low nanomolar 
values by compounds 117 and 139, but with no significant inhibition by some meta-
substituted compounds like 132 and 138. ABHD2 showed efficient sub-micromolar 
inhibition by all three tested compounds. DPP7 was not efficiently inhibited by any of the 
tested compounds, reflecting the significantly different structure when compared with 
DPP4, DPP8 and DPP9.286 Despite not being completely comparable, the results for 
DPP8 and DPP9 showed an interesting pattern, with a generally stronger inhibition of 
DPP8. These two enzymes share significant similarity, which makes the development of 
selective inhibitors a difficult task. The apparent preference of 4-Oxo-β-Lactams for 
DPP8 could guide future SAR studies into the different requirements for DPP8 and DPP9 
inhibition, being a promising result from our competitive ABPP studies. 
Overall, the results suggested compound selectivity can be slightly tuned between the 
DPP family and HNE/ABHD6, supporting the results that were previously obtained in 
the LC-MS/MS assays. Compounds with p-substituted N-aryl groups are generally more 
potent towards HNE and ABHD6, while compounds with m-substituted N-aryl groups 
are more potent towards DPP8 and DPP9. No ortho-substituted compounds were tested 




3.7. Development of a Clickable ABP 
 
A Clickable 4-Oxo-β-Lactam, 151, carrying a 3-diethyl substitution, an N-aryl group and 
an alkyne handle for CuAAC was synthesized using a 1-prop-2-ynylpiperazine. The 
synthesis followed the same path as the rest of the 4-Oxo-β-Lactam library, except for the 
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alkynylated piperazine building block, which was synthesized from Boc-piperazine and 
propargylamine and deprotected prior to the reaction with the 4-Oxo-β-Lactam bromide 
using TFA (Scheme 19). 
This potential ABP was tested in a competitive ABPP approach against FP-Rhodamine, 
showing a very selective labeling profile (Figure 59 – A). The compound seemed to be 
especially potent against a band at 25 kDa, which was potentially HNE, PR3, or both, 
showing almost complete suppression of FP labeling even at the lowest tested 
concentration of 0.1 µM. Other than that, only an additional band at 75 kDa was visibly 




Scheme 19 – Synthesis of a clickable 4-Oxo-β-Lactam 151 using 1-prop-2-ynylpiperazine. 
 
 
Labeling of the proteome by 151 was then tested by incubating the proteome with 
growing concentrations of the probe and clicking it with rhodamine-azide (Figure 59 – 
B). The probe showed a selective labeling pattern up to 1.0 µM concentration, with only 
a few visible bands at approximately 25 kDa, once again potentially being HNE or PR3, 
with significant increase in background labeling for higher concentrations. This 
compound will be valuable for future derivatization by click chemistry into other 








The application of 4-Oxo-β-Lactams in ABPP marked the first time that these compounds 
were tested with the end goal of establishing a comprehensive list of targets that could 
potentially be hit by the scaffold. 
Starting with an alkynylated 4-Oxo-β-Lactam, the synthesis of ABPs was straightforward 
using CuAAC chemistry. The compounds showed a reasonably selective protein profile 
and the LC-MS/MS experiments revealed a surprisingly restricted list of targets that 






Figure 59 – Competitive ABPP experiment (A) and full proteome reactivity experiment (B) with the 4-Oxo-β-Lactam 




β-Lactams to inhibit enzymes from the DPP and the ABHD enzyme families, among 
others. Unlike the case for the 3-Oxo-β-Sultams, these targets were inhibited in high 
stoichiometry, making the 4-Oxo-β-Lactam reactive group the optimal choice to pursue 
the development and application of ABPs in our project. 
The identification of previously unreported 4-Oxo-β-Lactam targets led us to devise a 
new strategy devoted to the pursuit of selective inhibitors of these targets. A library of 4-
Oxo-β-Lactam inhibitors was synthesized and evaluated using competitive ABPP 
techniques. The N-aryl 4-Oxo-β-Lactam compounds showed a selective profile of FP-
target labeling blocking, which preliminarily suggested a good degree of selectivity for 
these compounds. Mass spectrometry-based ABPP revealed that the compounds labeled 
the previously known targets HNE and PR3, but also hit enzymes from the ABHD and 
DPP families of serine hydrolases like ABHD6, DPP8, DPP9, DPP4, among other targets. 
Target validation using overexpressed serine hydrolases confirmed inhibition of these 
targets and revealed that inhibition of specific enzymes like HNE, DPP8 and DPP9 
proceeded with low nanomolar range IC50s, even when measured in the presence of a 
complete proteome. 
The results concerning a few specific targets were also noteworthy, namely the inhibition 
of DPP8 and DPP9. The 4-Oxo-β-Lactam is a novel chemotype for DPP8 and DPP9 
inhibition and is significantly different from previously identified chemotypes that target 
these enzymes. Additionally, there seems to be a preference for DPP8 inhibition, even 
though biochemical inhibition assays should be performed to confirm this data. 
Our study of the 4-Oxo-β-Lactam chemotype as a reactive group in ABPP had some 
limitations. The work focused on the U937 cell line proteome, chosen due to its native 
production of active HNE, which we knew was a target of the 4-Oxo-β-Lactams, and for 
this reason, the identified proteins were limited to the pool of enzymes present in the 
U937 proteome. A more in-depth study should analyze additional cell lines. Additionally, 
our work focused mainly on using whole cell lysates, limiting our knowledge on the cell 
permeability of the compounds. Chemically, while a diverse group of substituents was 
appended to the N-aryl moiety, the substitution at the 3-position was kept constant with 
the diethyl group, potentially introducing a bias towards enzymes like HNE and leaving 
one site of potential modification of the compound relatively unexplored in terms of 
chemical space.  
These limitations of our work can be easily addressed in future studies with the 4-Oxo-β-
Lactams and even come as an exciting prospect of the additional engageable enzymatic 
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entities that could potentially be addressed by this chemotype. Overall, we provided an 
unprecedented collection of information regarding the target profile of the 4-Oxo-β-
Lactams which will be valuable to guide future inhibitor development and potentially aid 
















In recent years, exciting advances have been made in the field of DPP8 and DPP9 
inhibition, with the publishing of their crystal structures, the discovery of pyroptosis 
induction via DPP8/9 inhibition, the numerous efforts to create new and selective 
inhibitors of these enzymes, among others.208,210,211 The future of research on DPP8 and 
DPP9 inhibition is dependent on the discovery of new chemotypes for inhibitor 
development and the pursuit of selectivity against related enzymes and between DPP8 
and DPP9 themselves. 
DPP8 and DPP9 emerged as targets of the 4-Oxo-β-Lactam reactive group during the 
mass spectrometry experiments performed with 4-Oxo-β-Lactam ABPs. The competitive 
approach we took with the library of N-aryl-4-Oxo-β-Lactams revealed that compounds 
with meta-substitution in the aromatic ring seemed to be particularly suited for DPP8 and 
DPP9 inhibition. Target validation with overexpressed enzymes suggested that there 
might be a slight preference for DPP8 inhibition when compared with DPP9. There are 
currently no selective inhibitors for either of these enzymes, despite many efforts to 
optimize known dual DPP8 and DPP9 selective inhibitors. These results prompted us to 
pursue the inhibition of DPP8 and DPP9 using 4-Oxo-β-Lactams. 
 
 
4.1. Comparison with known DPP8/DPP9 Inhibitors 
 
The inhibition of DPP8 and DPP9 by 4-Oxo-β-Lactams or similar chemotypes is, to the 
best of our knowledge, unprecedented. To compare 4-Oxo-β-Lactams with other known 
DPP8 and DPP9 structures we analyzed the structural similarity of compound 139 to 
known DPP8 and DPP9 inhibitors described in ChEMBL v24. To that end, a list of 
inhibitors was collected and curated, excluding weakly active compounds, whose 
annotation is potentially skewed by colloidal aggregation.287 Using the ECFP4-like 
Morgan fingerprint (radius 2, 2048 bits), we obtained an average Tanimoto index < 0.11 
when comparing compound 139 to known ligands of DPP8 and DPP9. In any case had 
the nearest neighbor a Tanimoto similarity higher than 0.161. For ligands with high 
similarity, the Tanimoto index approaches 1, whereas if the ligands are substantially 
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different the result is close to 0. Taken together, our data corroborated the 4-Oxo-β-
Lactam chemotype as a novel chemotype in DPP inhibitor chemical space. Moreover, 
compound 139 also displayed an unusual topological pharmacophore feature 





Figure 60 – Projection (t-distributed stochastic neighborhood embedding) of topological pharmacophore descriptor 
(CATS2) space. Orange: DPP8 ligands; Blue: DPP9 ligands. Gradient depicts activity values for individual 
compounds. Data shows that compound 139 (black dot) presents an unusual pattern among DDP8 and DPP9 ligands. 
 
 
4.2. Pyroptosis Induction  
 
Pyroptosis is a lytic form of programmed cell death dependent on caspase activation. The 
dual DPP8 and DPP9 inhibitor Val-BoroPro has been shown to induce pyroptosis in 
monocytes and macrophages and this process has been shown to involve the inhibition of 
DPP8 and DPP9. Recently, the application of DPP8/9 inhibitors in this pathway has 
shown promise as a treatment of acute myeloid leukemia.211,224,288 The study of the 
potential of 4-Oxo-β-Lactams to induce pyroptosis was pursued in collaboration with the 
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Bachovchin lab. In a preliminary experiment, a cell viability assay (CellTiter-Glo) was 
performed with a DPP8/9 inhibitor sensitive AML cell line, MV4;11. CellTiter-Glo 
measures cell viability by analyzing cellular ATP concentrations in the sample. Cell death 
results in a decrease in the levels of ATP in the well and a lower CellTiter-Glo signal. 
The cells were treated with the known DPP8/DPP9 inhibitor Val-BoroPro as control and 
4-Oxo-β-Lactam compounds for 24 h with a top dose of 20 µM. The results are presented 
in Table 4 and Figure 61. 
 
 
Table 4 – Pyroptosis IC50s (µM) for selected 4-Oxo-β-Lactam compounds in the AML cell line, MV4;11. 
 
Val-BoroPro 117 123 124 126 127 132 134 135 138 139 
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Figure 61 – Graphical representation of the cell viability assay performed for selected 4-Oxo-β-Lactam compounds. 
 
 
The results showed general micromolar IC50s for pyroptosis for our compounds when 
compared with the control Val-BoroPro, which showed an IC50 of 1 nM. The best 
compound, 139, had an IC50 of 750 nM. This compound showed the best inhibition of 
DPP8 and DPP9 in the previously described competitive ABPP assays, supporting these 
results and suggesting that DPP8 and DPP9 inhibition is the process responsible for 
induction of cell death. 
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Overall, the results showed an effect in cell viability upon incubation with the 4-Oxo-β-
Lactam compounds. This assay has been previously used as a measure of DPP8/DPP9 
inhibition-dependent cell death induction by pyroptosis and seems to agree with previous 
values of DPP8 and DPP9 inhibition for our compounds. Furthermore, these results 
support that 4-Oxo-β-Lactam compounds cross the cell membrane and can exert their 
effects in the intracellular environment. 
 
 
4.3. Kinetic assays and co-crystallization of DPP8 and DPP9 with Selected 4-
Oxo-β-Lactam Inhibitors 
 
The crystallographic structures of DPP8 and DPP9 were only recently published.208 In 
collaboration with the Huber Lab, which was responsible for this impactful publication 
in the field of DPP8 and DPP9 inhibition, selected 4-Oxo-β-Lactam compounds, namely 
132, 135, 138 and 139,  were tested in biochemical assays against DPP8 and DPP9 (Table 
5). These results confirmed the potent inhibition of DPP8 and DPP9 verified by 
competitive ABPP (see chapter 3) and generally agreed with the inhibitory pattern found 
in those experiments. With the exception of compound 132, which showed more potent 
inhibition for DPP9, all compounds seemed to more efficiently inhibit DPP8, with IC50 
values under 100 nM. An outstanding result was the inhibition of these enzymes by 
compound 139. This compound, which had previously resulted in the best IC50 values for 
DPP8 and DPP9 obtained in competitive ABPP, showed the best DPP9/DPP8 inhibition 
ratio, with approximately 20 times more potent inhibition of DPP8 than DPP9, a better 
result than that for most published compounds. As mentioned throughout this report, the 
pursuit of selectivity of inhibition between these enzymes is a highly sought result, 
emphasizing the importance of this outcome.   
 
Table 5 – Ki values for DPP8 and DPP9 inhibition by compounds 132, 135, 138 and 139 (cleavage of GP-AMC in 
the presence of inhibitors). 
 
Compound DPP8, Ki (nM) DPP9, Ki (nM) 
   
132 230.0 93.3 
135 25.7 151.9 
138 60.7 372.3 
139 44.9 849.1 
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In addition to the kinetic assays, co-crystallization experiments were performed between 
selected compound-target pairs. Successful co-crystallization was observed between 






Figure 62 – Co-crystallization of compound 132 with DPP8, revealing a covalent reaction with the catalytic Ser-755 
and the extension of the inhibitor across a hydrophobic canyon, a novel binding site for extended ligands, different 
from previously described ligand-DPP8 interactions. Ligand binding induces disordering of structures (colored in 




This crystal structure unveiled surprising details regarding DPP8 inhibition by 4-Oxo-β-
Lactams. Compound 132 inhibited DPP8 via a different binding mode when compared 
with previously described inhibitors of DPP8 and DPP9. A covalent bond is clearly 
defined between the 4-Oxo-β-Lactam and the catalytic serine of DPP8, via the expected 
mechanism of attack of the catalytic serine to one of the carbonyls of the 4-membered 
ring, inducing opening of the ring. The inhibition was associated with disordering of the 
substrate binding site and the catalytic machinery (colored in green in Figure 62), a 
previously unknown inhibitory mechanism. Additionally, the S1 subsite does not seem to 
accommodate the diethyl moiety, as was the case for the inhibition of HNE. The distal 
part of compound 132, containing the piperazine and the 4-bromo benzyl group interacted 
with a hydrophobic canyon, a novel binding site for extended ligands, which was not used 
by previously studied inhibitors. Ongoing studies seem to suggest that binding of these 
compounds with DPP8 and DPP9 exploits different features on each enzyme, an exciting 





In this chapter we expanded on the work developed for DPP8 and DPP9 inhibition by 4-
Oxo-β-Lactams. Following the exciting discovery that these enzymes are engaged by 4-
Oxo-β-Lactams, we demonstrated through similarity studies, that this reactive group was 
indeed a new chemotype for DPP8 and DPP9 inhibition, with significant differences from 
previously known inhibitors of these enzymes.  
Furthermore, the study of DPP8 and DPP9 inhibition showed that selected compounds 
from the library have an effect on pyroptosis induction. 
The most impactful result was, however, that 4-Oxo-β-Lactam compounds were able to 
achieve a level of selectivity between DPP8 and DPP9 inhibition that has been 
unfruitfully pursued for a long time with other chemotypes, with the exploiting of 
previously unrecognized binding sites in these enzymes, which will potentially have an 













Chapter 5 – Outreaching Projects and Collaborations 
 
 
In parallel to the main work developed during the PhD project, several side-projects were 
pursued, including collaborations with other research groups at iMed.ULisboa. These 
outreaching projects are described in this chapter, including the derivatization of 4-Oxo-
β-Lactams with an N-O bond to generate suicide inhibitors, the development of 4-Oxo-
β-Lactam on-off probes, the synthesis of peptidic vinyl sulfone ABPs for cysteine 




5.1. 4-Oxo-β-Lactams with N-O bond for suicide inhibitor development  
 
The 4-Oxo-β-Lactam chemotype was developed into potential suicide inhibitors by 
incorporation of an N-O bond. The concept involves the use of the 4-Oxo-β-Lactam core 
as a covalent modifier (Scheme 20 – A) and adding a leaving group via a tosylated N-O 
bond that will allow the suicide inhibitor mechanism to occur, following a Lossen 
rearrangement.289 Upon target engagement and opening of the 4-membered ring, a Lossen 
rearrangement expels the tosylated hydroxyl group and generates an isocyanate, a new 
electrophilic center which allows a second nucleophilic attack to render the enzyme 
irreversibly inhibited (Scheme 20 – B). 
To synthesize these compounds, we first need to obtain the corresponding malonic esters. 
Some esters were commercially available or directly available in the lab in large amounts. 
If not, they can be obtained from mono-substituted malonic esters or by introducing 
substituents in diethyl malonate. These reactions take advantage of the acidity of the 
malonic acid alpha protons. Once the malonic ester is ready the two ester groups are 
hydrolyzed using sodium hydroxide in ethanol to obtain the diacid. The diacid is 
converted into the diacyl chloride to allow cyclization into the 4-Oxo-β-Lactam by 
reacting with an appropriate amine. To introduce the N-O bond we used O-
benzylhydroxylamine (Scheme 21 – A) as the amine for cyclization. The protecting 
benzyl group from the hydroxylamine is removed by hydrogenation using triethylsilane 
with palladium on activated charcoal and the free hydroxyl is protected with a tosyl group, 








Scheme 20 – A. 4-Oxo-β-Lactam containing an N-O bond; these compounds will take advantage of the Lossen 
Rearrangement, which will lead to a suicide mechanism. B. Mechanism of HNE inhibition by 4-Oxo-β-Lactam 
suicide inhibitors. After attack of HNE to the 4-Oxo-β-Lactam ring, a Lossen rearrangement generates an isocyanate, 
which is then attacked a second time by HNE, leading to an irreversibly inactivated enzyme.  
 
 
The O-benzylhydroxylamine is obtained starting with N-hydroxyphtalimide. The free 
hydroxyl group is protected with a benzyl group using benzyl chloride in the presence of 
sodium bicarbonate and a phase transfer catalyst. The phthalimide group is deprotected 
in acidic medium using hydrochloric acid in acetic acid. The compound is obtained as the 
hydrochloric salt (Scheme 21 – A). Prior to usage, the salt is neutralized by washing with 
saturated sodium bicarbonate solution. 
A second inhibitor was prepared with an ethyl and a benzyl groups instead of a diethyl 
substitution. The synthesis followed a similar pathway after introduction of the benzyl 
group in the malonic ester. 
These two compounds, 152 and 153, and one of the benzylated intermediates, 164, were 
tested in biochemical assays against HNE using the same assay that was used with 3-Oxo-


















The IC50 for 152 was higher than anticipated, falling in the micromolar range, a 
significantly weaker HNE inhibition than usual for 4-Oxo-β-Lactams with 3,3-diethyl 
substitution. On the other hand, compound 153, which contains a benzyl group, displayed 
sub-micromolar range inhibition, a promising result.  Compound 164 presented the best 
inhibition result, with an IC50 of 82 nM. This compound might be suited for HNE 
inhibition, but the mechanism will not induce a Lossen rearrangement. 
Further optimization of these compounds is envisaged. Due to the requirement of the N-
O-Ts group for the Lossen Rearrangement-dependent mechanism and the preference of 
HNE for small substituents at the 3-position, the possibilities of creating chemical 
diversity with these compounds are limited. The synthesis of variants to target proteasome 
units and β-Lactamase by taking advantage of specific recognition elements for each of 
them are envisaged to be developed in the future. 
 
 
5.2. Synthesis of 4-Oxo-β-Lactam on-off probes 
 
In vivo applications of fluorescent ABPs usually benefit from using on-off probes, so only 
the fraction of the probe that has engaged a target produces fluorescence, greatly 
decreasing the background signal from unreacted probe.52 A 4-Oxo-β-Lactam on-off ABP 
was synthesized in collaboration with the Nanostructured Systems for Overcoming 
Biological Barriers group at iMed.ULisboa. The synthesis of the 4-Oxo-β-Lactam probe 
165 followed the previously described strategy of using p-toluidine as the ring-closing 
amine, radical bromination to introduce a bromine atom at the resulting methyl group and 
the introduction of the fluorophore via nucleophilic substitution. Umbelliferone was 
chosen as the fluorophore (Scheme 22). 
The probes are expected to release the coumarin tag upon engagement of the target 
enzyme, leading to the generation of fluorescence. (Scheme 23). Enzymatic inhibition 
assays have revealed that this compound has an IC50 value of 0.67 ± 0.19 nM for HNE 
















5.3. Synthesis and purification optimization of a fluorescein tagged 4-Oxo-β-
Lactam Activity-based probe 
 
Integrated in a previous project of the group, a 4-Oxo-β-Lactam ABP tagged with 
fluorescein was synthesized (Scheme 24). 
The synthesis for this compound followed a similar strategy to the one used for the 3-
Oxo-β-Sultam and 4-Oxo-β-Lactam derivatives synthesized in this PhD project, via 
cyclization of diethyl malonyl dichloride with propargylamine as a way to introduce a 
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click chemistry handle. The alkynylated 4-Oxo-β-Lactam was then derivatized by 
CuAAC reaction with azidoacetic acid-coupled fluoresceinamine, yielding the desired 
ABP. Purification of this compound was achieved via a reverse phase combi-flash 
chromatography column with a water:methanol gradient. This method allowed us to 
obtain the final compound 166, nevertheless with a poor yield of 8%. 
The compound was tested in biochemical inhibition assays against HNE using the 
previously described methods, revealing an IC50 of 66 nM. Incubation of this ABP with 
human neutrophils showed the probe permeates the cellular membrane. A gel-based assay 
showed efficient labeling of pure HNE enzyme.183 The compound was not used in 
proteomics experiments since other compounds, namely the rhodamine derivative 113 









5.4. Synthesis of a Vinyl Sulfone ABP to target Cysteine Proteases 
 
In collaboration with the Neuron-Glia Biology in Health and Disease group at 
iMed.ULisboa an ABP based on the vinyl sulfone reactive group and tagged with NBD 
to target cysteine proteases was synthesized.290 The synthesis of this molecule presented 
a good opportunity to diversify the set of ABPs synthesized during the PhD project and 
establish collaborations with other groups at the institute. This probe contained a peptidic 
linker, Val-HomoPhe, which functions as a recognition element. The complete synthesis 
of this probe is depicted in Scheme 25. Additionally, a non-probe compound capped with 
morpholine was synthesized.  
The synthesis started with the reduction of the carboxylic acid of Boc-protected homo-
phenylalanine 167 into an aldehyde, resulting in compound 168. Introduction of a phenyl-
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vinyl-sulfone reactive group was the following step, yielding compound 169. After 
deprotecting the Boc group the peptidic chain was extended by one aminoacid by 
coupling of Boc-protected leucine, which led to the vinyl sulfone dipeptide 171. After 
deprotection of the Boc in the newly introduced leucine, propiolic acid was coupled to 
introduce an alkyne handle. A CuAAC reaction with the NBD azide led to the final probe 
174.  
Compound 174 was delivered, together with a non-probe version 175, to the Neuron-Glia 
Biology in Health and Disease group at iMed.ULisboa for biologic assays. 
These dipeptidyl vinyl sulfone compounds were developed to target the Aβ-inflammatory 
process associated with Alzheimer’s Disease. Inflammatory mediators have gained 
increased recognition as prominent hallmarks in Alzheimer’s disease, involving 
activation of astrocytes and microglia. The vinyl sulfone reactive group is well 
established for the targeting of cysteine proteases.291 Particularly, cathepsin S seems to 
play a role in microglial activation and inhibition of cathepsins S, L, and B reduced the 
cellular accumulation of Aβ formation. 
The compounds were shown to function as effective inhibitors of microglia activation 
upon treatment with Aβ. Matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-
2 (MMP-2), the alarmin high mobility group box 1 (HMGB1) protein, the NLRP3-
inflammasome, IL-1β mRNA levels and miR-155 and miR-146a expression, which are 
all associated with neuroinflammation, were all found to be at control levels. These results 
suggest that vinyl sulfone-based compounds have therapeutic potential to control 
inflammation in neurodegenerative diseases like Alzheimer’s disease.290 
More recently Vaz et al. developed an amyotrophic lateral sclerosis cellular model based 
on overexpression of mutated superoxide dismutase 1 in an N9 microglia cell line. The 
vinyl sulfone compound was tested in this model and led to promotion of inflammatory 
resolution, with reduction of TNF-α, IL-1b, high mobility group box 1 protein, S100 
calcium-binding protein B, miR-155 expression and MMP-2 and MMP-9 activation. The 
cellular expression of miR-146a was found to be increased. These results agree with the 
previously established anti-inflammatory properties of this compound for other cell lines 
and disease models and further support that vinyl sulfone-based inhibitors are promising 










5.5. Synthesis of a TUDCA fluorescent Probe 
 
Fluorescent derivatives of bile acids can be used to study the effect of these molecules on 
cellular membranes. Biologically, bile acids are natural detergents that solubilize lipids 
for absorption in the digestive system. At micromolar concentrations, some bile acids, 
like as deoxycholic acid (DCA) or chenodeoxycholic acid (CDCA), have been shown to 
induce apoptosis through a series of different mechanisms, including activation of cell 
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death receptors, stimulation of p53, induction of mitochondrial disfunction, among other 
mechanisms, which result in caspase activation and apoptosis. On the other hand, other 
bile acids, like ursodeoxycholic acid (UDCA) and TUDCA, which are more hydrophilic, 
have been shown to present anti-apoptotic properties, including prevention of ROS 
formation, inhibition of mitochondrial disfunction and of death receptor activation.292,293 
Mello-Vieira and coworkers used fluorescent derivatives of DCA (more hydrophobic, 
Figure 64 – A) and UDCA (more hydrophilic, Figure 64 – B) to characterize the 
differences in bile acid binding of different bile acids. The study confirmed that 
hydrophobic bile acids have higher affinity for the cellular membrane and that both 
hydrophobic and hydrophilic bile acids have higher affinity for disordered membrane 
structures. Hydrophobic bile acids were shown to prevent the rigidification of lipid 
membranes induced by cholesterol, potentially affecting the dynamics of structures like 
lipid rafts, but hydrophilic bile acids showed no significant effect on membrane properties 
at physiologically relevant concentrations, suggesting a mechanism unrelated with 
modulation of membrane properties. Importantly, all the studied bile acids were shown 
to have limited penetration in the membrane, suggesting a more superficial 















Synthesis of a TUDCA probe was performed in collaboration with the Cellular Function 
and Therapeutic Targeting group at iMed.ULisboa. The synthetic strategy involved the 
derivatization of TUDCA with an alkyne moiety, for click chemistry coupling with NBD 
azide. The synthesis started with 2-(1,3-dioxoisoindolin-2-yl)ethane-1-sulfonyl chloride 
(178), to which an alkyne was attached by reaction with propargylamine in the presence 
of triethylamine, yielding compound 179. The phthalimide group of this compound is 
then removed by reaction with hydrazine in ethanol resulting in the deprotected form 180. 
The coupling of UDCA to the deprotected primary amine was performed via conventional 
peptide coupling methods using TBTU, yielding compound 181. The resulting TUDCA 
alkyne was clicked with NBD azide to provide the final ABP 182 using the same 
conditions that were optimized for 3-Oxo-β-Sultams (Scheme 26). The identity of the 
final compound was confirmed by mass spectrometry (Figure 65). The compound was 




















The activities described in this chapter complemented the study on the ABPP of serine 
hydrolases performed in the main project, allowing different chemistries and targets to be 
explored. The additional work on 4-Oxo-β-Lactam further showed the great potential of 
this reactive group in developing enzymatic inhibitors, with the N-O bond-containing 
compounds potentially being used in the future for proteasome and β-lactamase targeting 
via modification of specific recognition moieties. The vinyl sulfone probe allowed us to 
explore the targeting of the cysteine protease family and contributed to two publications 
with significant impact in the field. The work with the TUDCA probe in ongoing and will 
potentially make substantial contributions to the field of studying cellular membranes. 
Overall, these works highlight how previously known and established compounds can be 
further studied by applying ABPP techniques and provide new and exciting results in 
relevant fields of medicinal chemistry. 
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Chapter 6 – Conclusions and Future Perspectives 
 
ABPP is a powerful technique that allows the analysis of enzyme dynamics in complex 
proteomes. The application of ABPP techniques has allowed for significant advances in 
the study of diverse classes of enzymes and greatly contributed to the annotation of the 
proteome. By providing a functional readout of enzyme activities instead a simple 
quantification of protein expression, ABPP has contributed to the elucidation of the role 
of several enzymes in diverse human pathologies and for the mapping of enzyme 
dynamics across different pathologic phenotypes. The analysis of enzymatic activity in 
disease states has also contributed to biomarker discovery by detecting divergent 
enzymatic activity fingerprints by comparison with healthy tissues. 
In this work we sought to take advantage of ABPP tools to provide unprecedented data 
regarding underexplored 4-membered-ring reactive groups, namely 3-Oxo-β-Sultams and 
4-Oxo-β-Lactams.  
These compounds have shown efficient labeling of serine hydrolases in the past, but their 
application in ABPP remained unexplored. We aimed for the establishment of target 
profiles of both 3-Oxo-β-Sultams and 4-Oxo-β-Lactams and to perform a thorough 
analysis of the possible engageable targets in disease-relevant proteomes. Particularly, we 
were interested in HNE, a serine protease with a critical role in diseases like COPD and 
cancer. We had previously studied HNE as a target of 4-Oxo-β-Lactams and 3-Oxo-β-
Sultam have been shown to label the porcine variant, PPE. For the purpose of studying 
HNE activity in disease-relevant proteomes, we developed libraries of 3-Oxo-β-Sultam 
and 4-Oxo-β-Lactam compounds and ABPs and tested their reactivity and targets in the 
U937 cell line, which natively expresses HNE. 
The 3-Oxo-β-Sultam reactive group proved to be a versatile chemotype, easily derivatized 
for click chemistry applications, and allowed the development of a diverse library of 
compounds with minimal purification hindrances. When analyzing the proteome 
reactivity of the 3-Oxo-β-Sultam compounds we found that the molecules were highly 
reactive, labeling a large amount of proteins with limited selectivity. While the labeling 
of multiple proteins is not necessarily a negative result, given the multiple applications of 
broad reactivity probes in competitive ABPP and non-directed approaches, the relevant 
targets of 3-Oxo-β-Sultam compounds were found to be labeled with low stoichiometry 
in competitive experiments, which limited their possible applications as broad reactivity 
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ABPs. In a broader analysis of the full proteome engagement by these compounds we 
identified several proteasome subunits being inhibited with high target occupancy, 
suggesting additional interest of these compounds outside of the study of serine hydrolase 
inhibition. Despite the unfavorable results obtained for serine hydrolases with our 3-Oxo-
β-Sultam library, chemical modification of the 3-Oxo-β-Sultam reactive group has 
provided more stable iterations of these compounds in the past, meaning that the 3-Oxo-
β-Sultam still has significant potential to be explored. 
In addition to defining the target profile of these compounds, we were intrigued by the 
reaction mechanism of 3-Oxo-β-Sultams with serine hydrolases. Given the presence of 
two reactive groups in the 3-Oxo-β-Sultam ring, the inhibition mechanism could involve 
either acylation or sulfonylation of the enzyme’s active site. This had been previously 
studied for PPE, with the authors suggesting an inhibition mechanism by acylation of 
PPE’s active site. We provided, for the first time, crystallographic structures of both PPE 
and HNE inhibited with 3-Oxo-β-Sultams compounds. Our results contradicted the 
previously published results, revealing a sulfonylation mechanism for inhibition of PPE. 
Additionally, we also confirmed that the same mechanism takes place in HNE inhibition. 
Our unexpected results suggest that 3-Oxo-β-Sultam could be interesting compounds to 
study serine hydrolase sulfonylation, an underexplored inhibition strategy, and contribute 
to the pool of available sulfonylation tools in chemical biology. 
The 4-Oxo-β-Lactams have previously been developed as low nanomolar HNE inhibitors 
by our group. We synthesized rhodamine and biotin derivatives and tested them in gel-
based and mass-spectrometry-based ABPP. These experiments revealed a much more 
selective target profile when compared with the 3-Oxo-β-Sultams, but gel analysis 
showed that there might be additional targets, other than HNE, that could be efficiently 
labeled by out compounds. Mass-spectrometry-based assays revealed that the 4-Oxo-β-
Lactam chemotype is able to efficiently label other members of the serine hydrolase 
family of enzymes, including enzymes from the ABHD and the DPP families. 
Faced with these results we decided to pursue the repurposing of 4-Oxo-β-Lactams as 
inhibitors of these enzymes, with particular interest in the enzymes DPP8 and DPP9, for 
which there are currently no selective inhibitors. The synthesis of the 4-Oxo-β-Lactam 
ring was optimized into a new method that afforded unprecedented near-quantitative 
yields, a promising and exciting result for future work with 4-Oxo-β-Lactam libraries.  
A library of N-aryl 4-Oxo-β-Lactams was synthesized and evaluated in gel-based 
competitive ABPP against the well-established FP probes, revealing a selective profile of 
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target inhibition, with only a few targets being efficiently competed by the 4-Oxo-β-
Lactam compounds. Competitive mass spectrometry analysis against FP-biotin of 
selected compounds confirmed the inhibition of HNE, ABHD and DPP enzymes, with an 
apparent effect of the N-aryl moiety substitution pattern in determining compound 
selectivity. Target validation by gel competitive ABPP with overexpressed serine 
hydrolases confirmed the potent inhibition of these targets, with some compound-target 
pairs revealing low nanomolar inhibition values. Interestingly, there seems to be a small 
preference for inhibition of DPP8 when compared with DPP9. This was an exciting result 
given the fact that the two enzymes share similar structural features and substrate 
specificity, with no current know selective inhibitors for either of them. For this reason, 
we envisaged the 4-Oxo-β-Lactam chemotype as a starting point for the development of 
DPP8 and DPP9 inhibitors. For this purpose, we collaborated with some of the leading 
machine learning showed us that, when compared with existent DPP8 and DPP9 
inhibitors, the 4-Oxo-β-Lactam is novel chemotype that fits an unexplored section of 
chemical space. A mild effect on the induction of pyroptosis was identified, a process 
associated with DPP8 and DPP9 inhibition. 
Perhaps the most impactful result obtained in the course of this work was the discovery 
that 4-Oxo-β-Lactams inhibit DPP8 and DPP9. Kinetic assays with DPP8 and DPP9 for 
selected compounds confirmed low nanomolar Ki values, in general agreement with the 
IC50s we obtained in competitive ABPP, confirming the high potency of these 
compounds. One compound, LUSA91, showed a 20-fold preference for DPP8 when 
compared with DPP9, which is one of the best selectivity ratios ever achieved for DPP8 
and DPP9 inhibition, to the best of our knowledge. Co-crystallization experiments 
allowed us to obtain a crystallographic structure a 4-Oxo-β-Lactam complex with DPP8, 
which revealed a novel interaction mechanism that had previously not been identified for 
known DPP8/DPP9 inhibitors. The crystallographic structures of DPP8 and DPP9 were 
only very recently published, and achieving crystallization of a novel chemotype with 
these enzymes is a very exciting and promising result, which will certainly be of great 
value to guide future inhibitor development. The fact that some of our compounds have 
some of the best selectivity ratios ever achieved between DPP8 and DPP9 and that their 
mechanism seems to involve previously unidentified enzymatic structures suggests that 
taking advantage of the interactions with this motif could be the key to develop new and 




The results obtained in this work have highlighted the usefulness of the 4-Oxo-β-Lactam 
chemotype in inhibitor development and many opportunities to follow up on this results 
have emerged. 
We intend on continuing the study of 4-Oxo-β-Lactams as inhibitors of the DPP enzymes, 
optimizing our library of inhibitors using computational methods to design new 
molecules that take advantage of the crystallographic data described herein. 
Furthermore, our focus on the DPP family of enzymes overshadowed our discovery that 
4-Oxo-β-Lactams also inhibit important members of the ABHD family of enzymes and 
the development of new inhibitors for these enzymes will surely be pursued in future 
work. 
In addition to the collaborations described, we are currently studying the inhibition of 
rhomboid serine hydrolases by the 4-Oxo-β-Lactam compounds in collaboration with the 
Verhelst laboratory, with preliminary results showing some compounds present 
submicromolar IC50s for these enzymes, a promising result when compared with current 
known inhibitors of these enzymes and further proof of the versatility of 4-Oxo-β-
Lactams. 
Regarding our focus on HNE, one of the potential goals of our project was the application 
of the best ABPs in the validation of HNE as a biomarker of COPD. The 4-Oxo-β-Lactam 
ABPs proved to efficiently label HNE, supporting the feasibility of performing this study. 
Throughout the course of the project, however, new and unexpected targets of the 4-Oxo-
β-Lactam scaffold were identified and validated. A surprising but exciting result was the 
fact that most of the identified enzymes could be directly or indirectly related to COPD 
or other relevant respiratory diseases that can co-develop with COPD. Briefly, DPP4 has 
been shown to present increased immunostaining in the lung with chronic diseases like 
COPD, particularly in areas of tissue remodeling, while also showing increased activity 
in mouse models of induced asthma; FAP has been found to be increased in lung cancers, 
but this goes in line with its general increase in cancer tissues; PREP has been found to be 
highly expressed in neutrophils, macrophages and epithelial cells found in lung tissues of 
COPD patients, in the lungs of mice exposed to cigarette smoke and in patients with cystic 
fibrosis; DPP8 and DPP9 have been found upregulated in asthma and inflammation, with 
DPP9 also being associated with lung cancer. On the other hand, ABHD2 has been shown to 
have a protective role in the lung, with its inhibition seemingly contributing to the 
development of chronic lung disease. Collectively, these results emphasize the importance of 
using ABPP tools when studying new chemotypes given the extent of analysis of target 
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engagement that ABPP provides. Taking the example of using 4-Oxo-β-Lactam ABPs to 
measure HNE in COPD samples, we now know to evaluate the concomitant inhibition of 
enzymes like DPP4 and PREP, which can also have clear roles in COPD, but also in a 
prospective drug development project we know that we should avoid concomitant inhibition 
of enzymes like ABHD2, which could cause an antagonistic effect, the clear advantage being 
that ABPP can simultaneously help guide the development of these new inhibitors and the 
analysis of undesirable side-hits. Additionally, pathologic states can be more adequately 
evaluated if multiple variables are measured as a group biomarker. It is inherently more 
valuable to study a profile of enzymatic activities for different enzymatic entities as a 
hallmark of a disease or disease state than to limit the analysis to a single enzymatic entity. 
The application of ABPP techniques in the pharmaceutical industry could, via this path, 
identify problematic side-targets early in drug development, thus greatly increasing the 
potential of lead compounds. Our future work will involve the application of the 4-Oxo-
β-Lactam ABPs in human samples of healthy subjects and COPD patients of various 
disease stages. We will start by identifying HNE in these samples and then quantifying 
the enzymatic activity between different samples. The measurement of enzymes like 
DPP4, PREP and ABHD2 will assist in defining a potential panel of biomarkers of COPD 
stages. 
 
Overall, 4-membered ring reactive groups are highly valuable tools in ABPP and 
chemical biology. In particular, the 4-Oxo-β-Lactam chemotype has proven to be highly 
valuable as a lead for enzymatic inhibitor development and as the reactive group in ABP 
synthesis, which allowed us to identify previously unknown targets and repurpose these 
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Two publications are currently being prepared to report on the findings of the activity-
based protein profiling study of 3-Oxo-β-Sultam and 4-Oxo-β-Lactam activity-based 
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S1. General Considerations 
 
Chemicals, enzymes and solvents were purchased from reputable commercial suppliers 
and used without further purification. Compound purification by flash chromatography 
used SilicaFlash F60 silica gel (40–63 μm, 60 Å). When indicated, flash chromatography 
was performed in a Combi Flash RF-200 device from Teledyne Isco with RediSep 
normal- or reverse-phase (C18) silica flash columns. Chemical reactions were followed 
by thin layer chromatography (TLC) using Merck aluminium backed sheets coated with 
60 F254 silica gel and visualized in a UV lamp (λmax = 254 nm). Nuclear magnetic 
resonance experiments (1H and 13C NMR) were performed at room temperature on a 
Bruker Avance 300, Bruker DRX-500, Varian Inova-400 or Bruker DRX-600 (5 mm 
DCH Cryoprobe) instruments. Chemical shifts are reported in the δ scale in ppm, relative 
to tetramethylsilane (TMS).  Peak multiplicity is reported as: chemical shift, multiplicity 
(s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bm = 
broad multiplet), coupling constant (Hz). High-resolution mass spectra (HRMS) were 
obtained from an Agilent LC/MSD TOF mass spectrometer by electrospray ionization–
time-of-flight (ESI-TOF) at the TSRI Center for Mass Spectrometry or from a QqTOF 
Impact IITM mass spectrometer (Bruker Daltonics) at Instituto Superior Técnico. Low-
resolution mass spectra were recorded using Micromass Quattro Micro API mass 
spectrometer, using electrospray ionization technique. Protein separations by 
SDS−PAGE were performed using 10% acrylamide gels at 300V and samples were 
visualized by in-gel fluorescence scanning using a ChemiDoc MP system (Bio-Rad). The 
resulting data was processed using the Image Lab (5.2.1) software (Bio-Rad), SDS-PAGE 
images were optimized using appropriate imaging software to enhance contrast when 
needed or to crop parts of the image without scientific relevance. Culture media and 
supplements for cell culture were purchased from Life Technologies. Reagents and 
probes for cell treatment were prepared as stock solutions (1000x) in DMSO and stored 
at -20°C. Crystallography details for the work developed with the 3-Oxo-β-Sultams are 
presented in section S3. The crystallography experiments between 4-Oxo-β-Lactams and 
DPP8/DPP9 are ongoing and are presented in the main text as preliminary results; the 
experimental methods used the obtain the results will not be presented here. Pyroptosis 
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induction assays were performed by measuring cell viability of a DPP8/9 inhibitor 












(56) 2-benzyl-4,4-dimethyl-1,2-thiazetidin-3-one 1,1-dioxide. The dichloride 62 (663mg, 
2.8mmol) was stirred in dry diethyl ether (7mL) at 0ᵒC under nitrogen atmosphere. 
Benzylamine (0.920mL, 8.4mmol) in dry diethyl ether (7mL) was very slowly added 
dropwise. The reaction was stirred at 0ᵒC for 30 minutes and then allowed to reach room 
temperature and stirred overnight. The precipitate that formed was filtered and washed 
with hexane. Evaporation of the filtrate yielded 56 as white crystals (612mg, 2.6mmol, 
91%). 1H NMR (300 MHz, CDCl3) δ 7.29 (s, 5H), 4.51 (s, 2H), 1.64 (s, 6H). 
13C NMR 





(69) 4,4-dimethyl-2-(prop-2-yn-1-yl)-1,2-thiazetidin-3-one 1,1-dioxide. 2-
(chlorosulfonyl)-2-methylpropanoyl chloride (1,568g, 6,6mmol) was stirred in dry 
diethyl ether (17mL) at 0ᵒC under nitrogen atmosphere. Propargylamine (0.508mL, 
7.9mmol) in dry diethyl ether (9mL) was very slowly added dropwise. The reaction was 
stirred at 0ᵒC for 30 minutes and then triethylamine (2.114mL, 15.2mmol) in dry ether 
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(9mL) was slowly added. The reaction was allowed to reach room temperature and stirred 
overnight. The precipitate that formed was filtered and washed with diethyl ether. 
Evaporation of the filtrate yielded 69 as white crystals (920mg, 4.9mmol, 74%). 1H NMR 
(300 MHz, CDCl3) δ 4.22 (d, J = 2.6 Hz, 2H), 2.44 (t, J = 2.6 Hz, 1H), 1.75 (s, 6H). 13C 
NMR (75 MHz, CDCl3) δ 163.68, 83.62, 74.55, 73.92, 29.58, 18.36. Accurate mass: 





(71) 4,4-dimethyl-1,2-thiazetidin-3-one 1,1-dioxide. Dry diethyl ether was stirred in a 
pressure tube at -78ᵒC under nitrogen atmosphere. Ammonia gas was bubbled in the 
solvent, until the desired amount was obtained inside the tube by condensation. The 
dichloride 62 (300 mg, 1.27 mmol) was added very slowly dropwise through a septum. 
The reaction was stirred at -78ᵒC for 30 minutes and then left to reach room temperature 
and react overnight. The system was opened to allow evaporation of the excess ammonia 
and the solvent. The next day the solid residue that formed was dissolved with DCM and 
water and poured into an extraction flask. The product was extracted with DCM. The 
organic layers were dried and concentrated under reduced pressure, yielding the product 
71 as white crystals (92mg, 0.62mmol, 49%). 1H NMR (300 MHz, CDCl3) δ 1.76 (s, 1H). 






General method for the synthesis of benzylic azides (A): 200mg of an halogenated 
benzylic compound was dissolved in DMSO (30mL). Sodium Azide (1.3eq) was added 
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and the reaction was stirred overnight at room temperature under nitrogen atmosphere. 
Full conversion of the starting material was observed by TLC and a single new chemical 
entity was observed. 50mL of water were added to the solution and the product was 
extracted with diethyl ether (3 x 10 mL). The organic fractions were combined, dried with 
anhydrous sodium sulfate and filtered. 1 mL of DMSO was added to the solution and the 
diethyl ether was evaporated under reduced pressure, resulting in a solution of the 
respective azide in DMSO. The azides were stored as DMSO solutions and used without 
further purification to avoid concentration of potentially explosive azides. A quantitative 
yield was assumed for the calculation of the concentration of azide solutions.  (Az1) 
(azidomethyl)benzene. The compound was purchased from Sigma-Aldricht. (Az2) 1-
(azidomethyl)-4-chlorobenzene. Synthesized from 1-chloro-4-(chloromethyl)benzene 
using the general method A. (Az3) 1-(azidomethyl)-4-bromobenzene. Synthesized from 
1-bromo-4-(bromomethyl)benzene using the general method A. (Az4) 1-(azidomethyl)-
4-nitrobenzene. Synthesized from 1-(chloromethyl)-4-nitrobenzene using the general 
method A. (Az5) 1-(azidomethyl)-3-nitrobenzene. Synthesized from 1-(chloromethyl)-3-
nitrobenzene using the general method A. (Az6) 1-(azidomethyl)-2-nitrobenzene. 
Synthesized from 1-(bromomethyl)-2-nitrobenzene using the general method A. (Az7) 1-
(azidomethyl)-4-methoxybenzene. Synthesized from 1-(chloromethyl)-4-





General method for the derivatization of 3-Oxo-β-Sultams by CuAAC (B): Alkyne-
derived 3-Oxo-β-Sultam (69 or 92) was dissolved in DMSO and stirred at room 
temperature. CuSO4 (0.1 M, 10% eq.M) and Sodium Ascorbate (0.2 M, 20% eq.M) were 
added. After 10 minutes the corresponding azide was added. The reaction was stirred 








3-one 1,1-dioxide. From the general method B using azide 1-azido-4-bromobenzene 
(1.5eq). After stirring overnight, a white solid precipitated in the reaction medium. The 
solid was filtered and recrystallized from acetonitrile and water, yielding 93 as a white 
solid (36mg, 0.093mmol, 25%). 1H NMR (300 MHz, DMSO) δ 8.89 (s, 1H), 7.90 (d, J = 
9.0 Hz, 2H), 7.82 (d, J = 9.0 Hz, 2H), 4.85 (s, 2H), 1.68 (s, 6H). 13C NMR (75 MHz, 
DMSO) δ 164.64, 141.79, 136.08, 133.34, 122.50, 122.01, 84.00, 35.44, 18.20. ESI + [M 






dioxide. From the general method B using azide Az1 (1.2eq). After stirring overnight, the 
product was precipitated in the reaction medium by adding 5 mL of water. Filtration of 
the solid yielded 70 as a white solid (48mg, 0.15mmol, 40%). 1H NMR (300 MHz, 
DMSO) δ 8.21 (s, 1H), 7.39 – 7.26 (m, 5H), 5.63 (s, 2H), 4.75 (s, 2H), 1.64 (s, 6H). 13C 
NMR (75 MHz, DMSO) δ 164.62, 140.61, 136.46, 129.21, 128.60, 128.26, 124.60, 83.83, 






one 1,1-dioxide. From the general method B using azide Az4. After reacting overnight 
25 mL of water were added to the reaction. The product was extracted with ethyl acetate 
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(3 x 10 mL). The organic fractions were combined, dried with anhydrous sodium sulfate 
and concentrated under reduced pressure. The product was recrystallized from 
acetonitrile and water, yielding 96 as a white solid (16mg, 0.044mmol, 12%). 1H NMR 
(300 MHz, DMSO) δ 8.29 (s, 1H), 8.23 (d, J = 8.8 Hz, 2H), 7.50 (d, J = 8.8Hz, 2H), 5.81 
(s, 2H), 4.77 (s, 2H), 1.64 (s, 6H). 13C NMR (75 MHz, Acetone) δ 164.92, 148.72, 144.26, 
141.93, 129.70, 125.03, 124.68, 84.11, 53.32, 36.13, 18.28. ESI + [M + 1] = 366.18. 






one 1,1-dioxide. From the general method B using azide Az5. After reacting overnight 
10 mL of water were added to the reaction, causing a white solid to precipitate. The solid 
was filtered and washed with water, yielding 97 as a white solid (94 mg, 0.26 mmol, 
60%). 1H NMR (300 MHz, DMSO) δ 8.31 (s, 1H), 8.23 – 8.17 (m, 2H), 7.76 – 7.64 (m, 
2H), 5.81 (s, 2H), 4.77 (s, 2H), 1.64 (s, 6H). 13C NMR (75 MHz, DMSO) δ 164.61, 
148.33, 140.84, 138.57, 135.05, 130.87, 124.92, 123.61, 123.17, 83.85, 52.22, 35.60, 





(98) DiMe-3-Oxo-β-Sultam-Triazole-Bn-2-NO2. From the general method B using azide 
Az6. After reacting overnight 10 mL of water were added to the reaction, causing a white 
solid to precipitate. The solid was filtered and washed with water, yielding 98 as a white 
solid (69 mg, 0.19 mmol, 44%). 1H NMR (300 MHz, DMSO) δ 8.22 (s, 1H), 8.15 (d, J = 
7.8 Hz, 1H), 7.67 (dt, J = 25.6, 7.3 Hz, 2H), 6.94 (d, J = 7.5 Hz, 1H), 6.00 (s, 2H), 4.80 
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(s, 2H), 1.64 (s, 6H). 13C NMR (75 MHz, DMSO) δ 164.14, 147.45, 140.30, 134.33, 
131.08, 129.61, 125.10, 125.03, 83.41, 50.05, 35.20, 17.69. ESI + [M + 1] = 366.20. 






3-one 1,1-dioxide. From the general method B using azide Az3. After reacting overnight 
25 mL of water were added. The product was extracted with ethyl acetate (3 x 10 mL). 
The organic fractions were combined, dried with anhydrous sodium sulfate and 
concentrated under reduced pressure. The product was recrystallized from acetonitrile 
and water, yielding 95 as a white solid (176 mg, 0.817 mmol, 60%). 1H NMR (300 MHz, 
DMSO) δ 8.21 (s, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz, 2H), 5.61 (s, 2H), 
4.75 (s, 2H), 1.64 (s, 6H). 13C NMR (75 MHz, DMSO) δ 164.60, 140.68, 135.86, 132.13, 
130.55, 124.66, 121.88, 83.84, 52.52, 35.60, 18.15. ESI + [M + 1] = 401.1. Accurate 






thiazetidin-3-one 1,1-dioxide. From the general method B using azide Az7. After reacting 
overnight 25 mL of water were added. The product was extracted with ethyl acetate (3 x 
10 mL). The organic fractions were combined, dried with anhydrous sodium sulfate and 
concentrated under reduced pressure. The product was recrystallized from acetonitrile 
and water, yielding 99 as a white solid (95mg, 0.27mmol, 63%). 1H NMR (300 MHz, 
DMSO) δ 8.15 (s, 1H), 7.28 (d, J = 8.3 Hz, 2H), 6.92 (d, J = 8.4 Hz, 2H), 5.53 (s, 2H), 
4.73 (s, 2H), 3.73 (s, 3H), 1.63 (s, 6H). 13C NMR (75 MHz, DMSO) δ 164.17, 159.15, 
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140.15, 129.54, 127.88, 123.79, 114.11, 83.36, 55.14, 52.39, 35.16, 17.71. ESI + [M + 1] 





3-one 1,1-dioxide. From the general method B using azide Az2. After reacting overnight 
a white solid precipitated in the reaction medium. 5 mL of water were added, leading to 
further precipitation of the solid. The solid was filtered and recrystallized from ethyl 
acetate and hexane, yielding 94 as a white solid (71 mg, 0.20 mmol, 47%). 1H NMR (300 
MHz, DMSO) δ 8.22 (s, 1H), 7.45 (d, J = 8.6 Hz, 2H), 7.32 (d, J = 8.6 Hz, 2H), 5.63 (s, 
2H), 4.75 (s, 2H), 1.64 (s, 6H). 13C NMR (75 MHz, Acetone) δ 164.93, 141.73, 135.88, 








methylbenzenesulfonate. From the general method B and using the azide (3aR,6aR)-5-
(azidomethyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-yl 4-
methylbenzenesulfonate, which was readily available in the lab. After reacting overnight 
25 mL of water were added. The product was extracted with ethyl acetate (3 x 10 mL). 
The organic layers were combined, dried with anhydrous sodium sulfate and concentrated 
under reduced pressure. The product was purified by combi flash chromatography 
(hexane: ethyl acetate gradient, 100% hexane to 100% ethyl acetate), yielding 105 as a 
white solid (77mg, 0.14mmol, 36%). 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 7.4 Hz, 
2H), 7.73 (s, 1H), 7.40 (d, J = 6.9 Hz, 2H), 5.93 (s, 1H), 4.88 (s, 1H), 4.76 – 4.63 (m, 3H), 
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4.58 – 4.31 (m, 3H), 2.47 (s, 3H), 1.71 (s, 6H), 1.38 (s, 3H), 1.25 (s, 3H). 13C NMR (75 
MHz, CDCl3) δ 164.10, 146.23, 140.51, 132.37, 130.50, 128.03, 124.26, 113.02, 104.87, 
83.43, 83.27, 81.74, 77.52, 49.22, 35.89, 26.57, 26.26, 21.85, 18.48. ESI + [M + 1] = 






1,2,3-triazol-4-yl)methyl)-1,2-thiazetidin-3-one 1,1-dioxide. From the general method B 
and using the azide N-(3-azidopropyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine. After 
reacting overnight, the solid that formed in the reaction medium was filtered and washed 
with hexane, yielding 106 as an orange solid (174mg, 0.39mmol, 72%). 1H NMR (300 
MHz, DMSO) δ 9.52 (s, 1H), 8.50 (d, J = 8.9 Hz, 1H), 8.19 (s, 1H), 6.33 (d, J = 8.5 Hz, 
1H), 4.74 (s, 2H), 4.52 (t, J = 6.9 Hz, 2H), 3.48 (broad, 2H), 2.24 (q, 2H), 1.64 (s, 6H). 
13C NMR (75 MHz, DMSO) δ 164.15, 145.13, 144.52, 144.24, 139.91, 137.94, 124.11, 
121.04, 99.23, 83.44, 47.17, 35.19, 28.36, 17.71. ESI - [M - 1] = 449.17. Accurate mass: 





(66) 2-ethylbutanoic anhydride. 2-ethylbutanoic acid (10 mL, 79 mmol) was added to 
ethanol (40 mL) and then sodium (2.1 g, 91 mmol) was added. The reaction was stirred 
for 1h and then the solvent was evaporated under reduced pressure to yield sodium 2-
ethylbutanoate as a white solid (14.097 g). 2-ethylbutanoic acid (10 mL, 79 mmol) was 
stirred with thionyl chloride (7 mL) for 1 h. The excess of thionyl chloride was 
evaporated, yielding 2-ethylbutanoyl chloride as a colorless liquid (9.945 g). Sodium 2-
ethylbutanoate was dissolved in toluene (70 mL). 2-ethylbutanoyl chloride was slowly 
added to the solution. The reaction was refluxed at 115°C for 2h. Ice (70 g) was added to 
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the reaction solution. Upon melting of the ice, the reaction was poured into an extraction 
vessel and the toluene fraction was collected. This fraction was dried with anhydrous 
sodium sulfate and evaporated under reduced pressure, yielding 66 as a colorless liquid 
(9.945 g, 46mmol, 59% yield). 1H NMR (300 MHz, CDCl3) δ 2.22 (tt, J = 8.3, 5.7 Hz, 





(92) 4,4-diethyl-2-(prop-2-yn-1-yl)-1,2-thiazetidin-3-one 1,1-dioxide. 2-
(chlorosulfonyl)-2-ethylbutanoyl chloride (1.08g, 4.6 mmol) was stirred in dry diethyl 
ether (10 mL) at 0ᵒC under nitrogen atmosphere. Propargylamine (0.330 mL, 5.2 mmol) 
in dry diethyl ether (10 mL) was very slowly added dropwise. The reaction was stirred at 
0ᵒC for 30 minutes and then triethylamine (1.36 mL, 9.8 mmol) in dry ether (10 mL) was 
slowly added. The reaction was allowed to reach room temperature and stirred overnight. 
The precipitate that formed was filtered and washed with diethyl ether. The filtrate was 
evaporated, concentrated under reduced pressure and purified by combi flash 
chromatography to obtain the product 92 as a colorless oil (0.63 g, 2.9 mmol, 63% yield). 
1H NMR (300 MHz, CDCl3) δ 4.21 (d, J = 2.6 Hz, 2H), 2.42 (t, J = 2.6 Hz, 1H), 2.17 (qd, 
J = 7.5, 1.3 Hz, 4H), 1.13 (t, J = 7.5 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 163.07, 91.25, 






3-one 1,1-dioxide. From the general method B and using azide 1-azido-4-bromobenzene. 
After reacting overnight 25 mL of water were added. The product was extracted with 
ethyl acetate (3 x 10 mL). The organic layers were combined, dried with anhydrous 
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sodium sulfate and concentrated under reduced pressure, yielding a green oil. Washing 
of the crude oil with diethyl ether led to precipitation of 100 as a green solid (74 mg, 0.34 
mmol, 39%). 1H NMR (300 MHz, CDCl3) δ 8.06 (s, 1H), 7.64 (q, J = 9.0 Hz, 4H), 4.85 
(s, 2H), 2.18 (qd, J = 7.5, 1.2 Hz, 4H), 1.14 (t, J = 7.5 Hz, 6H). 13C NMR (75 MHz, 
Chloroform-d) δ 163.32, 135.72, 132.96, 132.77, 122.75, 122.04, 120.68, 91.01, 35.45, 






3-one 1,1-dioxide. From the general method B and using azide Az2. After reacting 
overnight 25 mL of water were added. The product was extracted with ethyl acetate (3 x 
10 mL). The organic layers were combined, dried with anhydrous sodium sulfate and 
concentrated under reduced pressure, yielding a colorless oil. Washing of the crude oil 
with diethyl ether led to precipitation of 101 as a white solid (66 mg, 0.19 mmol, 40%). 
1H NMR (300 MHz, Chloroform-d) δ 7.56 (s, 0H), 7.35 (d, J = 8.5 Hz, 0H), 7.18 (d, J = 
8.5 Hz, 0H), 5.51 (s, 0H), 4.75 (s, 0H), 2.14 (qd, J = 7.5, 1.9 Hz, 1H), 1.10 (t, J = 7.5 Hz, 
1H). 13C NMR (75 MHz, CDCl3) δ 163.33, 135.74, 133.00, 122.81, 122.07, 91.04, 






3-one 1,1-dioxide. From the general method B and using azide Az3. After reacting 
overnight 25 mL of water were added. The product was extracted with ethyl acetate (3 x 
10 mL). The organic layers were combined, dried with anhydrous sodium sulfate and 
concentrated under reduced pressure, yielding a colorless oil. Washing of the crude oil 
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with diethyl ether led to precipitation of 102 as a white solid (176 mg, 0.41 mmol, 60%). 
1H NMR (300 MHz, CDCl3) δ 7.69 (s, 1H), 7.50 (d, J = 8.3 Hz, 6H), 7.11 (d, J = 8.3 Hz, 
5H), 5.49 (s, 5H), 4.75 (s, 5H), 2.19 – 2.10 (m, 10H), 1.10 (t, J = 7.4 Hz, 16H). 13C NMR 
(75 MHz, Chloroform-d) δ 163.35, 133.44, 132.44, 129.69, 123.16, 91.05, 54.03, 35.65, 






one 1,1-dioxide. From the general method B and using azide Az4. After reacting 
overnight 25 mL of water were added. The product was extracted with ethyl acetate (3 x 
10 mL). The organic layers were combined, dried with anhydrous sodium sulfate and 
concentrated under reduced pressure, yielding a brown oil. Washing of the crude oil with 
diethyl ether led to precipitation of 103 as a brown solid (86 mg, 0,22 mmol, 47%). 1H 
NMR (300 MHz, CDCl3) δ 8.22 (d, J = 8.5 Hz, 2H), 7.70 (s, 1H), 7.37 (d, J = 8.5 Hz, 
2H), 5.66 (s, 2H), 4.78 (s, 2H), 2.15 (q, J = 7.3 Hz, 4H), 1.10 (t, J = 7.4 Hz, 6H). 13C NMR 
(75 MHz, CDCl3) δ 163.23, 148.11, 141.39, 128.47, 124.34, 91.06, 53.30, 35.60, 22.56, 






thiazetidin-3-one 1,1-dioxide. From the general method B and using azide Az7. After 
reacting overnight 25 mL of water were added. The product was extracted with ethyl 
acetate (3 x 10 mL). The organic layers were combined, dried with anhydrous sodium 
sulfate and concentrated under reduced pressure, yielding an orange oil. Washing of the 
crude oil with diethyl ether led to precipitation of 104 as a yellow solid (74 mg, 0.18 
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mmol, 41%). 1H NMR (300 MHz, CDCl3) δ 7.52 (s, 1H), 7.19 (d, J = 8.6 Hz, 2H), 6.87 
(d, J = 8.7 Hz, 2H), 5.44 (s, 2H), 4.71 (s, 2H), 3.78 (s, 3H), 2.12 (qd, J = 7.4, 1.7 Hz, 4H), 
1.08 (t, J = 7.5 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 163.33, 160.03, 129.82, 129.65, 
126.40, 122.69, 114.57, 90.91, 55.41, 53.93, 35.67, 22.61, 8.48. Accurate mass: 






1,2,3-triazol-4-yl)methyl)-1,2-thiazetidin-3-one 1,1-dioxide. From the general method B 
and using azide 88. After reacting overnight 25 mL of water were added. The product 
was extracted with ethyl acetate (4 x 10 mL). The organic layers were combined, dried 
with anhydrous sodium sulfate and concentrated under reduced pressure, yielding an 
orange oil. Washing of the crude oil with diethyl ether led to precipitation of 107 as an 
orange solid (132 mg, 0.27 mmol, 99%). 1H NMR (500 MHz, Chloroform-d) δ 8.45 (d, J 
= 8.6 Hz, 0H), 7.75 (s, 0H), 6.96 (s, 0H), 6.16 (d, J = 8.6 Hz, 0H), 4.80 (s, 0H), 4.59 (t, J 
= 6.4 Hz, 0H), 3.58 (d, J = 6.4 Hz, 0H), 2.44 (t, 0H), 2.16 (qd, J = 7.5, 4.8 Hz, 1H), 1.12 
(t, J = 7.5 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 163.37, 144.39, 144.10, 143.98, 136.76, 
123.87, 99.20, 91.25, 77.36, 47.93, 40.89, 35.73, 28.71, 22.61, 8.53. Accurate mass: 







thieno[3,4-d]imidazol-4-yl)pentanamide. From the general method B and using a 
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commercially available biotin azide (TCI). 25mL of distilled water were added. The 
product was extracted with 3 x 10mL of EtOAc. The organic fractions were combined, 
dried with anhydrous sodium sulfate and concentrated under reduced pressure, resulting 
in a colorless oil. Washing of the crude oils with diethyl ether resulted in the pure product 
109 as a colorless oil (0.07 g, 0.11 mmol, 91% yield); 1H NMR (300 MHz, Chloroform-
d) δ 7.82 (s, 0H), 7.28 (s, 0H), 6.59 (t, J = 5.5 Hz, 0H), 6.41 (s, 0H), 5.55 (s, 0H), 4.78 (s, 
0H), 4.56 (t, J = 5.0 Hz, 0H), 4.49 (dd, J = 7.9, 4.8 Hz, 0H), 4.31 (dd, J = 8.2, 4.3 Hz, 0H), 
3.89 (t, J = 5.1 Hz, 0H), 3.62 – 3.48 (m, 1H), 3.41 (q, J = 5.1 Hz, 0H), 3.15 (td, J = 7.3, 
4.5 Hz, 0H), 2.90 (dd, J = 12.8, 4.9 Hz, 0H), 2.72 (d, J = 12.8 Hz, 0H), 2.27 – 2.08 (m, 
1H), 1.77 – 1.58 (m, 1H), 1.45 (q, J = 7.5 Hz, 0H), 1.12 (t, J = 7.4 Hz, 1H). 13C NMR (75 
MHz, Chloroform-d) δ 173.28, 163.53, 163.31, 140.40, 124.04, 90.91, 70.48, 70.14, 
69.96, 69.34, 61.79, 60.12, 55.45, 50.48, 41.01, 40.53, 39.16, 35.85, 35.62, 28.10, 25.53, 







(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium. From the general method 
B and using the previously described rhodamine azide. 25mL of distilled water were 
added. The product was extracted with 3 x 10mL of EtOAc. The organic fractions were 
combined, dried with anhydrous sodium sulfate and concentrated under reduced pressure, 
resulting in a pink oil. The compound was purified using preparative thin layer 
chromatography (ethyl acetate: methanol – 9:1 eluent). 108 was obtained as a light pink 
solid (0.018 g, 0.02 mmol, 15% yield). 1H NMR (300 MHz, CDCl3) δ 7.78 – 7.74 (m, 
1H), 7.69 (s, 1H), 7.33 – 7.28 (m, J = 5.6, 3.1 Hz, 2H), 6.97 – 6.92 (m, 1H), 6.33 (s, 1H), 
6.30 (s, 1H), 6.26 (d, J = 2.5 Hz, 2H), 6.15 (dd, J = 8.9, 2.6 Hz, 2H), 4.63 (s, 2H), 4.39 (t, 
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J = 5.0 Hz, 2H), 3.68 (t, J = 12.8, 7.9 Hz, 2H), 3.43 (s, 4H), 3.39 – 3.31 (m, 2H), 3.31 – 
3.15 (m, 12H), 3.05 (t, J = 7.3 Hz, 2H), 2.09 – 1.98 (m, J = 14.8, 7.5, 1.9 Hz, 4H), 1.09 – 








(111) 3,3-diethyl-1-(prop-2-yn-1-yl)azetidine-2,4-dione. Diethylmalonyl dichloride was 
dissolved in dioxan and cooled to 0ºC. Propargylamine in dioxan was very slowly added 
to the reaction. The suspension was stirred for 10 minutes and then triethylamine in 
dioxan was slowly added to the reaction. The reaction was allowed to reach room 
temperature and stirred overnight under nitrogen atmosphere. The solid in suspension was 
filtered and the filtrate was evaporated. The crude was purified by combi flash 
chromatography, yielding 111 as a colorless oil (70mg, 0.39mmol, 21%). 1H NMR (300 
MHz, CDCl3) δ 4.02 (d, J = 2.6 Hz, 2H), 2.29 (t, J = 2.6 Hz, 1H), 1.70 (q, J = 7.5 Hz, 







xanthen-3-ylidene)-N-ethylethanaminium. Compound 111 (30 mg, 0.167 mmol) was 
dissolved in DMSO (1 mL). CuSO4 (1% (aq.) 10 eq. M) and sodium ascorbate (1% (aq.) 
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10 eq. M) were added and the solution was stirred for 10 minutes at room temperature. 
The azide 91 (1.1 eq) was added and the reaction was stirred for one hour. Water (5 mL) 
was added to the reaction and the product was extracted with 3 x 1 mL of EtOAc. The 
organic fractions were combined, dried with anhydrous sodium sulfate, and evaporated 
under reduced pressure. The product was purified via preparative thin layer 
chromatography, yielding 113 as a pink oil (25 mg, 0.030 mmol, 18%). 1H NMR (500 
MHz, Chloroform-d) δ 7.90 – 7.84 (m, 1H), 7.74 (s, 1H), 7.44 – 7.39 (m, 2H), 7.09 – 7.03 
(m, 1H), 6.43 (s, 1H), 6.41 (s, 1H), 6.36 (d, J = 2.6 Hz, 2H), 6.26 (dd, J = 8.9, 2.6 Hz, 
2H), 4.60 (s, 2H), 4.50 – 4.46 (m, 2H), 3.79 (dd, J = 5.4, 4.6 Hz, 2H), 3.53 (s, 4H), 3.50 
– 3.45 (m, 2H), 3.42 – 3.38 (m, 2H), 3.33 (q, J = 7.1 Hz, 10H), 3.17 (dd, J = 8.0, 6.7 Hz, 
2H), 1.72 (q, J = 7.5 Hz, 4H), 1.16 (t, J = 7.0 Hz, 12H), 0.94 (t, J = 7.5 Hz, 6H). 13C NMR 
(151 MHz, Chloroform-d) δ 173.30, 167.77, 153.31, 152.79, 148.30, 140.63, 131.93, 
130.49, 128.37, 127.51, 123.33, 123.24, 122.25, 107.60, 105.06, 97.31, 70.54, 70.09, 
70.00, 69.99, 69.50, 68.90, 67.34, 64.35, 52.98, 49.91, 43.90, 38.79, 33.59, 23.07, 12.15, 







d]imidazol-4-yl)pentanamide. Compound 111 (30 mg, 0.167 mmol) was dissolved in 
DMSO (1 mL). CuSO4 (1% (aq.) 10 eq. M) and sodium ascorbate (2% (aq.) 10 eq. M) 
were added and the solution was stirred for 10 minutes at room temperature. A Biotin-
PEG3-azide (1.1 eq) was added and the reaction was stirred for one hour. Water (5 mL) 
was added to the reaction and the product was extracted with 3 x 1 mL of EtOAc. The 
organic fractions were combined, dried with anhydrous sodium sulfate, and evaporated 
under reduced pressure. The crude mixture was washed with diethyl ether, yielding 
compound 112 as a colorless oil (43 mg, 0.069 mmol, 41%). 1H NMR (500 MHz, 
Chloroform-d) δ 7.79 (s, 1H), 6.70 (s, 1H), 6.42 (s, 1H), 5.49 (s, 1H), 4.64 (s, 2H), 4.56 
(t, J = 5.0 Hz, 1H), 4.52 (dd, J = 7.8, 4.8 Hz, 1H), 4.33 (dd, J = 7.8, 4.5 Hz, 2H), 3.89 (t, 
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J = 5.0 Hz, 6H), 3.61 (s, 2H), 3.58 (t, J = 5.1 Hz, 2H), 3.48 – 3.40 (m, 1H), 3.17 (s, 1H), 
2.92 (d, J = 12.2 Hz, 1H), 2.76 (d, J = 12.8 Hz, 2H), 2.24 (t, J = 7.4 Hz, 1H), 1.83 – 1.60 
(m, 8H), 1.49 – 1.40 (m, 2H), 0.97 (t, J = 7.5 Hz, 6H). 13C NMR (126 MHz, Chloroform-
d) δ 173.84, 173.32, 71.03, 70.57, 70.41, 70.40, 70.07, 69.95, 69.42, 61.81, 60.21, 55.55, 
50.41, 40.53, 39.15, 35.93, 34.03, 28.19, 28.11, 25.59, 23.52, 9.21. Accurate mass: 





(114) 3,3-diethyl-1-(p-tolyl)azetidine-2,4-dione. Diethyl malonyl dichloride (1.5 g, 7.61 
mmol) was dissolved in DCM (15 mL) and the mixture was cooled to 0°C. p-toluidine 
(0.75 eq.) and triethylamine (2 eq.) were mixed with DCM (30 mL) and added dropwise. 
The reaction was stirred for 1h at 0°C and then allowed to reach room temperature and 
stirred for an additional 4h. The solvent was evaporated under reduced pressure. The solid 
residue was purified by column chromatography (hexane 9:1 ethyl acetate) to yield 
compound 114 as a colorless oil (1.202 g, 5.20 mmol, 91 %). 1H NMR (500 MHz, 
Chloroform-d) δ 7.71 (d, J = 8.4 Hz, 2H), 7.21 (dt, J = 8.1, 0.7 Hz, 2H), 2.35 (s, 3H), 1.85 
(q, J = 7.5 Hz, 4H), 1.06 (t, J = 7.5 Hz, 6H). 13C NMR (126 MHz, Chloroform-d) δ 172.39, 





(115) 1-(4-(bromomethyl)phenyl)-3,3-diethylazetidine-2,4-dione. The toluidine-
modified 4-Oxo-β-Lactam (1 g, 4.32 mmol) was dissolved in acetonitrile (40 mL). NBS 
(1.1 eq) and benzoyl peroxide (0.1 eq.). The reaction was refluxed overnight. The solvent 
was evaporated under reduced pressure. The brominated compound was purified by 
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column chromatography (hexane 9:1 ethyl acetate), which yields the product 115 with 





(131) 3,3-diethyl-1-(m-tolyl)azetidine-2,4-dione. Diethyl malonyl dichloride (1.5 g, 7.61 
mmol) was dissolved in DCM (15 mL) and the mixture was cooled to 0°C. m-toluidine 
(0.75 eq.) and triethylamine (2 eq.) were mixed with DCM (30 mL) and added dropwise. 
The reaction was stirred for 1h at 0°C and then allowed to reach room temperature and 
stirred for an additional 4h. The solvent was evaporated under reduced pressure. The solid 
residue was purified by column chromatography (hexane 9:1 ethyl acetate) to yield 
compound 131 as a colorless oil (1.294 g, 5.59 mmol, 98 %). 1H NMR (300 MHz, 
Chloroform-d) δ 7.70 – 7.54 (m, 0H), 7.29 (t, J = 7.8 Hz, 0H), 7.08 (ddt, J = 7.6, 1.8, 0.9 





(S1) 1-(3-(bromomethyl)phenyl)-3,3-diethylazetidine-2,4-dione. The toluidine-modified 
4-Oxo-β-Lactam (1 g, 4.32 mmol) was dissolved in acetonitrile (40 mL). NBS (1.1 eq.) 
and benzoyl peroxide (0.1 eq.). The reaction was refluxed overnight. The solvent was 
evaporated under reduced pressure. The brominated compound was purified by column 
chromatography (hexane 9:1 ethyl acetate), which yields the product S1 with remnants 








(140) 3,3-diethyl-1-(o-tolyl)azetidine-2,4-dione. Diethyl malonyl dichloride (1.5 g, 7.61 
mmol) was dissolved in DCM (15 mL) and the mixture was cooled to 0°C. o-toluidine 
(0.75 eq.) and triethylamine (2 eq.) were mixed with DCM (30 mL) and added dropwise. 
The reaction was stirred for 1h at 0°C and then allowed to reach room temperature and 
stirred for an additional 4h. The solvent was evaporated under reduced pressure. The solid 
residue was purified by column chromatography (hexane 9:1 ethyl acetate) to yield 
compound 140 as a colorless oil (1.056 g, 4.57 mmol, 80 %).1H NMR (500 MHz, 
Chloroform-d) δ 7.29 – 7.27 (m, 0H), 7.25 – 7.23 (m, 0H), 2.35 (s, 0H), 1.88 (q, J = 7.5 
Hz, 1H), 1.14 (t, J = 7.5 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 172.81, 133.83, 





(S2) 1-(2-(bromomethyl)phenyl)-3,3-diethylazetidine-2,4-dione. The toluidine-modified 
4-Oxo-β-Lactam (781 mg, 3.38 mmol) was dissolved in acetonitrile (31 mL). NBS (1.1 
eq.) and benzoyl peroxide (0.1 eq.). The reaction was refluxed overnight. The solvent was 
evaporated under reduced pressure. The brominated compound was purified by column 
chromatography (hexane 9:1 ethyl acetate), which yields product S2 with remnants on 










dione. Compound 115 (60 mg, 0.19 mmol) was dissolved in acetonitrile (2 mL). 1-(4-
bromobenzyl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Compound 117 
was purified from the crude mixture by preparative thin-layer chromatography (hexane 
2:1 EtOAc) and obtained as a colorless oil (31 mg, 0.064 mmol, 33 %). 1H NMR (600 
MHz, Chloroform-d) δ 7.76 (d, J = 8.5 Hz, 2H), 7.42 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.5 
Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H), 3.50 (s, 2H), 3.45 (s, 2H), 2.45 (s, 4H), 1.85 (q, J = 7.5 
Hz, 4H), 1.06 (t, J = 7.5 Hz, 6H). 13C NMR (151 MHz, Chloroform-d) δ 172.32, 137.28, 
136.99, 132.76, 131.43, 130.92, 130.03, 120.97, 119.25, 72.22, 62.54, 62.35, 53.09, 






dione. Compound 115 (60 mg, 0.19 mmol) was dissolved in acetonitrile (2 mL). 1-
(pyridin-4-yl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Product 121 was 
purified from the crude mixture by preparative thin-layer chromatography (DCM 9:1 
MeOH) and obtained as a colorless oil (8.6 mg, 0.022 mmol, 11 %). 1H NMR (500 MHz, 
Chloroform-d) δ 8.26 (d, J = 6.0 Hz, 0H), 7.82 (d, J = 8.5 Hz, 0H), 7.41 (d, J = 8.5 Hz, 
0H), 6.70 (d, 0H), 3.57 (s, 0H), 3.43 – 3.40 (m, 1H), 2.60 – 2.57 (m, 1H), 1.88 (q, J = 7.5 
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Hz, 1H), 1.09 (t, J = 7.5 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 172.35, 155.92, 
146.00, 136.27, 133.07, 129.99, 119.45, 107.93, 72.34, 62.34, 52.37, 46.15, 24.10, 9.38. 






dione. Compound 115 (60 mg, 0.19 mmol) was dissolved in acetonitrile (2 mL). 1-(4-
bromophenyl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Product 122 was 
purified from the crude mixture by preparative thin-layer chromatography (hexane 4:1 
EtOAc) and obtained as a colorless oil (50 mg, 0.11 mmol, 55 %). 1H NMR (500 MHz, 
Chloroform-d) δ 7.80 (d, J = 8.5 Hz, 0H), 7.42 (d, J = 8.1 Hz, 0H), 7.35 – 7.30 (m, 0H), 
6.79 – 6.75 (m, 0H), 3.58 (s, 0H), 3.18 (s, 0H), 2.61 (s, 1H), 1.86 (q, J = 7.5 Hz, 1H), 1.07 
(t, J = 7.5 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 172.22, 150.32, 132.79, 131.86, 
129.94, 119.23, 117.63, 111.78, 72.15, 62.40, 52.85, 48.94, 23.98, 9.27. Accurate mass: 






diethylazetidine-2,4-dione. Compound 115 (60 mg, 0.19 mmol) was dissolved in 
acetonitrile (2 mL). 1-(bis(4-fluorophenyl)methyl)piperazine (1.1 eq.) was added, 
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followed by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 mL was 
added. The compound was extracted with 3 x 3 mL of ethyl acetate. The organic fractions 
were collected, combined, dried with anhydrous sodium sulfate and evaporated under 
reduced pressure. Product 123 was purified from the crude mixture by preparative thin-
layer chromatography (hexane 4:1 EtOAc) and obtained as a colorless oil (49.8 mg, 0.096 
mmol, 50 %). 1H NMR (600 MHz, Chloroform-d) δ 7.76 (d, J = 8.5 Hz, 2H), 7.42 (d, J 
= 8.3 Hz, 2H), 7.36 (d, J = 8.5 Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H), 3.50 (s, 2H), 3.45 (s, 
2H), 2.45 (s, 8H), 1.85 (q, J = 7.5 Hz, 4H), 1.06 (t, J = 7.5 Hz, 6H). 13C NMR (151 MHz, 
Chloroform-d) δ 172.33, 137.33, 137.05, 132.75, 131.43, 130.92, 130.02, 120.95, 119.24, 







2,4-dione. Compound 115 (60 mg, 0.19 mmol) was dissolved in acetonitrile (2 mL). 1-
(4-methoxybenzyl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Product 124 was 
purified from the crude mixture by preparative thin-layer chromatography (hexane 3:1 
EtOAc) and obtained as a colorless oil (36.6 mg, 0.087 mmol, 45 %). 1H NMR (500 MHz, 
Chloroform-d) δ 7.83 (d, J = 8.3 Hz,2H), 7.45 (d, J = 8.0 Hz, 2H), 6.94 – 6.89 (m, 2H), 
6.87 – 6.83 (m, 2H), 3.79 (s, 3H), 3.63 (s, 2H), 3.14 (s, 4H), 2.67 (s, 4H), 1.88 (q, J = 7.5 
Hz, 4H), 1.09 (t, J = 7.5 Hz, 6H). 13C NMR (126 MHz, Chloroform-d) δ 172.33, 153.89, 
145.88, 137.07, 132.80, 130.03, 119.29, 118.31, 114.54, 72.24, 62.60, 55.68, 53.31, 







diethylazetidine-2,4-dione. Compound 115 (60 mg, 0.19 mmol) was dissolved in 
acetonitrile (2 mL). 6-bromo-4-(piperazin-1-yl)quinoline (1.1 eq.) was added, followed 
by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 mL was added. 
The compound was extracted with 3 x 3 mL of ethyl acetate. The organic fractions were 
collected, combined, dried with anhydrous sodium sulfate and evaporated under reduced 
pressure. Product 125 was purified from the crude mixture by preparative thin-layer 
chromatography (EtOAC) and obtained as a white solid (22.1 mg, 0.042 mmol, 22 %). 
1H NMR (500 MHz, Chloroform-d) δ 8.70 (d, J = 5.2 Hz, 0H), 8.12 (d, J = 2.2 Hz, 0H), 
8.00 (d, J = 9.0 Hz, 0H), 7.83 (d, J = 8.5 Hz, 0H), 7.74 (dd, J = 9.0, 2.2 Hz, 0H), 7.47 (d, 
J = 8.3 Hz, 0H), 6.88 (d, J = 5.2 Hz, 0H), 3.70 (s, 0H), 3.33 (s, 1H), 2.80 (s, 1H), 1.86 (q, 
J = 7.5 Hz, 1H), 1.07 (t, J = 7.5 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 172.22, 
156.17, 150.96, 147.95, 132.90, 132.60, 131.64, 129.99, 126.09, 124.80, 119.46, 119.28, 







diethylazetidine-2,4-dione. Compound 115 (60 mg, 0.19 mmol) was dissolved in 
acetonitrile (2 mL). 6-bromo-2-methyl-4-(piperazin-1-yl)quinoline (1.1 eq.) was added, 
followed by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 mL was 
added. The compound was extracted with 3 x 3 mL of ethyl acetate. The organic fractions 
were collected, combined, dried with anhydrous sodium sulfate and evaporated under 
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reduced pressure. Product 126 was purified from the crude mixture by preparative thin-
layer chromatography (EtOAc) and obtained as a white solid (37.4 mg, 0.070 mmol, 36 
%).  1H NMR (500 MHz, Chloroform-d) δ 8.09 (d, J = 2.2 Hz, 1H), 7.95 (s, 1H), 7.84 (d, 
J = 8.5 Hz, 2H), 7.72 (dd, J = 9.0, 2.2 Hz, 1H), 7.46 (d, J = 8.5 Hz, 2H), 6.76 (s, 1H), 
3.68 (s, 2H), 3.29 (s,3H), 2.81 – 2.96 (m, 8H), 1.89 (q, J = 7.5 Hz, 4H), 1.10 (t, J = 7.5 
Hz, 6H). 13C NMR (126 MHz, Chloroform-d) δ 172.34, 160.10, 156.26, 147.99, 136.83, 
132.93, 132.51, 131.10, 130.03, 125.99, 123.44, 119.37, 118.54, 110.41, 72.27, 62.56, 






diethylazetidine-2,4-dione. Compound 115 (46 mg, 0.15 mmol) was dissolved in 
acetonitrile (0.5 mL). 5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline (1.1 eq.) was 
added, followed by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 
mL was added. The compound was extracted with 3 x 3 mL of ethyl acetate. The organic 
fractions were collected, combined, dried with anhydrous sodium sulfate and evaporated 
under reduced pressure. Product 127 was purified from the crude mixture by preparative 
thin-layer chromatography (hexane 4:1 EtOAc) and obtained as a yellow oil (22 mg, 
0.054 mmol, 37 %). 1H NMR (500 MHz, Chloroform-d) δ 7.79 (d, J = 8.5 Hz, 2H), 7.44 
(d, J = 8.5 Hz, 2H), 6.56 (s, 1H), 6.44 (s, 1H), 5.87 (s, 2H), 3.67 (s, 2H), 3.54 (s, 2H), 
2.75 (dt, J = 43.4, 5.8 Hz, 4H), 1.86 (q, J = 7.5 Hz, 4H), 1.07 (t, J = 7.5 Hz, 6H). 13C 
NMR (126 MHz, Chloroform-d) δ 172.35, 146.27, 145.89, 132.93, 130.03, 127.20, 
119.39, 108.59, 106.62, 100.76, 72.26, 62.00, 56.06, 50.55, 29.84, 24.10, 9.38. Accurate 






(128) 1-(4-((dibenzylamino)methyl)phenyl)-3,3-diethylazetidine-2,4-dione. Compound 
115 (25 mg, 0.081 mmol) was dissolved in acetonitrile (0.5 mL). Dibenzylamine (1.1 eq.) 
was added, followed by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. 
Water 5 mL was added. The compound was extracted with 3 x 3 mL of ethyl acetate. The 
organic fractions were collected, combined, dried with anhydrous sodium sulfate and 
evaporated under reduced pressure. Product 128 was purified from the crude mixture by 
preparative thin-layer chromatography (hexane 2:3 EtOAc) and obtained as a white solid 
(11 mg, 0.026 mmol, 32 %). 1H NMR (500 MHz, Chloroform-d) δ 7.79 (d, J = 8.5 Hz, 
2H), 7.45 (d, J = 8.2 Hz, 2H), 7.41 – 7.37 (m, 4H), 7.32 (t, J = 7.5 Hz, 4H), 7.26 – 7.22 
(m, 2H), 3.55 (s, 1H), 1.85 (q, J = 7.5 Hz, 1H), 1.06 (t, J = 7.5 Hz, 1H). 13C NMR (126 
MHz, Chloroform-d) δ 172.23, 139.36, 138.47, 132.56, 129.48, 128.72, 128.29, 126.98, 






Compound 115 (50 mg, 0.16 mmol) was dissolved in acetonitrile (1 mL). Naphthalen-1-
amine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the reaction was heated to 
60°C for 4h. Water 5 mL was added. The compound was extracted with 3 x 3 mL of ethyl 
acetate. The organic fractions were collected, combined, dried with anhydrous sodium 
sulfate and evaporated under reduced pressure. Product 129 was purified from the crude 
mixture by preparative thin-layer chromatography (hexane 1:1 EtOAc) and obtained as a 
colorless oil (13 mg, 0.035 mmol, 22 %).1H NMR (500 MHz, Chloroform-d) δ 7.89 – 
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7.82 (m, 4H), 7.54 – 7.45 (m, 5H), 7.35 – 7.29 (m, 2H), 6.61 (d, J = 6.7 Hz, 1H), 4.55 (s, 







Compound 115 (50 mg, 0.16 mmol) was dissolved in acetonitrile (1 mL). Quinolin-5-
amine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the reaction was heated to 
60°C for 4h. Water 5 mL was added. The compound was extracted with 3 x 3 mL of ethyl 
acetate. The organic fractions were collected, combined, dried with anhydrous sodium 
sulfate and evaporated under reduced pressure. Product 130 was purified from the crude 
mixture by preparative thin-layer chromatography (EtOAc) and obtained as a yellow oil 
(17 mg, 0.046 mmol, 28 %). 1H NMR (500 MHz, Chloroform-d) δ 8.63 (dd, J = 4.3, 1.6 
Hz, 1H), 7.93 (d, J = 9.1 Hz, 1H), 7.90 (dd, J = 7.2, 1.1 Hz, 1H), 7.84 (d, J = 8.5 Hz, 2H), 
7.47 (d, J = 8.6 Hz, 2H), 7.27 (dd, J = 4.2 Hz, 1H), 7.17 (dd, J = 9.0, 2.6 Hz, 1H), 6.68 
(d, J = 2.6 Hz, 1H), 4.47 (s, 0H), 1.87 (q, J = 7.5 Hz, 1H), 1.08 (t, J = 7.5 Hz, 1H). 13C 
NMR (126 MHz, Chloroform-d) δ 172.29, 146.20, 145.86, 143.12, 137.47, 134.32, 
133.07, 130.27, 130.17, 128.30, 121.55, 121.53, 119.73, 103.60, 72.30, 47.90, 24.07, 






dione. Compound S1 (46 mg, 0.15 mmol) was dissolved in acetonitrile (1 mL). 1-(4-
bromobenzyl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
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reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Product 132 was 
purified from the crude mixture by preparative thin-layer chromatography (hexane 2:1 
EtOAc) and obtained as a colorless oil (26 mg, 0.054 mmol, 36 %). 1H NMR (500 MHz, 
Chloroform-d) δ 7.77 (t, J = 1.9 Hz, 1H), 7.72 (d, J = 8.2, 1.6 Hz, 1H), 7.46 – 7.41 (m, 
2H), 7.36 (t, J = 7.8 Hz, 1H), 7.29 – 7.25 (m, 2H), 7.23 (d, J = 8.1 Hz, 2H), 3.56 (s, 2H), 
3.51 (s, 2H), 2.55 (s, 8H), 1.86 (q, J = 7.5 Hz, 4H), 1.07 (t, J = 7.5 Hz, 6H). 13C NMR 
(126 MHz, Chloroform-d) δ 172.40, 140.00, 137.40, 133.88, 131.44, 130.95, 129.22, 
127.54, 120.95, 119.89, 118.07, 72.14, 62.57, 62.38, 53.13, 24.06, 9.38. Accurate mass: 






dione. Compound S1 (46 mg, 0.15 mmol) was dissolved in acetonitrile (1 mL). 1-(4-
bromophenyl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Product 133 was 
purified from the crude mixture by preparative thin-layer chromatography (hexane 4:1 
EtOAc) and obtained as a colorless oil (40 mg, 0.085 mmol, 57 %). 1H NMR (500 MHz, 
Chloroform-d) δ 7.81 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.39 (t, J = 7.7 Hz, 1H), 7.35 – 
7.30 (m, 3H), 6.78 (d, J = 9.0 Hz, 2H), 3.62 (s, 2H), 3.20 (s, 4H), 2.65 (s, 4H), 1.86 (q, J 
= 7.5 Hz, 4H), 1.08 (t, J = 7.5 Hz, 6H). 13C NMR (126 MHz, Chloroform-d) δ 172.39, 
150.49, 139.84, 133.95, 131.95, 129.32, 127.48, 119.85, 118.19, 117.72, 111.82, 72.17, 







yl)methyl)phenyl)azetidine-2,4-dione. Compound S1 (46 mg, 0.15 mmol) was dissolved 
in acetonitrile (1 mL). 1-(4-methoxybenzyl)piperazine (1.1 eq.) was added, followed by 
K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 mL was added. The 
compound was extracted with 3 x 3 mL of ethyl acetate. The organic fractions were 
collected, combined, dried with anhydrous sodium sulfate and evaporated under reduced 
pressure. Product 134 was purified from the crude mixture by preparative thin-layer 
chromatography (hexane 3:1 EtOAc) and obtained as a colorless oil (29 mg, 0.069 mmol, 
46 %). 1H NMR (500 MHz, Chloroform-d) δ 7.81 (s, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.43 
– 7.30 (m, 2H), 6.92 – 6.88 (m, 2H), 6.85 – 6.80 (m, 2H), 3.76 (s, 3H), 3.64 (s, 2H), 3.14 
(s, 4H), 2.68 (s, 4H), 1.86 (q, J = 7.5 Hz, 4H), 1.08 (t, J = 7.5 Hz, 6H). 13C NMR (126 
MHz, Chloroform-d) δ 172.40, 153.89, 145.91, 139.95, 133.92, 129.28, 127.56, 119.92, 







diethylazetidine-2,4-dione. Compound S1 (46 mg, 0.15 mmol) was dissolved in 
acetonitrile (1 mL). 1-(bis(4-fluorophenyl)methyl)piperazine (1.1 eq.) was added, 
followed by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 mL was 
added. The compound was extracted with 3 x 3 mL of ethyl acetate. The organic fractions 
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were collected, combined, dried with anhydrous sodium sulfate and evaporated under 
reduced pressure. Product 135 was purified from the crude mixture by preparative thin-
layer chromatography (hexane 4:1 EtOAc) and obtained as a colorless oil (43 mg, 0.056 
mmol, 56 %). 1H NMR (500 MHz, Chloroform-d) δ 7.75 (t, J = 1.7 Hz, 1H), 7.72 (d, J = 
8.0 Hz, 1H), 7.39 – 7.30 (m, 6H), 6.95 (t, J = 8.7 Hz, 4H), 4.22 (s, 1H), 3.55 (s, 2H), 2.56 
– 2.34 (m, 8H), 1.85 (q, J = 7.5 Hz, 4H), 1.06 (t, J = 7.5 Hz, 4H). 13C NMR (126 MHz, 
Chloroform-d) δ 172.39, 162.88, 160.93, 139.93, 138.46, 138.44, 133.86, 129.41, 129.34, 
129.21, 127.56, 119.90, 118.05, 115.56, 115.39, 74.63, 72.13, 62.58, 53.40, 51.84, 24.04, 






dione. Compound S1 (46 mg, 0.15 mmol) was dissolved in acetonitrile (1 mL). 1-
(pyridin-4-yl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Product 136 was 
purified from the crude mixture by preparative thin-layer chromatography (DCM 9:1 
MeOH) and obtained as a yellow oil (22 mg, 0.056 mmol, 38 %). 1H NMR (500 MHz, 
Chloroform-d) δ 8.25 (d, J = 6.7 Hz, 2H), 7.82 (t, J = 1.9 Hz, 1H), 7.79 – 7.73 (m, 1H), 
7.39 (t, J = 7.8 Hz, 1H), 7.26 – 7.23 (m, 1H), 6.82 – 6.76 (m, 2H), 3.59 (s, 2H), 3.57 – 
3.51 (m, 4H), 2.63 – 2.60 (m, 4H), 1.86 (q, J = 7.5 Hz, 4H), 1.07 (t, J = 7.5 Hz, 6H). 13C 
NMR (126 MHz, Chloroform-d) δ 172.39, 156.59, 143.29, 139.08, 134.13, 129.52, 
127.35, 119.70, 118.48, 107.61, 72.27, 62.22, 52.26, 46.21, 24.05, 9.37. Accurate mass: 







diethylazetidine-2,4-dione. Compound S1 (46 mg, 0.15 mmol) was dissolved in 
acetonitrile (1 mL). 6-bromo-4-(piperazin-1-yl)quinoline (1.1 eq.) was added, followed 
by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 mL was added. 
The compound was extracted with 3 x 3 mL of ethyl acetate. The organic fractions were 
collected, combined, dried with anhydrous sodium sulfate and evaporated under reduced 
pressure. Product 137 was purified from the crude mixture by preparative thin-layer 
chromatography (EtOAc) and obtained as a white solid (44 mg, 0.084 mmol, 57 %). 1H 
NMR (500 MHz, Chloroform-d) δ 8.69 (d, J = 5.2 Hz, 0H), 8.14 (d, J = 2.2 Hz, 0H), 8.02 
(d, J = 8.9 Hz, 0H), 7.86 (d, J = 1.9 Hz, 0H), 7.79 – 7.76 (m, 0H), 7.74 (dd, J = 8.9, 2.2 
Hz, 0H), 7.41 (t, J = 7.8 Hz, 0H), 7.35 (d, J = 7.8 Hz, 0H), 6.89 (d, J = 5.2 Hz, 0H), 3.71 
(s, 0H), 3.35 (d, J = 5.3 Hz, 1H), 2.82 (s, 1H), 1.87 (q, J = 7.5 Hz, 1H), 1.08 (t, J = 7.5 
Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 172.29, 156.14, 151.22, 148.21, 139.69, 
133.92, 132.46, 131.82, 129.26, 127.37, 126.12, 124.92, 119.71, 119.37, 118.14, 109.64, 






diethylazetidine-2,4-dione. Compound S1 (46 mg, 0.15 mmol) was dissolved in 
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acetonitrile (1 mL). 6-bromo-2-methyl-4-(piperazin-1-yl)quinoline (1.1 eq.) was added, 
followed by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 mL was 
added. The compound was extracted with 3 x 3 mL of ethyl acetate. The organic fractions 
were collected, combined, dried with anhydrous sodium sulfate and evaporated under 
reduced pressure. Product 138 was purified from the crude mixture by preparative thin-
layer chromatography (EtOAc) and obtained as a white solid (47 mg, 0.088 mmol, 59 %). 
1H NMR (500 MHz, Chloroform-d) δ 8.08 (d, J = 2.2 Hz, 1H), 7.91 – 7.84 (m, 2H), 7.76 
(ddd, J = 8.0, 2.1, 1.2 Hz, 1H), 7.68 (dd, J = 8.9, 2.2 Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 
7.32 – 7.30 (m, 1H), 6.75 (s, 1H), 3.67 (s, 2H), 3.26 (s, 4H), 2.77 (s, 1H), 2.67 (s, 1H), 
1.87 (q, J = 7.5 Hz, 1H), 1.08 (t, J = 7.5 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 
172.29, 159.97, 156.19, 147.86, 139.74, 133.92, 132.39, 130.97, 129.24, 127.34, 125.90, 
123.33, 119.68, 118.42, 118.12, 110.32, 72.08, 62.45, 53.01, 52.18, 25.63, 23.94, 9.27. 






diethylazetidine-2,4-dione. Compound S1 (46 mg, 0.15 mmol) was dissolved in 
acetonitrile (1 mL). 5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline (1.1 eq.) was 
added, followed by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 
mL was added. The compound was extracted with 3 x 3 mL of ethyl acetate. The organic 
fractions were collected, combined, dried with anhydrous sodium sulfate and evaporated 
under reduced pressure. Product 139 was purified from the crude mixture by preparative 
thin-layer chromatography (hexane 4:1 EtOAc) and obtained 139 as a yellow oil (34 mg, 
0.084 mmol, 56 %). 1H NMR (500 MHz, Chloroform-d) δ 7.82 – 7.81 (m, 1H), 7.78 – 
7.73 (m, 1H), 7.41 (d, J = 7.4 Hz, 2H), 6.58 (s, 1H), 6.46 (s, 1H), 5.88 (s, 2H), 3.74 (s, 
2H), 3.61 (s, 2H), 2.82 (d, J = 26.2 Hz, 4H), 1.86 (q, J = 7.5 Hz, 4H), 1.07 (t, J = 7.5 Hz, 
6H). 13C NMR (126 MHz, Chloroform-d) δ 172.38, 146.17, 145.81, 140.19, 133.89, 
129.34, 127.62, 127.48, 127.37, 119.88, 118.22, 108.59, 106.61, 100.71, 72.14, 62.19, 






dione. Compound S2 (50 mg, 0.15 mmol) was dissolved in acetonitrile (1 mL). 1-(4-
bromobenzyl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Product 141 was 
purified from the crude mixture by preparative thin-layer chromatography (hexane 2:1 
EtOAc) and obtained as a colorless oil (18 mg, 0.037 mmol, 23 %). 1H NMR (300 MHz, 
Chloroform-d) δ 7.49 – 7.39 (m, 3H), 7.36 – 7.23 (m, 3H), 7.20 – 7.14 (m, 2H), 3.58 (s, 
2H), 3.43 (s, 2H), 2.39 (s, 8H), 1.91 (q, J = 7.5 Hz, 4H), 1.13 (t, J = 7.5 Hz, 6H). 13C 
NMR (75 MHz, Chloroform-d) δ 172.88, 137.25, 134.31, 131.44, 131.33, 130.93, 129.98, 
128.96, 128.08, 126.21, 120.98, 70.13, 62.38, 60.01, 53.41, 53.04, 23.73, 9.54. 






dione. Compound S2 (46 mg, 0.15 mmol) was dissolved in acetonitrile (1 mL). 1-(4-
bromophenyl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Product 142 was 
purified from the crude mixture by preparative thin-layer chromatography (hexane 4:1 
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EtOAc) and obtained as a colorless oil (20 mg, 0.043 mmol, 29 %). 1H NMR (500 MHz, 
Chloroform-d) δ 7.58 (d, J = 6.7 Hz, 1H), 7.42 – 7.30 (m, 5H), 6.77 – 6.73 (m, 2H), 3.77 
(s, 2H), 3.17 (d, J = 5.4 Hz, 4H), 2.65 (s, 4H), 1.91 (q, J = 7.5 Hz, 4H), 1.13 (t, J = 7.5 
Hz, 6H). 13C NMR (75 MHz, Chloroform-d) δ 172.87, 150.38, 133.87, 131.96, 131.41, 
130.08, 129.03, 128.28, 126.26, 117.65, 111.85, 70.20, 59.99, 53.26, 48.93, 23.77, 9.54. 






2,4-dione. Compound S2 (46 mg, 0.15 mmol) was dissolved in acetonitrile (1 mL). 1-(4-
methoxybenzyl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Product 143 was 
purified from the crude mixture by preparative thin-layer chromatography (hexane 3:1 
EtOAc) and obtained as a colorless oil (23 mg, 0.054 mmol, 37 %). 1H NMR (600 MHz, 
Chloroform-d) δ 7.54 – 7.50 (m, 1H), 7.37 – 7.32 (m, 2H), 7.31 – 7.29 (m, 1H), 6.90 – 
6.85 (m, 2H), 6.85 – 6.81 (m, 2H), 3.76 (s, 2H), 3.65 (s, 2H), 3.10 – 2.93 (m, 4H), 2.60 – 
2.45 (m, 4H), 1.92 (q, J = 7.5 Hz, 4H), 1.14 (t, J = 7.5 Hz, 12H). 13C NMR (151 MHz, 
Chloroform-d) δ 172.88, 153.86, 145.80, 134.09, 131.43, 130.04, 128.99, 128.17, 126.20, 









dione. Compound S2 (46 mg, 0.15 mmol) was dissolved in acetonitrile (1 mL). 1-
(pyridin-4-yl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the 
reaction was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted 
with 3 x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried 
with anhydrous sodium sulfate and evaporated under reduced pressure. Product 144 was 
purified from the crude mixture by preparative thin-layer chromatography (DCM 9:1 
MeOH) and obtained as a colorless oil (13 mg, 0.033 mmol, 22 %). 1H NMR (600 MHz, 
Chloroform-d) δ 7.48 – 7.45 (m, 1H), 7.43 – 7.40 (m, 2H), 7.34 – 7.28 (m, 2H), 7.27 – 
7.25 (m, 1H), 7.18 – 7.15 (m, 2H), 3.58 (s, 2H), 3.42 (s, 2H), 2.38 (s, 8H), 1.91 (q, J = 
7.5 Hz, 4H), 1.13 (t, J = 7.5 Hz, 6H). 13C NMR (151 MHz, Chloroform-d) δ 172.84, 
137.30, 134.28, 131.39, 131.30, 130.88, 129.92, 128.93, 128.04, 126.17, 120.91, 70.09, 






diethylazetidine-2,4-dione. Compound S2 (46 mg, 0.15 mmol) was dissolved in 
acetonitrile (1 mL). 6-bromo-4-(piperazin-1-yl)quinoline (1.1 eq.) was added, followed 
by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 mL was added. 
The compound was extracted with 3 x 3 mL of ethyl acetate. The organic fractions were 
collected, combined, dried with anhydrous sodium sulfate and evaporated under reduced 
pressure. Product 145 was purified from the crude mixture by preparative thin-layer 
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chromatography (EtOAc) and obtained as a white solid (26 mg, 0.050 mmol, 34 %). 1H 
NMR (500 MHz, Chloroform-d) δ 8.73 (d, J = 5.5 Hz, 1H), 8.11 (d, J = 2.2 Hz, 1H), 8.03 
(d, J = 9.0 Hz, 1H), 7.76 (dd, J = 9.0, 2.1 Hz, 1H), 7.56 – 7.49 (m, 1H), 7.41 – 7.29 (m, 
3H), 6.86 (d, J = 5.5 Hz, 1H), 3.75 (s, 2H), 3.45 – 3.23 (m, 4H), 2.69 (t, J = 4.7 Hz, 4H), 
1.93 (q, J = 7.5 Hz, 4H), 1.16 (t, J = 7.5 Hz, 6H). 13C NMR (126 MHz, Chloroform-d) δ 
172.81, 157.49, 148.52, 133.84, 133.29, 131.27, 130.01, 129.35, 129.07, 128.44, 126.48, 
126.35, 123.80, 119.97, 108.67, 70.19, 59.66, 52.97, 52.03, 23.72, 9.47. Accurate mass: 






diethylazetidine-2,4-dione. Compound S2 (46 mg, 0.15 mmol) was dissolved in 
acetonitrile (1 mL). 6-bromo-2-methyl-4-(piperazin-1-yl)quinoline (1.1 eq.) was added, 
followed by K2CO3 (1.1 eq.) and the reaction was heated to 60°C for 4h. Water 5 mL was 
added. The compound was extracted with 3 x 3 mL of ethyl acetate. The organic fractions 
were collected, combined, dried with anhydrous sodium sulfate and evaporated under 
reduced pressure. Product 146 was purified from the crude mixture by preparative thin-
layer chromatography (EtOAc) and obtained as a white solid (28 mg, 0.052 mmol, 35 %). 
1H NMR (500 MHz, Chloroform-d) δ 8.06 – 7.98 (m, 2H), 7.74 (d, J = 8.9 Hz, 1H), 7.54 
(d, J = 6.8 Hz, 1H), 7.42 – 7.34 (m, 2H), 7.31 (d, J = 7.0 Hz, 1H), 6.70 (s, 1H), 3.74 (s, 
2H), 3.33 (s, 4H), 2.72 (s, 3H), 2.68 (s, 4H), 1.93 (q, J = 7.4 Hz, 4H), 1.16 (t, J = 7.4 Hz, 
6H). 13C NMR (126 MHz, Chloroform-d) δ 172.81, 134.03, 133.38, 131.27, 130.00, 
129.07, 128.43, 126.38, 126.31, 122.24, 119.32, 109.41, 70.18, 59.70, 52.97, 51.99, 






(119) Benzyl 4-((3,3-diethyl-2,4-dioxoazetidin-1-yl)methyl)benzoate. Diethyl malonyl 
dichloride was dissolved in DCM and the mixture was cooled to 0°C. The amine handle 
benzyl 4-(aminomethyl)benzoate and triethylamine were dissolved in DCM and added to 
the reaction dropwise. The reaction was stirred for 1h at 0°C and then allowed to reach 
room temperature and stirred for an additional 4h. The solvent was evaporated under 
reduced pressure and the crude mixture was purified by flash column chromatography 
(hexane 9:1 EtOAc to hexane 1:1 EtOAc) to yield the final product 119 as a colorless oil 
(126 mg, 0.34 mmol, 23 %). 1H NMR (500 MHz, Chloroform-d) δ 8.06 (d, J = 8.4 Hz, 
2H), 7.51 – 7.29 (m, 7H), 5.36 (s, 2H), 4.51 (s, 2H), 1.73 (q, J = 7.5 Hz, 4H), 0.92 (t, J = 
7.5 Hz, 6H). 13C NMR (126 MHz, Chloroform-d) δ 174.17, 166.03, 140.05, 136.02, 
130.49, 130.16, 128.76, 128.46, 128.42, 128.37, 71.21, 66.99, 42.45, 23.80, 9.34. 





(120) 4-((3,3-diethyl-2,4-dioxoazetidin-1-yl)methyl)benzoic acid. Compound XX (100 
mg, 0.27 mmol) was dissolved in MeOH (1 mL). Palladium on activated charcoal (20 
mg) was added. Triethylsilane (10 eq.) was slowly added dropwise while the reaction was 
stirred vigorously. The reaction was stirred at room temperature for 5 minutes. The 
mixture was diluted with ethyl acetate and filtered. The filtrate was evaporated under 
reduced pressure. The crude mixture was purified by flash column chromatography and 
the final product 120 was obtained as a white solid (40 mg, 0.15 mmol, 53 %). 1H NMR 
(500 MHz, Chloroform-d) δ 8.10 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 4.54 (s, 
2H), 1.74 (q, J = 7.5 Hz, 4H), 0.93 (t, J = 7.5 Hz, 6H). 13C NMR (126 MHz, Chloroform-
d) δ 174.21, 171.21, 140.88, 131.02, 129.26, 128.54, 71.26, 42.46, 23.83, 9.34. Accurate 






dione. Compound 115 (40 mg, 0.11 mmol) was dissolved in acetonitrile (1 mL). 1-(prop-
2-yn-1-yl)piperazine (1.1 eq.) was added, followed by K2CO3 (1.1 eq.) and the reaction 
was heated to 60°C for 4h. Water 5 mL was added. The compound was extracted with 3 
x 3 mL of ethyl acetate. The organic fractions were collected, combined, dried with 
anhydrous sodium sulfate and evaporated under reduced pressure. Product 151 was 
purified from the crude mixture by preparative thin-layer chromatography (EtOAc) and 
obtained as a colorless oil (15 mg, 0.042 mmol, 33 %). 1H NMR (300 MHz, Chloroform-
d) δ 7.77 (d, J = 8.5 Hz, 2H), 7.37 (d, J = 8.5 Hz, 2H), 3.51 (s, 2H), 3.29 (d, J = 2.5 Hz, 
2H), 2.65 – 2.44 (m, 8H), 2.24 (t, J = 2.4 Hz, 1H), 1.85 (q, J = 7.5 Hz, 4H), 1.06 (t, J = 
7.5 Hz, 6H). 13C NMR (126 MHz, Chloroform-d) δ 172.36, 137.07, 132.79, 130.02, 
119.28, 78.96, 73.34, 72.26, 62.49, 52.98, 51.98, 46.92, 24.11, 9.38. 
 
 






amine hydrobromide (0.75 g, 3.43 mmol) was dissolved in DMSO (30 mL). Sodium azide 
(0.267 g, 1.2 eq.) was added and the reaction was stirred overnight. The next day NBD-
Cl (0.752 g, 3.77 mmol) was added, followed by triethylamine (0.549 mL, 3.94 mmol). 
The reaction was stirred for 4 h. A dilution was done with water (50 mL) and the product 
was extracted with 4 x 15 mL of EtOAc. The organic fractions were combined, dried with 
anhydrous sodium sulfate and concentrated under reduced pressure. The crude was 
purified by flash column chromatography, to yield product 88 as an orange solid (0.378 
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g, 1.44 mmol, 46% yield over two steps). 1H NMR (300 MHz, CDCl3) δ 8.47 (d, J = 8.6 
Hz, 1H), 6.63 (s, 1H), 6.22 (d, J = 8.7 Hz, 1H), 3.66 (q, J = 6.6 Hz, 2H), 3.61 – 3.56 (m, 






(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium. Rhodamine B (0.025 g, 
0.052 mmol) was dissolved in dry DCM (1 mL) and the solution was cooled to 0°C. HOBt 
(2 eq.) was added with DIPEA (1 eq.), followed by TBTU (2eq.). The reaction was stirred 
for 30 min. 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-amine (3 eq.) was added 
with DIPEA (3 eq.) and the reaction was refluxed overnight. The next day the solvent 
was evaporated under reduced pressure. The product was purified by preparative thin-
layer chromatography, yielding product 91 as a pink oil (this reaction was used as a proof-
of-concept, no mass of product was determined). 1H NMR (300 MHz, DMSO) δ 7.81 – 
7.73 (m, 1H), 7.55 – 7.44 (m, 2H), 7.06 – 6.98 (m, 1H), 6.39 – 6.28 (m, J = 17.9, 8.4 Hz, 
6H), 3.56 – 3.52 (m, 2H), 3.50 – 3.38 (m, 11H), 3.37 – 3.26 (m, 4H), 3.20 – 3.08 (m, 4H), 



















dione. 1-(4-(bromomethyl)phenyl)-3,3-diethylazetidine-2,4-dione was suspended in dry 
DCM. Umbelliferone (1.1 eq.) and potassium carbonate (1.1 eq.) were added. The 
reaction was refluxed overnight. The solvent was evaporated under reduced pressure and 
the product was purified by flash column chromatography. Compound 165 was obtained 
as a white solid (0.045 g, 0.11 mmol, 28% yield). 1H NMR (300 MHz, CDCl3) δ 7.93 – 
7.85 (m, 2H), 7.63 (d, J = 9.5 Hz, 1H), 7.48 (d, J = 8.6 Hz, 2H), 7.38 (d, J = 8.6 Hz, 1H), 
6.90 (dd, J = 8.6, 2.4 Hz, 1H), 6.86 (d, J = 2.4 Hz, 1H), 6.26 (d, J = 9.5 Hz, 1H), 5.12 (s, 
2H), 1.86 (q, J = 7.5 Hz, 4H), 1.07 (t, J = 7.5 Hz, 6H). 13C NMR (75 MHz, Chloroform-
d) δ 172.18, 161.68, 161.16, 155.90, 143.42, 134.39, 133.88, 128.97, 128.48, 119.55, 







(prop-2-yn-1-yl)azetidine-2,4-dione (0.07 g, 0.39 mmol) was dissolved in DMSO (2 mL). 
CuSO4 (400 µL, 0.1 M) and sodium ascorbate (400 µL, 0.2 M) were added and the 
reaction was stirred for 10 minutes at room temperature. The azide 2-azido-N-(3',6'-
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dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)acetamide (1 eq.) was then 
added and the reaction was stirred overnight. The reaction was diluted with water, leading 
to a yellow precipitate. The solid was filtered and further purification was attempted by 
recrystallization with different pairs of solvents (EtOAc, hexane, MeOH, acetonitrile and 
DCM) with no success. The solid was purified using reverse phase combi flash 
chromatography (100% water to 100% MeOH gradient ), yielding compound 166 as a 
yellow solid (19 mg, 8%). 1 H NMR (300 MHz, (CD3)2SO) δ 10.97 (s, 1H), 8.25 (d, J = 
1.8 Hz, 1H), 8.15 (s, 1H), 7.81 (dd, J = 8.4; 1.9 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 6.66 (d, 
J = 2.3 Hz, 2H), 6.58 (t, J = 8.5 Hz, 3H), 6.53 (dd, J = 8.7; 2.3 Hz, 2H), 5.59 (d,  J = 8.0, 
1H), 5.41 (s, 2H), 4.63 (s, 2H), 1.68 (q, J = 7.7 Hz, 4H), 0.88 (q, J = 7.7 Hz, 6H). 13C 
NMR (75 MHz, (CD3)2SO) 173.8, 169.0, 165.3, 157.1, 152.5, 141.1, 140.4, 129.6, 129.3, 
127.4, 126.7, 125.5, 125.3, 114.4, 113.4, 110.1, 102.7, 88.7, 70.4, 52.7, 33.8, 23.2, 9.4. 
ESI (+) m/z: 610.2 [M+H]+ , 649.38 [M+K]+ (Exact mass calcd.: 609.19). 
 
 





(156) O-benzylhydroxylamine hydrochloride. Sodium bicarbonate (2.1 g, 25 mmol) was 
suspended in a mixture of DCM (18 mL) and distilled water (34 mL). Tert-
butylammonium sulfate (0.42 g, 1.23 mmol) was added, followed by benzyl chloride (1.7 
mL, 14.8 mmol). N-hydroxyphtalimide (2 g, 12.3 mmol) was slowly added over 30 
minutes. The reaction was refluxed at 45°C for 5h. The benzyl-protected N-
hydroxyphthalimide was extracted with 30 x 30 mL of DCM. The organic fractions were 
combined, dried with sodium sulfate and evaporated under reduced pressure, yielding a 
white solid. 1H NMR (300 MHz, CDCl3) δ 7.83 – 7.78 (m, 2H), 7.76 – 7.71 (m, 2H), 7.56 
– 7.51 (m, 2H), 7.40 – 7.35 (m, 3H), 5.21 (s, 2H). This product was suspended in acetic 
acid (20 mL) and hydrochloric acid 37% (7.2 mL) was added. The reaction was refluxed 
at 75°C for 5 hours. The reaction was cooled and DCM was added, causing product 156 
to precipitate as a white crystalline solid (0.911 g, 12.4 mol, 91% yield over two steps). 
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Prior to use, this compound is neutralized by washing with sodium bicarbonate. 1H NMR 





(164) 1-(benzyloxy)-3,3-diethylazetidine-2,4-dione. O-benzylhydroxylamine 156 (1,1 
eq.) in dioxane (10mL/eq. of amine) was slowly added to diethylmalonyl dichloride in 
dioxane (10 mL/eq. of dichloride) at 0°C. Triethylamine (2.1 eq.) in dioxane (5 mL/eq. 
of TEA) was slowly added to the reaction. The reaction was allowed to reach room 
temperature and stirred overnight under nitrogen atmosphere. The solid that formed in 
the reaction medium was filtered and the filtrate evaporated and purified by combi flash 
chromatography. Compound 164 was obtained as a white solid (0.219 g, 0.89 mmol, 19% 
yield). 1H NMR (300 MHz, CDCl3) δ 7.39 – 7.25 (m, 5H), 5.04 (s, 2H), 1.54 (q, J = 7.5 





(161) 3-benzyl-1-(benzyloxy)-3-ethylazetidine-2,4-dione. O-benzylhydroxylamine 156 
(1,1 eq.) in dioxane (10mL/eq. of amine) was slowly added to 2-benzyl-2-ethylmalonyl 
dichloride 160 in dioxane (10 mL/eq. of dichloride) at 0°C. Triethylamine (2.1 eq.) in 
dioxane (5 mL/eq. of TEA) was slowly added to the reaction. The reaction was allowed 
to reach room temperature and stirred overnight under nitrogen atmosphere. The solid 
that formed in the reaction medium was filtered and the filtrate evaporated and purified 
by combi flash chromatography. Compound 161 was obtained as a white solid (0.4 g, 1.3 
mmol, 21% yield). 1H NMR (300 MHz, CDCl3) δ 7.40 – 7.17 (m, 10H), 4.52 (s, 2H), 






(S3) 3,3-diethyl-1-hydroxyazetidine-2,4-dione. The 4-Oxo-β-Lactam 164 was dissolved 
in MeOH. Palladium on activated charcoal was added. The reaction was vigorously 
stirred under nitrogen atmosphere. TES (10 eq.) was slowly added to the reaction, which 
was stirred for 10 min. The palladium was filtered and washed with ethyl acetate. The 
filtrate was evaporated under reduced pressure, resulting in a crude colorless oil, which 





(162) 3-benzyl-3-ethyl-1-hydroxyazetidine-2,4-dione. The benzylated 4-Oxo-β-Lactam 
161 was dissolved in MeOH. Palladium on activated charcoal was added. The reaction 
was vigorously stirred under nitrogen atmosphere. TES (10 eq.) was slowly added to the 
reaction, which is stirred for 10 min. The palladium was filtered and washed with ethyl 
acetate. The filtrate was evaporated under reduced pressure, resulting in a crude colorless 





(152) 3,3-diethyl-2,4-dioxoazetidin-1-yl 4-methylbenzenesulfonate. The crude reaction 
from the TES hydrogenation containing compound S3 was dissolved in dry DCM. 
Pyridine (1,1 eq.) was added, followed by 4-methylbenzenesulfonyl chloride (1,1 eq.). 
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The reaction was stirred overnight. The solvent was evaporated under reduced pressure 
and the product was purified by flash column chromatography. Compound 152 was 
obtained from 3-benzyl-3-ethyl-1-hydroxyazetidine-2,4-dione as a white solid (0.084 g, 
0.22 mmol, 41% yield); 1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 8.4 Hz, 2H), 7.38 – 
7.29 (m, 5H), 7.21 – 7.14 (m, 2H), 2.99 (s, 2H), 2.47 (s, 3H), 1.85 (q, J = 7.5 Hz, 2H), 
1.05 (t, J = 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.29, 147.33, 133.94, 130.32, 





(153) 3-benzyl-3-ethyl-2,4-dioxoazetidin-1-yl 4-methylbenzenesulfonate. The crude 
reaction from the TES hydrogenation containing compound 162 was dissolved in dry 
DCM. Pyridine (1,1 eq.) was added, followed by 4-methylbenzenesulfonyl chloride (1,1 
eq.). The reaction was stirred overnight. The solvent was evaporated under reduced 
pressure and the product was purified by flash column chromatography. Compound 153 
was obtained as a white solid (0.105 g, 0.34 mmol, 47% yield); 1H NMR (300 MHz, 
CDCl3) δ 7.94 (dt, 2H), 7.39 (dd, J = 8.6, 0.6 Hz, 2H), 2.45 (s, 3H), 1.80 – 1.65 (m, 4H), 
0.56 (t, J = 7.5 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 172.52, 170.80, 147.50, 132.54, 





(158) Diethyl 2-benzyl-2-ethylmalonate. Sodium ethoxide (1.1 eq. to malonic ester) was 
prepared by dissolving sodium in ethanol. Diethyl 2-benzylmalonate (2.5g, 10 mmol) was 
added, and the reaction was stirred for 30 minutes. Iodoethane (1.1 eq.) was added and 
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the reaction was refluxed for 5 h. Compound 158 was obtained from diethyl 2-
benzylmalonate as a yellow oil (2.689 g, 9.66 mmol, quant. yield). 1H NMR (300 MHz, 
CDCl3) δ 7.32 – 7.19 (m, 3H), 7.10 (dd, J = 7.6, 1.8 Hz, 2H), 4.25 – 4.14 (m, J = 9.8, 6.8, 
3.1 Hz, 4H), 3.25 (s, 2H), 1.85 (q, J = 7.5 Hz, 2H), 1.26 (t, J = 7.1 Hz, 6H), 0.94 (t, J = 





(159) 2-benzyl-2-ethylmalonic acid. The disubstituted malonic ester 158 (2.689 g, 9.66 
mmol) was dissolved in ethanol (20 mL) and sodium hydroxide (20 mL, 2M) was added. 
The reaction was refluxed for 5 h. The reaction media was poured into an extraction vessel 
with 50 mL of water and the remaining starting material was extracted with 3 x 30 mL 
ethyl acetate. The aqueous fraction was acidified and the product was extracted with 3 x 
30 mL ethyl acetate. Concentration of these fractions resulted in the correspondent 
malonic acid 159, obtained as a white solid (2.145 g, 9.65 mmol, quant. yield). 1H NMR 
(300 MHz, CDCl3) δ 7.36 – 7.13 (m, 5H), 3.32 (s, 2H), 2.06 (q, J = 7.4 Hz, 2H), 1.01 (t, 
J = 7.5 Hz, 3H).  
 
 





(168) tert-butyl (1-oxo-4-phenylbutan-2-yl)carbamate. 2-((tert-butoxycarbonyl)amino)-
4-phenylbutanoic acid (500mg, 1.79mmol) was dissolved in dry dichloromethane (DCM) 
(4mL). Triethylamine (TEA) (0.252µL, 1.8mmol) was added to the solution, which was 
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stirred for 20 minutes. O-(Benzotriazol–1-yl)-N,N,N′,N′-tetramethyluronium 
tetrafluoroborate (TBTU) (0.581mg, 1.81mmol) was added to the mixture and the 
solution was stirred for one hour. N-O-dimethylhydroxylamine (0.195mg, 2,0mmol) was 
added and the reaction was stirred at room temperature overnight. The reaction mixture 
was diluted with DCM and washed with hydrochloric acid (3M), followed by washing 
with potassium hydrogen sulfate and a third washing step with brine. The organic fraction 
was collected and dried with sodium sulfate, filtered and concentrated under reduced 
pressure, yielding a crude mass of 440mg, which was dried under vacuum overnight. This 
mass was dissolved in dry THF (8mL) and cooled to 0ᵒC. Lithium aluminum hydride 
(70.2mg, 1.85mmol) was added to the solution, which was stirred under nitrogen 
atmosphere for one hour. The reaction was quenched with 20mL of potassium hydrogen 
sulfate (10%). The aqueous phase was extracted with diethyl ether until there was no 
evidence of product remaining in the aqueous phase, as analyzed by TLC. The organic 
layers were combined and concentrated under reduced pressure, yielding 168 as a 





(169) tert-butyl (E)-(5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl)carbamate. Diethyl 
((phenylsulfonyl)methyl)phosphonate (342mg, 1.2mmol) was dissolved in dry THF 
(8mL) and the solution was cooled to -10ᵒC. Sodium hydride 60% (24mg, 1mmol) was 
added and the solution was stirred for 10 minutes before a cooled solution of compound 
168 was added. The solution was stirred for 4 hours and then diluted with diethyl ether 
and washed with brine three times. The organic layers were combined, dried with sodium 
sulfate, filtered and concentrated under reduced pressure, yielding a yellow oil, which 
was purified by combi flash chromatography, resulting in compound 169 as a colorless 






(170) (E)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-aminium 2,2,2-trifluoroacetate. 
Compound 169 was dissolved in DCM (3mL). Trifluoroacetic acid (TFA) (3mL, 
39.2mmol) was added and the reaction was stirred for 3 hours. The solution was 
concentrated under reduced pressure. The crude mass was dissolved in DCM and 







yl)amino)pentan-2-yl)carbamate. Boc-protected valine (123mg, 0.53mmol) was 
dissolved in DMF (7.5mL). TEA (75µL, 0.54mmol) was added to the solution, followed 
by hydroxybenzotriazole (HOBt) (1 eq.) and then TBTU (1 eq.). The mixture was stirred 
at 0ᵒC for 30 minutes under nitrogen atmosphere. Compound 170 (1.1 eq.) was dissolved 
in a mixture of DMF (7.5mL) and TEA (1 eq.) and this solution was added to the reaction, 
which was stirred overnight at room temperature under nitrogen atmosphere. HCl 3M (10 
mL) was added to the mixture and the product was extracted with 3 x 3 mL of ethyl 
acetate. The organic layers were combined, dried with sodium sulfate and concentrated 
under reduced pressure. The resulting colorless oil was purified by combi flash 








2-aminium 2,2,2-trifluoroacetate. Compound 171 (175mg, 0.34mmol) was dissolved in 
DCM (4mL) and TFA (4mL) was added. The solution was stirred at room temperature 
for 3 hours. The solution was concentrated under reduced pressure. The crude mass was 
dissolved in DCM and evaporated three times, yielding 172 as a white solid (180.4mg, 






propiolamidopentanamide. Propiolic acid (30µL, 0.49mmol) and TEA (1 eq.) were 
dissolved in DMF (12mL) and stirred at 0ᵒC. HOBt (1.1 eq.) and TBTU (1.1 eq.) were 
added and the reaction was stirred for 30 minutes. Compound 172 (180.4mg, 0.34mmol) 
in DMF (12mL) and TEA (1.1 eq.) was added to the reaction, which was allowed to reach 
room temperature and stirred overnight. The solution was diluted with HCl 3M (20 mL) 
and extracted with 3 x 5 mL of EtOAc. The organic phases were combined, dried with 
sodium sulfate and concentrated under reduced pressure. Combi flash chromatography 
purification yielded compound 173 as a colorless oil (73mg, 0.15mmol, 38%). 1H NMR 
(300 MHz, CDCl3) δ 7.85 – 7.79 (m, 2H), 7.50 (m, 3H), 7.24 – 7.11 (m, 3H), 7.06 – 7.01 
(m, 2H), 6.90 (dd, J = 15.1, 5.5 Hz, 1H), 6.46 (dd, J = 15.1, 1.4 Hz, 1H), 4.66 – 4.50 (m, 
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2H), 2.78 (s, 1H), 2.63 – 2.52 (m, 2H), 1.95 – 1.82 (m, 2H), 1.61 – 1.46 (m, 3H), 0.84 (d, 







1,2,3-triazole-4-carboxamide. Compound 162 (73mg, 0.15mmol) was dissolved in DMF 
(0.75mL). CuSO4 (1% (aq.), 10% eq. M) and sodium ascorbate (2% (aq.), 10% eq. M) 
were added to the solution, which was stirred under nitrogen atmosphere for 10 minutes. 
NBD-azide 88 (1.1 eq.) was added to the reaction, which was stirred overnight. Water 
(10 mL) was added to the reaction medium and the product was extracted with 3 x 5 mL 
ethyl acetate. The organic fractions were combined, dried with anhydrous sodium sulfate 
and concentrated under reduced pressure. The crude was purified by combi flash 
chromatography, yielding compound 174 as an orange solid (30mg, 0.04mmol, 28%). 1H 
NMR (500 MHz, Acetone) δ 8.51 (d, J = 8.8 Hz, 1H), 8.48 (s, 1H), 8.35 (s, 1H), 7.90 – 
7.86 (m, 2H), 7.86 – 7.81 (m, 1H), 7.78 (d, J = 8.2 Hz, 1H), 7.73 – 7.69 (m, 1H), 7.65 – 
7.61 (m, 2H), 7.22 (t, J = 7.4 Hz, 2H), 7.18 – 7.13 (m, 3H), 6.98 (dd, J = 15.1, 4.9 Hz, 
1H), 6.70 (d, J = 15.1 Hz, 1H), 6.48 (d, J = 8.7 Hz, 1H), 4.78 – 4.68 (m, 3H), 4.70 – 4.62 
(m, 1H), 3.79 (s, 2H), 2.79 – 2.60 (m, 2H), 2.59 – 2.52 (quint, J = 6.9 Hz, 2H), 1.92 – 
1.66 (m, 5H), 0.94 (dd, J = 16.0, 6.1 Hz, 6H). 13C NMR (126 MHz, Acetone) δ 172.6 (C-
3), 160.9 (C-24), 147.4 (C-19), 145.6 (C-34), 145.2 (C-38), 143.7 (C-26), 142.2 (C-13), 
142.0 (C-44), 137.8 (C-37), 134.3 (C-47), 131.6 (C-20), 130.3 (C-45, C-49), 129.3 (C-
15, C-17), 129.3 (C-14, C-18), 128.3 (C-46, C-48), 127.2 (C-30), 126.8 (C-16), 52.8 (C-
10), 50.1 (C-2), 48.7 (C-35), 42.0 (C-32), 36.2 (C-11), 32.8 (C-12), 25.7 (C-5), 23.4 (C-










dioxoisoindolin-2-yl)ethane-1-sulfonyl chloride (0.3 g, 1.1 mmol) was dissolved in dry 
DCM (10 mL). Triethylamine (0.153 mL, 1.1 mmol) was added, followed by 
propargylamine (0.07 g, 1.1 mmol). The reaction was stirred for 2 h. The solvent was 
evaporated under reduced pressure and the product was purified by combi flash 
chromatography, yielding a white solid (0.28 g, 0.96 mmol, 86% yield). 1H NMR (300 
MHz, Acetone) δ 7.86 (s, 4H), 6.67 (t, J = 5.7 Hz, 1H), 4.15 (t, J = 7.0 Hz, 2H), 4.03 – 
3.98 (m, 2H), 3.58 (t, J = 7.0 Hz, 2H), 2.87 (t, 1H). 13C NMR (75 MHz, Acetone) δ 168.40, 






dioxoisoindolin-2-yl)ethane-1-sulfonamide (0.27 g, 0.92 mmol) was dissolved in EtOH 
(5 mL). Hydrazine 98% (0.05 mL, 2.23 mmol) was added and the reaction was refluxed 
for 5 h. The solvent was evaporated under reduced pressure and the compound was used 










yl)sulfamoyl)ethyl)pentanamide. UDCA (0.435 g, 1.11 mmol) was dissolved in DMSO 
(4 mL). HOBt (1.1 eq.) was added, followed by TBTU (1.1 eq.) and the reaction was 
stirred for 30 min. The crude from the phthalimide deprotection reaction of N-(but-3-yn-
1-yl)-2-(1,3-dioxoisoindolin-2-yl)ethane-1-sulfonamide was added and the reaction was 
stirred overnight. Water (20 mL) was added and the product was extracted with 3 x 5 mL 
of EtOAc. The organic fractions were combined, dried with anhydrous sodium sulfate, 









yl)methyl)sulfamoyl)ethyl)pentanamide. The crude mixture containing 170 (100 mg) was 
dissolved in DMF (0.75mL). CuSO4 (1% (aq.), 10% eq. M) and sodium ascorbate (2% 
(aq.), 10% eq. M) were added to the solution, which was stirred under nitrogen 
atmosphere for 10 minutes. NBD-azide 88 (1.1 eq.) was added to the reaction, which was 
stirred overnight. Water (10 mL) was added to the reaction medium and the product was 
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extracted with 3 x 5 mL ethyl acetate. The organic fractions were combined, dried with 
anhydrous sodium sulfate and concentrated under reduced pressure. The crude was 







S3. Crystallography Section 
 
Crystals of Porcine Pancreatic Elastase (PPE) were obtained as previously described. 
183,294 In summary, PPE (SERVA Electrophoresis GmbH, Heidelberg, Germany), was 
dissolved in Milli-Q water to a final concentration of 20 mg.mL-1 (~0.8 mM), and used 
for crystallization trials without further purification. 100 mM stock solutions were 
prepared for ligands 94, 95, 96 and 102 in 100% (V/V) dimethyl sulfoxide (DMSO). PPE 
crystals were obtained at 20oC using the sitting-drop vapor diffusion method by mixing 
equal volumes of protein and crystallization solution consisting of 70 % (V/V) MPD (2-
methyl-2,4-pentanediol), 10 mM sodium/potassium phosphate buffer pH 5.9 (this 
solution was chosen based on previous crystallization reports of PPE).295,296 HNE (Elastin 
Products Co., Inc. Owensville, Missouri, USA , No. SE563) was crystallized in 24% PEG 
Smear Broad, 0.1 M Tris-HCl pH 7.2, 0.1 M potassium thiocyanate and 0.1M sodium 
bromide. 
Complexes of PPE and HNE with inhibitors were obtained by co-crystallization. 
Elastases were first incubated with each inhibitor in 5X molar excess for 15-30 min (PPE) 
or 60-90 min (HNE), at room temperature, with final DMSO concentration around 3% 
(V/V). Crystals of putative complexes of both enzymes were grown under similar 
crystallization conditions as for the apo-protein, testing various concentrations and ratios 
of protein: precipitant and drop volumes (at 20oC). In some of the drops, nucleation had 
to be promoted using seeding techniques, namely microseeding.297 
For X-ray diffraction data collection, crystals were harvested from the drops and directly 
flash-cooled in liquid nitrogen. The crystallization solution of PPE with 70% MPD is 
already cryoprotectant, whereas for HNE, ethylene glycol was added to the crystallization 
solution to a final concentration of 20% (V/V). In alternative, 25% (V/V) PEG Smear High, 
0.1 M sodium acetate pH 4.5 and 20% (V/V) ethylene glycol was tested. 
Data were collected at beamlines ID23 and ID30A-3 at the European Synchrotron 
Radiation Facility (ESRF, Grenoble, France), and I03 and I24 at the Diamond Light 
Source (Didcot, Oxfordshire, UK), synchrotrons. The programs XDS,298 POINTLESS299 
and AIMLESS,300 all within the autoPROC pipeline,301 were used to integrate, determine 
space group and scale the data, respectively. STARANISO,302  also within the autoPROC 
pipeline, was used to analyze the anisotropy of the data and, eventually, extend the 
resolution to a higher limit. Data collection and reduction statistics are depicted in Tables 
S1 and S2. Molecular replacement solutions for PPE and HNE datasets were obtained 
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with PHASER,303 as implemented in the PHENIX suite of programs,304,305 using the 
coordinates of 4YM9 (PDB entry183,294) for PPE and 1HNE for HNE (PDB entry),306 
devoid of any ligands and solvent molecules, as search models. Initial crystallographic 
refinement was performed with BUSTER‐TNT307 using the macro “Missing Atoms” and 
“‐L” flag (“presence of an unknown ligand”), to render clear electron density for the 
putative ligands. Iterative model building and refinement were carried out with programs 
COOT308 and BUSTER‐TNT307 until model convergence and satisfactory overall quality 
statistics were achieved. Hydrogen atoms were added with zero occupancy before each 
refinement cycle with the program HYDROGENATE, which uses reduce from the 
MolProbity suite.309 Final refinements were performed with phenix.refine305 from the 
PHENIX suite of programs.304 Structure validation was carried out with MolProbity309 as 
implemented in phenix.refine. Final refinement and validation statistics are shown in 
tables S1 and S2. All figures were rendered with PyMol.310  
Accession codes: The atomic coordinates and structure factor amplitudes of PPE:94, 
PPE:95, PPE:96 and HNE:102 complex structures were deposited in the Protein Data 
Bank (PDB) as entries 6QBU, 6QEN, 6QEO, and 6SMA, respectively. 
 
Table S1. Data collection and refinement statistics for complexes PPE:7 and PPE:8. 
 PPE:94 PPE:95 
PDB Entry 6QBU 6QEN 
 autoPROC/STARANISO autoPROC/AIMLESS autoPROC/STARANISO autoPROC/AIMLESS 
Data collection     
Synchrotron ESRF (Grenoble – France) DLS (Oxford – UK) 
Beamline ID30A-3 I03 
Wavelength (Å) 0.976 0.976 
Resolution range 
(Å)a 
45.57 – 1.38 
(1.45 – 1.38) 
45.57 – 1.53 
(1.56 – 1.53) 
34.05 – 1.20 
(1.30 – 1.20) 
34.05 – 1.41 
(1.44 – 1.41) 
Space group P 21 21 21 P 21 21 21 
Unit cell     
       a, b, c (Å) 50.55, 57.55, 74.59 51.13, 57.71, 74.65 
        α, β, γ (o) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Total no. of 
reflections 
154 232 (6 552) 129 339 (6 576) 198 534 (11 131) 164 442 (8 329) 
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No. of unique 
reflections 
38 592 (1 929) 32 333 (1 617) 49 274 (2 466) 42 081 (2 116) 
Multiplicity 4.0 (3.4) 4.0 (4.1) 4.0 (4.5) 3.9 (3.9) 
Completeness 
spherical (%) 
84.3 (28.2) 97.2 (99.9) 70.0 (15.6) 98.0 (98.4) 
Completeness 
ellipsoidal (%) 
91.8 (57.6) - 93.5 (70.2) - 
<I/σ(I)> 11.4 (1.2) 13.3 (2.1) 14.5 (1.5) 16.7 (2.2) 
Rmerge (%)
b 5.4 (73.3) 5.0 (49.2) 3.4 (75.0) 3.2 (43.6) 
Rpim (%)c 2.9 (44.6) 2.6 (25.7) 1.9 (39.1) 1.8 (24.7) 
CC1/2 (%)
d 99.9 (57.8) 99.9 (81.9) 99.9 (65.7) 99.9 (86.1) 
Refinement     
Rcryst (%)
e 13.32 (21.31) - 14.20 (21.65) - 
Rfree (%)
f 16.34 (26.00) - 17.40 (27.39) - 
RMSD bonds (Å)g 0.007 - 0.008 - 
RMSD angles (o) 0.98 - 0.98 - 
Protein residues Val-16 – Asn-245 - Val-16 – Asn-245 - 
Ramachandran 
plot 
    
        Most 
favoured (%) 
97.9 - 97.5 - 
        Outliers (%) 0.0 - 0.0 - 
Rotamer outliers 
(%) 
0.0 - 0.5 - 
Clashscoreh 0.81 - 2.72 - 
MolProbity scorei 0.78 - 1.16 - 
B-factors (Å2)     
        Protein 18.81 - 23.42 - 
Ligands/ions 27.94 - 28.21 - 
[a] Information in parenthesis refers to the last resolution shell. 
[b] 𝑅𝑚𝑒𝑟𝑔𝑒 = ∑ ∑ |𝐼𝑖(ℎ𝑘𝑙) − 𝐼(ℎ𝑘𝑙)|̅̅ ̅̅ ̅̅ ̅̅ ̅𝑖 /ℎ𝑘𝑙 ∑ ∑ 𝐼𝑖(ℎ𝑘𝑙)𝑖ℎ𝑘𝑙 . 
[c] 𝑅𝑝.𝑖.𝑚 =  ∑ [1/(𝑁 − 1)
1
2  ∑ |𝐼𝑖(ℎ𝑘𝑙) − 𝐼(ℎ𝑘𝑙)̅̅ ̅̅ ̅̅ ̅̅𝑖 |/ℎ𝑘𝑙 ∑ ∑ 𝐼𝑖(ℎ𝑘𝑙)𝑖ℎ𝑘𝑙 . 
[d] CC1/2 as described in Karplus & Diederichs (2012). Science, 336(6084): 1030–1033. 
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[e] 𝑅𝑐𝑟𝑦𝑠𝑡 =  ∑ ∑ ∑
{||𝐹𝑜(ℎ,𝑘,𝑙)|−|𝐹𝑐(ℎ,𝑘,𝑙)||}
∑ ∑ ∑ |𝐹𝑜(ℎ,𝑘,𝑙)|𝑙𝑘ℎ
𝑙𝑘ℎ , where Fo and Fc are the observed and calculated structure factors for reflection h, 
respectively. 
[f] Rfree was calculated the same way as Rcryst but using only 5% of the reflections which were selected randomly and omitted from 
refinement. 
[g] RMSD, root mean square deviation. 
[h] Clashscore is the number of unfavorable all-atom steric overlaps ≥ 0.4Å per 1000 atoms. Word et al.,(1999). Mol Biol, 
285(4):1711-33. 
[i] MolProbity score provides a single number that represents the central MolProbity protein quality statistics; it is a log-weighted 
combination of clashscore, Ramachandran not favored and bad side-chain rotamers, giving one number that reflects the 
crystallographic resolution at which those values would be expected. 
 
 
Table S2. Data collection and refinement statistics for complexes PPE:9 and HNE:17. 
 PPE:96 HNE:102 
PDB Entry 6QEO 6SMA 
 autoPROC/STARANISO autoPROC/AIMLESS autoPROC/AIMLESS 
Data collection    
Synchrotron ESRF (Grenoble – France) DLS (Oxford – UK) 
Beamline ID23 I24 
Wavelength (Å) 0.967 1.649 
Resolution range (Å)a 33.94 – 1.30 
(1.35 – 1.30) 
33.94 – 1.42 
(1.44 – 1.42) 
62.83 – 2.59 
(2.63 – 2.59) 
Space group P 21 21 21 C2 
Unit cell    
       a, b, c (Å) 
50.74, 57.71, 74.66 
116.67, 105.91, 79.47 
 
        α, β, γ (o) 90.0, 90.0, 90.0 90.0, 121.1, 90.0 
Total no. of reflections 210 764 (6 935) 187 811 (6 811) 85 806 (4 020) 
No. of unique reflections 49 091 (2 456) 41 396 (1 917) 24 564 (1 254) 
Multiplicity 4.3 (2.8) 4.5 (3.6) 3.5 (3.2) 
Completeness spherical (%) 88.9 (40.6) 98.0 (91.5) 95.1 (97.3) 
Completeness ellipsoidal (%) 91.8 (52.0) - - 
<I/σ(I)> 13.4 (1.2) 15.7 (2.2) 6.6 (1.8) 
Rmerge (%)
b 4.5 (65.2) 4.4 (42.8) 23.4 (126.4) 
Rpim (%)c 2.4 (44.4) 2.2 (24.6) 13.3 (75.5) 
CC1/2 (%)
d 99.9 (62.8) 99.9 (83.8) 96.6 (36.7) 
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Refinement    
Rcryst (%)
e 13.01 (21.55) - 20.79 (27.19) 
Rfree (%)
f 16.74 (26.07) - 25.76 (31.39) 
RMSD bonds (Å)g 0.009 - 0.002 
RMSD angles (o) 1.17 - 0.547 
Protein residues Val-16 – Asn-245 - Ile-16 – Gln-233 
Ramachandran plot    
        Most favoured (%) 97.5 - 97.4 
        Outliers (%) 0.0 - 0.0 
Rotamer outliers (%) 0.5 - 0.2 
Clashscoreh 1.59 - 3.50 
MolProbity scorei 1.01 - 1.27 
B-factors (Å2)    
        Protein 17.70 - 40.93 
Ligands/ions 22.94 - 57.54 
[a] Information in parenthesis refers to the last resolution shell. 
[b] 𝑅𝑚𝑒𝑟𝑔𝑒 = ∑ ∑ |𝐼𝑖(ℎ𝑘𝑙) − 𝐼(ℎ𝑘𝑙)|̅̅ ̅̅ ̅̅ ̅̅ ̅𝑖 /ℎ𝑘𝑙 ∑ ∑ 𝐼𝑖(ℎ𝑘𝑙)𝑖ℎ𝑘𝑙 . 
[c] 𝑅𝑝.𝑖.𝑚 =  ∑ [1/(𝑁 − 1)
1
2  ∑ |𝐼𝑖(ℎ𝑘𝑙) − 𝐼(ℎ𝑘𝑙)̅̅ ̅̅ ̅̅ ̅̅𝑖 |/ℎ𝑘𝑙 ∑ ∑ 𝐼𝑖(ℎ𝑘𝑙)𝑖ℎ𝑘𝑙 . 
[d] CC1/2 as described in Karplus & Diederichs (2012). Science, 336(6084): 1030–1033. 
[e] 𝑅𝑐𝑟𝑦𝑠𝑡 =  ∑ ∑ ∑
{||𝐹𝑜(ℎ,𝑘,𝑙)|−|𝐹𝑐(ℎ,𝑘,𝑙)||}
∑ ∑ ∑ |𝐹𝑜(ℎ,𝑘,𝑙)|𝑙𝑘ℎ
𝑙𝑘ℎ , where Fo and Fc are the observed and calculated structure factors for reflection h, 
respectively. 
[f] Rfree was calculated the same way as Rcryst but using only 5% of the reflections which were selected randomly and omitted from 
refinement. 
[g] RMSD, root mean square deviation. 
[h] Clashscore is the number of unfavorable all-atom steric overlaps ≥ 0.4Å per 1000 atoms. Word et al.,(1999). Mol Biol, 
285(4):1711-33. 
[i] MolProbity score provides a single number that represents the central MolProbity protein quality statistics; it is a log-weighted 
combination of clashscore, Ramachandran not favored and bad side-chain rotamers, giving one number that reflects the 






S4. Enzymatic Assays 
 
S4.1.  Enzymatic Inhibition Assays for Human Neutrophil Elastase 
 
HNE assays were carried out in a total volume of 200µL per well. Each assay well 
contained 155 µL of 0.1 M HEPES pH 6.9, 20 µL of HNE (stock solution 1.7 μM in 0.05 
M acetate buffer, pH 5.5) and 5 µL of the tested compound. After incubation at room 
temperature for 30 minutes, 20 µL of fluorogenic substrate (MeO-Suc-Ala-Ala-Pro-Val-
AMC, Merck, Germany) is added. DMSO was used as control. Enzymatic inhibition 
assays were carried out at 25ºC for a period of 30 minutes. The reaction was monitored 
with a FLUOstar Omega (BMG Lactech, Germany) microplate reader, at the excitation 
wavelength of 360 nM and emission wavelength of 460 nM. IC50s were determined by 
non-linear regression using GraphPad PRISM software. For all experiments, stock 
solutions of the tested compounds were prepared and diluted in DMSO. 
 
S4.2.  Inhibition Assay for Chymotrypsin 
 
Inhibition assays for chymotrypsin (Calbiochem) were performed in 0.05 M Tris-HCl, 
0.138 M NaCl, pH 8.0 with 30 nM human pancreas chymotrypsin, test compounds in pre-
determined concentrations, and 100 μM substrate (Suc-Ala-Ala-Pro-Phe-7-amino-4-
methylcoumarin, Bachem). DMSO was used as control. The reaction was monitored like 
for HNE (see S4.1). 
 
S4.3.  Inhibition Assay for Urokinase 
 
Inhibition assays for urokinase (Calbiochem) were performed in 0.05 M Tris-HCl, 0.138 
M NaCl, pH 8.0, with 30 U/mL human urine urokinase, test compounds in pre-determined 
concentrations, and 50 μM substrate (Z-Gly-Gly-Arg-AMC.HCl, Bachem). DMSO was 
used as control. The reaction was monitored like for HNE (see S4.1). 
 
S4.4.  Inhibition Assay for Trypsin 
 
Inhibition assays for trypsin (Calbiochem) were performed in 0.05 M Tris-HCl, 0.138 M 
NaCl, pH 8.0, with 30nM human pancreas Trypsin, test compounds in pre-determined 
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concentrations, and 50 μM substrate (Z-Gly-Gly-Arg-AMC.HCl, Bachem). DMSO was 
used as control. The reaction was monitored like for HNE (see S4.1). 
 
S4.5.  Inhibition Assay for Thrombin 
 
Inhibition assays for thrombin (Calbiochem) were performed in 0.01 M sodium 
phosphate, 0.138 M NaCl, 0.1% PEG 6000, pH 7.0, with 1.7 U/mL human plasma 
thrombin, test compounds in pre-determined concentrations, and 50 μM substrate (Z-Gly-
Gly-Arg-AMC.HCl, Bachem). DMSO was used as control. The reaction was monitored 
like for HNE (see S4.1). 
 
S4.6.  Inhibition Assay for Kallikrein 
 
Inhibition assays for kallikrein (Calbiochem) were performed in 0.05 M Tris-HCl, 0.138 
M NaCl, pH 8.0, with 2 nM human plasma kallikrein, test compounds in pre-determined 
concentrations, and 50 μM substrate (H-Pro-Phe-Arg-AMC acetate salt, Bachem). 
DMSO was used as control. A positive control was also used (Gabexate mesylate, 
Aldrich). The reaction was monitored like for HNE (see S4.1). 
 
S4.7. Inhibition Assay for DPP8/DPP9 
 
Inhibition assays for DPP8 and DPP9 were performed at the lab of Robert Huber. The 
results were obtained by measurement of the release of fluorescence by GP-AMC when 





S5.1. Cell Culture and Handling 
 
U937 cells were cultured in tissue culture flasks using RPMI-1640 medium, 
supplemented with fetal bovine serum (final concentration of 10%) and L-glutamine. 
Cells were seeded at 2 X 105 viable cells/mL and cultured by addition of fresh media 
every 2 to 3 days, maintaining cell density below 2 X 106 viable cells/mL. Cells were 
cultured in 95% air and 5% carbon dioxide, at 37°C. SILAC-U937 cells were generated 
by culturing U937 cells in RPMI-1640 medium supplemented with isotopically labeled 
arginine for a minimum of 5-8 passages. Aliquots were frozen after in the corresponding 
SILAC media and stored in liquid nitrogen for future use. After thawing, cells were 
passaged a minimum of three times before being used in experiments. 
HEK293T cells were cultured in tissue culture plates using DMEM medium, 
supplemented with fetal bovine serum (final concentration of 10%) and L-glutamine. A 
subcultivation ratio of 1:3 to 1:5 was used for passaging cells every 2 to 3 days when the 
cells reached approximately 80% confluency. Cells were cultured in 95% air and 5% 
carbon dioxide, at 37°C. 
 
S5.2. E. coli transformation with serine hydrolase plasmid DNA and Transfection 
into HEK293T for transient expression of Serine Hydrolases 
 
The plasmids encoding the serine hydrolases that were overexpressed were readily 
available in the Cravatt lab. The plasmids were transformed into E. coli. Briefly, 16 uL 
of E. coli suspension were mixed with 2 uL of DNA. The mixture was incubated at 0°C 
for 30 minutes. Heat-shock at 42°C was done for 30 seconds to induce internalization of 
the DNA. The cells were put back in ice for 5 minutes. S. O. C. media (600uL) was added 
and the mixture was incubated at 37°C for 1h. After this, 10uL were plated (100uL SOC 
media was added to increase the volume) in an LB-CARB (ampicilin) plate and incubated 
overnight at 37°C. The next day ampicilin resistant colonies had grown. A single colony 
was picked and suspended in 5mL of LB media. The suspension was incubated overnight 
with shaking at 37°C. The next day a miniprep was done to extract the DNA. The DNA 
samples were quantified using a nanodrop equipment (nucleic acid measurement). All 
constructs were sequenced prior to use. 
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HEK293T cells were seeded at 5 X 105 cells/mL and grown for 48h. A transfection 
mixture was prepared: per transfection experiment, 200 µL of serum-free DMEM media 
were mixed gently with 2 µg of plasmid DNA. 6 µg of PEI (1 mg/mL solution) were 
added and the mixture was mixed vigorously and incubated for 30 minutes. The mixture 




1 µL of the tested compound (50 X concentrated) or DMSO was incubated for 30 minutes 
with 50 µL of whole cell lysate, which was normalized to 1 mg/mL of protein 
concentration. In case of a competitive experiment, 1 µL of probe (50 X concentrated) is 
added and incubated for 30 minutes. The reaction is quenched by adding 18 µL of loading 
buffer mixture. The samples are loaded into a 10% polyacrylamide gel (14% in the 
competitive ABPP gels to determine the IC50 of HNE). Gels were run at constant voltage 
of 300 V for 3 to 3.5h. In-gel fluorescence scanning was done to obtain the labelled 
protein profile. 
 
S5.3.1. Click-chemistry for gel-based assays 
 
A premix of click reagents is prepared by adding (for 110 µL) TBTA (60 µL of 1.7 mM), 
CuSO4 (20 µL of 50 mM in dH2O), biotin or rhodamine azide (10 µL of 10 mM in 
DMSO) and TCEP (20 µL x 50mM [14 mg/ mL] in PBS), mixing well between each 
reagent. 6 µL of premix are added per sample and allowed to react for 1h at room 
temperature. The reaction is quenched by adding loading buffer. 
 
 
S5.4. SILAC ABPP-MudPIT 
 
SILAC U937 whole cell lysates were normalized to a concentration of 1 mg/mL. The 
tested compound and the control are incubated with either light or heavy SILAC whole 
cell lysates for 30 minutes. (If the experiment is competitive, both samples are then treated 
with biotinylated probe for 30 minutes) The reaction is quenched by adding each sample 
to cold MeOH on ice. Both samples are combined in this step by adding to the MeOH. 
0.5 mL of cold CHCl3 are then added and the sample is vortexed. 1 mL of cold PBS is 
added, and the mixture is vortexed, causing the proteins to precipitate. A centrifugation 
221 
 
at 5000 rpm for 10 minutes yields a protein disc in the interface between PBS and the 
organic solvents. The protein disc is isolated and washed with cold 1:1 mixture of MeOH 
and CHCl3 (1mL, 3 X). 2 mL of cold MeOH are added and the protein disc is sonicated. 
0.5 mL of CHCl3 is added. Centrifugation at 5000 rpm for 10 minutes yields a protein 
pellet.  
Denature, Reduce, Alkylate: 
500 µL of 6M urea in PBS are added. 50 µL of a mixture of TCEP (200 mM in PBS) and 
K2CO3 (600 mM in PBS), to give a final concentration of TCEP of 100 mM, was added 
and the protein pellet is sonicated into suspension. 20 µL of 10% SDS is added and the 
suspension is incubated for 30 minutes at 37°C while shaking. 70 µL of iodoacetamide 
(400 mM) are added and the mixture is incubated at room temperature in the dark for 30 
minutes. 120 µL of 10% SDS are added and then the sample is diluted with 5 mL of PBS, 
giving a final concentration of 0.25% SDS.  
Streptavidin Enrichment: 
100 µL of streptavidin beads per sample are washed 3 times with 0.25% SDS in PBS and 
then the total volume of bead suspension is diluted to 500 µL per sample. 500 µL of bead 
suspension is added to each sample. An incubation for 2.5h at room temperature while 
rotating is performed. After enrichment, a centrifugation (1400 rpm, 3 minutes) is done 
to pellet the beads. The supernatant is removed, and the beads are washed 3 times with 
10 mL of 0.25% SDS in PBS. The beads are transferred to a low-bind tube and washed 3 
times with 1 mL of PBS and 3 times with 1 mL of ddH2O. 
Trypsinization: 
A trypsin premix is prepared by diluting trypsin (20 ug) with 2mL of 2M urea and adding 
TEAB for a final concentration of 100 mM (TEAB). 200 µL of trypsin mix is added to 
each sample. The samples are incubated overnight (14h) at 37°C. 
The reaction is transferred into a biospin column and eluted into a LoBind tube. 16 µL of 
formic acid are added to a final formic acid concentration of 5%. The sample is then run 
in a LC-MS/MS or stored at -20°C. 
Digested peptides are pressure-loaded on to a biphasic capillary column containing a 
strong cation exchange resin and then reverse phase stationary phase. Loaded samples 
were analyzed by LC-MS/MS on an LTQ-Orbitrap (Thermo Scientific). The results were 
searched using the ProLuCID algorithm against a human reverse-concatenated non-
redundant (gene-centric) FASTA database, assembled from the Uniprot database. SILAC 
ratios were quantified using CIMAGE software (described in Weerapana et al., 2010). 
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S5.4.1. ReDiMe Variation 
 
If the procedure uses a ReDiMe protocol the samples are not combined after incubation 
in the probes and all the sample processing, including denaturation, reduction, alkylation, 
streptavidin enrichment and trypsinization.  
For each final ReDiMe sample, two separate samples need to be prepared for the two 
conditions being tested, usually treated sample and control, one will be the light sample 
and one will be the heavy sample. To the light sample light formaldehyde (8 µL of 4% 
stock solution) is added and to the heavy sample heavy formaldehyde (8 µL of 4% stock 
solution) is added. 8 µL of 0.6M NaBH3CN is added to both samples. 1h of incubation at 
room temperature is done while shaking and then 32 µL of 1% NH4OH in water is added, 
followed by 16 µL of formic acid to a final formic acid concentration of 5%. Light and 
heavy samples and combined, including beads. The supernatant is transferred to a biospin 






S6. Competitive ABPP Gels 















Fig S3 – Competitive ABPP in U937 whole cell lysates for compounds 114, 131, 140, 141, 143. 
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